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Abstract 
Light-Oxygen-Voltage (LOV) domains are flavoproteins that are part of photoreceptors 
found in plants, prokaryotes and algae. LOV domains act as biological switches in response 
sensors to oxygen, redox potential or light, making them ideal for use as an optogenetics 
tool. The protein-switch is activated by formation of a covalent adduct between the flavin 
cofactor and an internal cysteine residue, causing changes in the hydrogen bonding network 
in the core of the protein. This results in a conformational change in the LOV domain leading 
to undocking of an amphiphilic helix that is generally coupled to a catalytic or transcriptional 
activation domain.  
In this investigation the LOV2 domain of phototropin 1 from Avena sativa has been modified 
to control protein-protein interactions in apoptosis by incorporating the Bcl homology 
region 3 (BH3) of a key pro-apoptotic protein (Bid) to the mobile helix of AsLOV2 (J). The 
design, cloning, production and structure of these hybrid proteins (AsLOV-Bid1-4) are 
discussed and their photo-switching characteristics are examined using UV/Vis and CD 
spectroscopy. Half-lives of the proteins varied between 13 min and 7.5 min, with small 
deviation between UV/Vis and CD half-life measurements for each protein. A further 
investigation on the binding of AsLOV2-Bid proteins to Bcl-xL, the natural binding partner of 
Bid, has been conducted in the dark and light states using fluorescence anisotropy 
measurements. The results verified that AsLOV-Bid1-4 bound to Bcl-xL effectively in the light 
state with KD values at less than 300 nM. However, AsLOV-Bid2 also bound in the dark state 
with KD at 1 mM.  
A second LOV domain, YtvA from Bacillus subtilis is characterised using UV/Vis and CD 
spectroscopy. YtvA is a homodimeric photo-switch, with a longer relaxation half-life than 
Avena sativa LOV2, making it more suitable for use as an optogenetics tool. Here, 
investigations on amino acid residues key for the dimerisation of this protein were 
performed, before any hybrid proteins could be engineered. Residues V27 and I113, were 
replaced with aspartate residues by site-directed mutagenesis to explore the effects on the 
protein quaternary structure using size-exclusion chromatography. Comparing against 
standards mutant I113D is considered as monomeric, however further experiments need to 
be conducted to verify this. 
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2 
1.1 Light energy 
Light from the sun is the Earth’s most important source of energy. Directly or indirectly, light 
is essential for most living organisms, from photosynthesis, movement and growth in plants, 
gene-expression responses in micro-organisms to vision in animals. This energy reaches the 
earth as photons of electromagnetic radiation. Photons are absorbed by light sensing 
molecules, often by co-factor chromophores within protein complexes, which allow the 
absorption of photons of wavelengths beyond the UV spectrum of proteins alone.1 Energy 
form the photon, promotes an electron in the chromophore to excited states (Sn) from the 
ground state (S0, Figure 1.1). The host protein must then interact somehow with the excited 
state of the chromophore to transduce the absorption of a photon into a chemical or 
physical response. Energy is dissipated to the surrounding environment by non-radiative 
transitions through vibrational-relaxation between vibrational spin levels, and internal-
conversion occurring between two overlapping vibrational spin levels from different 
electronic states. The electrons can then return to the ground state from the first excited 
state (S1-S0) by emission of photons through a radiative transition (fluorescence). An 
alternative pathway is through intersystem-crossing, a non-radiative transition that involves 
changes in spin multiplicity from singlet to triplet state (S1-T1), finally returning to ground 
state from the first excited triplet state (T1-S0, Figure 1.1) by emission of radiative 
phosphorescence or by delayed fluorescence, thermally obtaining enough energy to return 
to the first excited singlet state then to ground state (T1-S1-S0). 
  
Figure 1.1: Jablonski diagram
2 
illustrating electronic states at different energy levels (bold lines) and vibrational 
spin levels (thin lines). Absorption and emission radiation are shown by straight arrows, and non-radiative 
relaxation, conversion and inter-system crossing are shown by dotted arrows.  
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Although light is vital for existence on earth, certain wavelengths of light can also damage 
living organisms; ultra-violet (UV) radiation (UV-C: 200-280 nm, UV-B: 280-330 nm, and UV-
A: 320-400 nm) is absorbed by proteins and nucleic acids, from which high exposure can 
cause DNA lesions.64 Failure to repair these mutagenic DNA lesions can lead to genetic 
diseases65 and predisposition to various cancers,80  most notably skin melanoma.3,4,67 A 
major form of DNA lesion is the covalent link between adjacent pyrimidine bases68,69 
forming cyclobutane-pyrimidine dimers (Figure 1.2), that cause distortion of the DNA 
structure and therefore prevent replication and gene expression,70  The p53 oncogene is 
commonly mutated due to UV induced DNA damage.64,66,71 
 
 
Figure 1.2: Pyrimidine dimer of two thymine bases showing covalent cross-links in red. 
 
On the contrary, visible-light (400-700 nm) radiation (Figure 1.3) is known not to cause 
direct damage; rather it has paved the way for further investigation on photo-sensory 
systems that utilise light at these wavelengths. There are various classes of chromophores 
that absorb light at different wavelengths according to their chemical structure (Sections 1.2 
and 1.3). These chromophores are usually part of larger photo-sensory protein complexes 
that use light energy for biological processes, such as photosynthesis.  
 
 
 
Figure 1.3: Illustration of the visible region of the electromagnetic spectrum. 
 
 
 Wavelength (nm) 
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1.2 Photosynthesis 
Photosensitive proteins in photosynthetic organisms use light as a source of energy to drive 
endergonic chemical processes or as a signal for morphological changes. Photosynthesis in 
plants, many bacteria and algae converts light energy to chemical energy in the form of ATP 
and NADPH. This complex procedure is mediated by the chloroplast reaction centres that 
bind pigments such as chlorophyll molecules that absorb energy from photons in the blue-
green region (400-700 nm) of the electromagnetic spectrum. Chlorophyll-a (Figures 1.4 and 
1.5A), absorbs at wavelengths between 400-450 nm and 650-700 nm, and chlorophyll-b 
(Figures 1.4 and 1.5B) at 450-500 nm and 600-650 nm.5 Chlorophylls vary in chemical 
structures and differ from bacteriochlorophylls (Figure 1.5A-D). Light-harvesting antenna 
complexes envelop the reaction centres and aid the capture and transfer of energy through 
additional pigments such as pheophytin (Figure 1.5 E) and -carotene (Figures 1.4 and 1.5F).  
 
 
 
Figure 1.4: Absorption spectra of chlorophyll a (purple), chlorophyll b (blue), -carotene 
(xanthophyll) (orange) individually and together (dotted green), including the 
photochemical efficiency (solid green) as a measure of the amount of oxygen released by 
leaves.
63
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Figure 1.5: Structure of: A) chlorophyll-a, B) chlorophyll-b, C) bacteriochlorophyll-a, D) 
bacteriochlorophyll-b, E) bacteriopheophytin and F) -carotene.  
 
In plants and many bacteria chlorophyll dimers (often called the ‘’special pair’’) are present 
in the reaction centres6 (Figure 1.6). They form lower energy states than single chlorophyll 
molecules present in the antenna complexes leading to a resonance energy transfer from 
excited states of single chlorophyll molecules to the special-pair (electron acceptor). The 
special pair in bacterial cells absorb light maximally at 960 nm wavelength, it is therefore 
often referred to as pigment 960 (P960) when excited and is quickly converted to P960+ 
following the transfer of electrons through single chlorophyll-b molecules to neighbouring 
quinone (plastoquinone in plants, Figure 1.7) electron acceptors (QA then QB) that are 
present in the cell membrane (Figure 1.9). QB is part of the electron-transport chain and its 
close proximity to the cytoplasm (bacteria) results in the uptake of protons, which in turn is 
reduced from Q to QH2 once a second electron is accepted. This results in the formation of a 
proton gradient (electrochemical gradient) in the cell membrane (thylakoid membrane in 
plants) that drives the synthesis of ATP6 through the ATP Synthase complex. Photosynthetic 
archaea use bacteriorhodopsin (Figure 1.8) to generate ATP also using an electrochemical 
gradient.7 
  
F 
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Figure 1.6: Plant photosystem II reaction center showing the ‘’special-pair’’ chlorophyll 
dimer (P680) in orange.
156 
 
 
Figure 1.7: A) Plastoquinone (oxidized form, Q) and B) plastoquinol (reduced form, QH2). 
The change is highlighted in red and n = 6 to 10 isoprene units. 
 
 
Figure 1.8: Bacteriorhodopsin in red: A) All trans retinal and B) 13-cis retinal. 
B 
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In green plants electron transfer occurs by charge separation through photosystem I (PSI) 
and photosystem II (PSII) (Figure 1.9). These photosystems closely resemble the reactions in 
the bacterial reaction centers in that it cycles a quinone from its oxidised form 
(plastoquinone) to its reduced form of (plastoquinol, Figure 1.7). The special-pair in plants 
(Figure 1.6) differs from that of bacteria in that it absorbs at 680 nm and is referred to P680 
and P680+. P680+ is a strong oxidant which is neutralised by electrons from two water 
molecules bound to a manganese cluster (Mn4Ca, contains multiple oxidation states Mn
2+, 
Mn3+, Mn4+, Mn5+) forming a single oxygen molecule (Figure 1.9). Initially the electrons are 
donated from a tyrosine residue of PSII, forming a radical that removes electrons from the 
manganese ions, in bacteria cytochromes are responsible for the transfer of electrons. 
Another important pigment in plant photosynthesis is the cytochrome (bf) complex which 
links PSI with PSII and transfers the flow of electrons to from plastiquinol (QH2) to the Q-
cycle in the thylakoid lumen via a copper binding protein called plastocyanin (Pc). Similarly 
to bacterial cells, the ATP Synthase complex uses the electrochemical gradient to generate 
ATP (Figure 1.9). 6 
 
 
Figure 1.9: The electron transport-chain in plants, illustrating the transfer of electrons (e
-
), the Q-
cycle (Q QH2  Q), the proton gradient (H
+
) and the generation of NADPH (PSI and ferredoxin) 
and ATP through the ATP Synthase complex.
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1.3 Photosensing 
Rhodopsins, phytochromes,8 xanthopsins9 and phototropins are all examples of 
photoreceptors that control activation of biological pathways. For example, rhodopsins are 
a group of retinal (Figure 1.8) binding photoreceptors that are the basis for visual perception 
in animals. The retinal chromophore is covalently linked by a Schiff base to a lysine residue 
of opsin, a protein component of rhodopsin. Retinal in its protonated state absorbs at 
wavelengths between 440-500 nm. The energy from a photon causes a cis-trans 
isomerisation of 11-cis retinal (Figure 1.10) and triggers conformational changes within 
rhodopsin.6 This results in the activation of a series of signalling cascades10 leading to the 
regeneration of 11-cis retinal in the visual photo-transduction pathway (visual cycle).  
 
  
Figure 1.10: Photoisomerisation of retinal chromophore from 11-cis-retinal to all-trans retinal. 
 
Both phytochromes and xanthopsins contain chromophores that follow a similar cis-trans 
activation process, where phytochromes absorb in the red/far-red region (620-740 nm), and 
xanthopsins such as photoactive yellow protein (PYP)9 absorb at the blue region (420-475 
nm). Phytochromes consist of light-sensing tetra-pyrrole chromophores (Figure 1.11A) that 
forms a thio-ether linkage to a conserved cysteine residue. Phytochromes regulate plant 
responses, such as photoperiodism (flowering) and are also involved in regulating root 
development72 and other responses like chloroplast movement, cytoplasmic motility, 
h
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germination of seeds and the synthesis of chlorophyll molecules.73 Xanthophylls are yellow 
pigmented carotenoids that are mainly long-chain hydrocarbons containing hydroxyl groups 
(Figure 1.11B). They mainly absorb light for photosynthesis in plants6 although, -
cryptoxanthine has been found to have provitamin-A activity and was determined to 
stimulate osteoblastic bone formation in vitro and also prevent bone loss in human 
models.71 
 
  
 
 
Figure 1.11: A) Phytochromobilin, a phytochrome tetra-pyrrole and B) cryptoxanthine, a 
xanthophyll. 
 
Phototropins are another type of blue-light photo-receptors that regulate directional 
growth in plants, a process known as phototropism.11 Phototropins are serine/threonine 
protein kinases that mediate phototropism through light-activated autophosphorylation, 
which is initiated by two light-oxygen-voltage (LOV) domains. These are flavoproteins, 
containing a flavin mononucleotide (FMN, Figure 1.12A) or flavin adenine dinucleotide (FAD, 
Figure 1.12B) cofactor, which sensitise phototropins to blue light.  
B 
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1.4 LOV Domains 
1.4.1 Morphological features of LOV domains 
Light-Oxygen-Voltage (LOV) domains belong to the per-ARNT-sim (PAS) family34 of 
molecular switches that act as internal sensors of oxygen, redox potential and light18 using 
covalently bound flavin cofactors (FMN or FAD).19 They are found in plants, fungi and 
bacteria and function as light sensitive component of kinases,20-22 DNA binding domains,23,24 
STAS (sulfate transporter anti-sigma factor antagonist) domains25 and as single LOV 
domains26 that function as DNA-binding proteins (such as EL222)74,75 or are usually coupled 
to other effector domains such as, the VVD LOV domain and white collar-1 (WC-1) protein 
complex (WCC), which regulates circadian clock function in fungus Neurospora crassa. 27 
These LOV domains function as reversible photo-switches30 to regulate a range of blue light 
responses such as phototropism,11,20 chloroplast mobility,28 stomatal opening29 and bacterial 
cell-cell attachment.21 LOV domains comprise of five alpha helices (C, D, E, F and J) 
and five beta sheets (A, B, G, H and I) forming an anti-parallel beta sheet (2 4 3) 
which is coupled to the kinase domain through an amphipathic helix18 also referred to as the 
Jlinker (Figure 1.13). 
 
 
Figure 1.12: Structure of A) FMN and B) FAD. 
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Figure 1.13: The structure of Avena sativa phot1 LOV2 (dark state) 
showing the position of the FMN (yellow) between helices E and F. 
Model generated using VMD 1.8.7. (PDB: 2V1B). 
 
1.4.2 FMN-cysteine adduct 
Studies on the photochemistry of the FMN-C4a-cysteine adduct were first performed on 
phot1 AsLOV232,35 and later followed by other LOV domains, which also demonstrated 
photoreactions with comparable mechanisms.36 The mechanism of the primary 
photoreaction has been the subject of considerable debate with three possible mechanisms 
proposed for the formation of FMN-C4a-cysteine adduct. Crosson and Moffat, suggested 
that a concerted mechanism takes place, the S-C adduct forming from a triplet state 
generated by the direct transfer of a proton from the cysteine thiol to the N5 position of the 
FMN. They used X-ray crystallographic studies to show that the cysteine residue 450 is 
located a short distance (4.2 Å) from the FMN (C4a) position, therefore favouring the 
transfer of a proton which would eliminate the electronic-charge on the isoalloxazine ring 
formed from photo-excitation.37 An alternative pathway involves a putative ionic 
mechanism, where the FMN triplet state triggers protonation and formation of a reactive 
carbocation at the C4a position, due to the increased electronegativity at the N5 position of 
the isoalloxazine ring.35,37 The reactive carbocation at the C4a position then undergoes 
nucleophilic attack by the thiol of cysteine.38 A third possibility was described by Kay et al., 
who proposed that the FMN-cysteine adduct formation occurs via a radical pair mechanism 
J
F
E
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(Figure 1.14)39 that involves the transfer of a hydrogen atom39-42 from the cysteine to the N5 
of the isoalloxazine of the flavin resulting in a radical pair (FMNH• - H2C-S
•) in the triplet 
state. The cysteine radical (-CH2-S
•) proximity to the isoalloxazine ring initiates spin-orbital 
coupling, followed by inter-system crossing between triplet and singlet states resulting in an 
FMN-C4a-cysteine adduct formation. Although semiquinone formation cannot be directly 
detected by spectroscopy, various studies using mutants of AsLOV2 where the key cysteine 
is replaced by other residues39-42have supported the radical-pair mechanism.  
 
 
Figure 1.14: Radical pair mechanism, showing the triplet (3), singlet (1) states and the 
intersystem crossing (ISC) between both states.  
 
 
3 
1 
3 
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1.4.3 Arabidopsis thaliana Phot1/2 
In Arabidopsis thaliana (At), two phototropins (phot1 and phot2) have been discovered 
comprising two light sensing light-oxygen-voltage domains (LOV1 and LOV2) situated at the 
N-terminal region and a serine/threonine protein kinase domain (Figure 1.15).11,12 
 
 
Figure 1.15: Diagram of Arabidopsis thaliana phototropin structure 
annotated with residue numbers. 
 
In At phot1 and phot2, LOV1 and LOV2 are almost structurally identical comprising the 
common five alpha helices and five beta strands.11,12 The isolated LOV1 domain relaxes with 
a half-life of 11.5 sec. whereas LOV2 relaxes with a half-life of 27 seconds.32 The LOV2 
domain, mediates light-dependent autophosphorylation20 and is coupled to the kinase 
domain through the J helix.18 LOV1 however is unable to elicit autophosphorylation in the 
absence of LOV2.20 Although the exact function of LOV1 is unclear, studies suggest that it 
may have a role in receptor dimerisation.33  
  
LOV1 LOV2 Kinase 
LOV1 LOV2 
130 559 404 224 
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1.4.4 Avena sativa LOV2 
Avena sativa (As) LOV2 is similar to AtLOV2 with 91.6 % sequence similarity,62 with the FMN 
cofactor positioned at the N-terminal half of the LOV domain, between helices E and F 
(Figure 1.13). AsLOV2 was one of the first LOV domains discovered for regulating 
phototropism and has been used in a wide range of studies including the studies on photo-
switching dynamics. The Jα helix was first identified by Gardner and co-workers and the 
NMR structure of AsLOV2 (Figure 1.13) revealed that in the dark state the J helix is docked 
to the β-sheet of the LOV core,48,18 suggesting that the monomeric nature of AsLOV2 is 
primarily due to the flexibility of the Jα, which prevents the formation of LOV dimers 
through β-sheet interactions.43 Harper et al. using NMR spectroscopy and limited 
proteolysis demonstrated kinase-activity in the dark-state of full length phototropin in 
absence of the J helix,18 indicating that dimerisation through β-sheet interactions between 
the LOV-core and the kinase domain takes place in the absence of J. Light induced covalent 
adduct formation between the FMN and an internal cysteine (C450), displaces the amino 
acid residues of the Jα from the central β-sheet, which leads to the undocking of the J 
which then regulates the activity of the kinase domain.49  
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1.4.4.1  AsLOV2 as an Optogenetics tool 
1.4.4.1.1 Introduction to Optogenetics 
Interactions between intracellular proteins regulate signalling processes and pathways vital 
to the function of cells. These signalling pathways can often be observed by directly tagging 
proteins using fluorescent proteins. Optogenetics is derived from the Greek word for visible 
(optos) and it is the technique of introducing genetically engineered light-sensitive proteins 
into a live cell or an organism, to monitor its localisation and/or effect within a cell.50  
Examples of such optogenetic tools have been demonstrated with various biological 
protein-switches. Toettcher and co-workers, demonstrated light activated interactions 
between phytochrome (Phy) and phytochrome-interacting factor (PIF) to direct reversible 
protein translocation, in fibroblast cells.157  Red light has also been used to control motility 
of fibroblast cells, which were demonstrated through fusions between phytochrome B and 
PIF6.158 Optogenetics has been used to photo-control DNA-binding where, Morgan and 
Wolley demonstrated photo-control of DNA-binding protein GCN4 (leucine zipper bZIP) 
when fused with PYP. The fusion protein was found to bind 10-fold more weakly than wild-
type and once light-irradiated, the DNA-binding affinity was enhanced by double in 
comparison to the wild-type GCN4 protein.159 Further modification on the GCN4-PYP gene 
by removal of a heptad repeat from the leucine zipper to improve its packing with PYP core, 
resulted in a reverse action where the protein bound DNA better in its dark state than in the 
light.160,161 However, this study still remains to be more widely tested and the a question 
remains to whether it will reach the stage of in vivo testing. 
The most successful optogenetics tool up to date is the green-fluorescent protein (GFP) 
from jelly fish, Aequorea victoria. Its wide-scale use in science has awarded its founders the 
Nobel Prize in chemistry 2008. Despite its success, GFP has several disadvantages such as, its 
use is restricted to aerobic systems,162 it displays pH sensitivity163  and is a relatively large 
protein.164 Recent research has been aimed at producing LOV-based fluorescent probes, and 
has resulted in a small (11 kDa) photo-reversible fluorescent protein called iLOV, engineered 
from At Phot2 LOV2. It has been established to perform better than GFP as a fluorescent 
reporter for plant viral infections.164 Recent advances in producing LOV domain based 
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photo-switches has excelled, with AsLOV2 being widely used as a basis for engineered 
fusions, of which a few are discussed below.  
1.4.4.1.2 LOV-TAP 
Strickland et al. produced and screened 12 fusions of AsLOV2-J to the Escherichia coli 
tryptophan repressor protein (TrpR) to form a family of LOV-TAP (tryptophan activated 
protein) proteins. The fusion was conducted through the C-terminal J to 13 different N-
terminal TrpR truncations as schematically illustrated below (Figure 1.16). The best example 
showed regulation of the DNA-binding activity with weak (788 nM) DNA binding in the dark 
state and 5-fold higher activity in the light state.51 Subsequently the design was optimised 
and the dark state binding was reduced by introducing single point mutations (G528A, I532A 
and N538E) and double mutations (G528A and N538E) to stabilise the J-hybrid. This 
resulted in a much improved light state binding of 64-fold.52  
 
 
Figure 1.16: An illustration of photo-switching of LOV-TAP (LOV domain in green) from 
inactive form (purple) in the dark state (FMN in red) to active form (orange) in the light 
state (FMN in blue). 
 
1.4.4.1.3 LOV-DHFR 
Lee et al. produced more drastic fusions by inserting AsLOV2 in-between the F-G loop and 
the C-E loopof dihydrofolate reductase (DHFR, Figure 1.17), an enzyme required for 
folate metabolism. They expected to use the photo-switching mechanism of AsLOV2 to 
enhance the rate of hydride transfer in the reduction of 7,8-dihydrofolate (H2F) to 5,6,7,8-
tetrahydrofolate (H4F). However, the designs led to distortions in the enzymatic function of 
DHFR and enzyme activity and substrate binding were reduced by more than half. No photo-
activation was demonstrated in vivo although, photo-switching revealed an increase of 1.5-2 
fold enzyme activity in vitro. In this case, regulation using light was not as successful.53 
h
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Figure 1.17: An illustration of photo-switching of LOV-DHFR (LOV domain in green) from 
inactive form (purple) in the dark state (FMN in red) to active form (orange) in the light 
state (FMN in blue). 
 
1.4.4.1.4 LOV-Rac 
Perhaps the most impressive of the AsLOV2-derived optogenetic switches is the Rac1 
GTPase fusion. Rac1 is an important GTPase responsible for regulating many cellular process 
through actin cytoskeletol reorganisation (motility, cell-cell adhesion and cell growth).76 
Rac1 has therefore been a useful tool for de-regulating and controlling cancer cell 
motility97,78 and growth.79 Wu et al. fused the N-terminus of Rac1 (Isoleucine, residue 4) to 
the C-terminal J of AsLOV2,so that access to the active site of PA-Rac1 (Photoactivatable-
Rac1) by its effector domain (Pak) is blocked (caged, Figure 1.18)X-ray crystallographic 
studies revealed dark state caging of the PA-Rac1 variant, whereas irradiation led to binding 
to Pak protein at approximately the same affinity as wild-type Rac1 which was 
demonstrated in mouse-embryo fibroblasts stably expressing PA-Rac1. Additionally, this 
mechanism of blue light activation has been sufficient to control the motility of fibroblast 
cells expressing PA-Rac1.54 The success of PA-Rac1 as an optogenetic tool has been 
portrayed in more recent studies on controlling neutrophil motility in developing zebra fish 
embryos55 and Drosophila ovary cells.56  
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Figure 1.18: An illustration of photo-switching of LOV-Rac (LOV domain in green) from 
inactive form (purple) in the dark state (FMN in red) to active form (orange) in the light 
state (FMN in blue). 
 
1.4.4.1.5 TULIPs 
Tunable, light-controlled interacting protein tags (TULIPs), are AsLOV2-peptide (LOVpep) 
fusions that function as optogenetic dimerisation tags that bind to proteins containing 
localisation signals to specific sites in yeast or mammalian cells. Fusions of small peptide 
sequences were made via overlapping parts of the C-terminus of J helix in order to adapt a 
docked -helical peptide conformation in the dark state therefore, caging the peptide 
sequence and preventing it binding to its effector domain (PDZ). Longer fusions showed 
sensitivity both in the light and dark states. Studies showed that the translocation in HeLa 
cells was reversible in three cycles of photo-excitation and recovery, using ePDZb1-mCherry 
co-localised with GFP-LOVpep. Strickland and co-workers also succeeded in controlling 
MAPK activation and cellular growth arrest using LOVpepCA (constitutively-active LOVpep 
variant) fused to Mid2 under the control of GAL1 promoter.57  
1.4.4.1.6 Photo-activated Caspase-7 
Caspase-7 is an executioner caspase (Section 1.5.3) usually present in cells in an inactive 
form, referred to as pro-domain (or pro-enzyme) that is activated upon internal proteolytic 
cleavage by caspase-8 or caspase-9. A recent study of the regulation of apoptosis used a 
fusion between the AsLOV2 domain and the catalytic domain of caspase-7 which formed an 
auto-inhibitory pseudoprodomain (LOV2-JCaspase-7 complex), where in the dark state it 
is presumed that the LOV2 domain is packed against the caspase cleavage site, preventing 
autolysis (auto-inhibition). This was activated upon light illumination, thus releasing its auto-
inhibition once the unfolding of LOV2-J took place. They showed positive results in vivo by 
testing the mortality of transfected COS7 cells upon photoactivation.58  
h
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1.4.5 Bacillus subtilis YtvA  
Bacillus subtilis (Bs) YtvA was the first bacterial blue-light photoreceptor found to contain an 
FMN binding LOV domain.44,45 A large group of bacterial LOV domains were later discovered, 
which contain histidine-kinase domains.46,22 However in YvtA, the LOV domain (Figure 1.19) 
is connected to a C-terminal sulfate transporter anti-sigma factor antagonist (STAS) domain 
(YtvA-LOV-STAS), which upon activation positively regulates the DNA-binding transcription 
factor SigmaB,47 which regulates environmental stress responses165,166,167 in Bacillus subtilis 
by transcribing over 150 genes whose products protect against threats to the cell.25 Studies 
by Buttani et al. have shown that the STAS domain also has NTP-binding properties.119 YtvA 
possessing a single LOV domain (YtvA-LOV) has been crystallised in its dark state, revealing 
head-to-head dimers between LOV domains. Unlike AsLOV2,48 the J helix is not docked 
onto the LOV core in the dark state and irradiated dark state crystals show little structural 
change.45 The photo-recovery time is 10-fold longer for YtvA-LOV45 than for AsLOV2.32,35  
 
Figure 1.19: The structure of Bacillus subtilis YtvA-LOV (dark state) showing the 
position of the FMN (yellow). Model generated using VMD 1.8.7. (PDB: 2PR5). 
N 
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1.4.5.1 YtvA-LOV as an Optogenetics tool 
1.4.5.1.1 YF1 
The LOV domain from Bs YtvA has been fused to a bacterial haem-binding PAS-histidine 
kinase (FixL) that is part of a two component system FixL/FixJ which regulates nitrogen 
metabolism in response to oxygen sensitivity. YtvA has been used to alter the signal 
specificity of FixL from oxygen to light by replacing its PAS domain with YtvA-LOV.59 This YF1 
fusion was active in the dark state (Figure 1.20) with irradiation leading to a 1000-fold 
decrease in its kinase activity. The study explored the importance of the lengths of the linker 
between the two domains, suggesting that amphipathic  helix linkers in dimeric fusion 
kinases form coiled coils.60 Light-induced changes in the YtvA-LOV domain are passed to the 
histidine kinase domain via a small 4-5° rotational movement in the coiled-coil linker.45 
Further research resulted in dual-sensing FixL variants (YHF and HYF), that have both a light 
sensing YtvA-LOV domain and a oxygen sensing FixL-PAS domain fused together for stronger 
signal activation. Autoradiographic studies using [γ-32P]ATP for detecting phosphate 
incorporation into FixJ, revealed reduced activity of YHF in the presence of either light or 
oxygen, and almost complete inhibition of activity in the presence of both.60  
 
 
Figure 1.20: An illustration of photo-switching of YF1/YHF (LOV domain in green) from 
active form (orange) in the dark state (FMN in red) to inactive form (purple) in the light 
state (FMN in blue). 
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1.4.5.1.2 YtvA-Lipase 
YtvA-LOV has also been fused to the N-terminus of Bs lipase A enzyme via the J helix 
(nLOV-BSLA). Light activated lipase activity was demonstrated using a standard assay for 
detecting lipase activity using p-nitrophenylpalmitate as a substrate that changes colour 
when converted to p-nitrophenolate. The assay therefore detects the enzymatic cleavage of 
the ester bond in pNPP in the presence of light-activated nLOV-BSLA.61 
1.5 Apoptosis 
1.5.1 Physical role and morphological features of apoptosis 
Apoptosis is the vital process of non-accidental cell death, also referred to as type I 
‘programmed cell death’ by Lockshin and Williams in 196480 and further reviewed by 
Lockshin and Zakeri in 2001.81 Apoptosis originates from the Greek word meaning ‘’falling 
off" or "to drop off’’ in similarity to falling leaves from trees.82 It is required for tissue 
development83 and homeostasis of multicellular organisms. Caenorhabditis elegans is an 
important model organism for research on apoptosis; during their development over 1000 
somatic cells are generated of which, around 13% of cells are premeditatedly eliminated 
during the process of morphogenesis.84-87 Apoptosis also plays an important role in 
mammalian development including the formation of separate digits by death of inter-digital 
mesenchymal tissue,88 the development of the cranial cavity89 and development of 
reproductive organs, during which the uterus is deleted in males (Müllerian duct) and the 
male organs are deleted in females (Wolffian duct).83 
Apoptosis is characterised by morphological changes of which ‘cell shrinkage’ is a key 
feature, followed by chromatin condensation and nuclear fragmentation (karyorrhexis) 
leading to 'budding' and formation of apoptotic bodies enclosed by intact cell membrane 
decorated by markers which encourage phagocytosis.82,86 Programmed necrosis 
(necroptosis) is another form of programmed cell death caused by cell membrane damage 
or depletion of energy and impairment of cell membrane ionic channels, leading to cell 
swelling (oncotic necrosis) then 'blebbing' and leakage of cellular contents which can 
stimulate strong local immune responses.90,91 Studies on knock-out mice lacking genes for 
the protein Apaf-1, which binds to cytochrome c (Section 1.5.4 and Figure 1.23) resulted in 
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slow activation of inter-digital cell death, suggesting that an alternative cell death 
mechanism (necrosis) took place.92 
Defects or dysfunction in apoptotic signalling can lead to autoimmune diseases and cancer, 
while excessive apoptosis can enhance ischaemic diseases and neurodegenerative 
disorders.93 Researches in cancer therapy often target the "programmed cell death" 
pathways, such as the activation of p53 of the intrinsic pathway by ionizing radiation in 
radiotherapy.94 There are three major apoptosis pathways resulting in the activation of 
members of a network of caspases (cysteine aspartate proteases).95,96 Caspases 8 and 9 are 
key components of the extrinsic and intrinsic pathways respectively and both lead to the 
activation of caspases 3,6 and 7, which are known as the executioner caspases and perform 
the downstream functions common to apoptotic pathways. 
 
1.5.2 Bcl-2 family of proteins 
The Bcl-2 (B-cell lymphoma) family of proteins are key regulators of apoptosis. Their 
function depends on their ability to form hetero-dimers with anti-apoptotic members (Bcl-2, 
Bcl-xL, Bcl-w, Mcl-1).
102 Full-length pro-apoptotic members of the Bcl family (Bak, Bax) are 
capable of homo-oligomerising to modulate the outer mitochondrial membrane 
permeabilisation for the release of cytochrome c.103 Both pro-apoptotic and anti-apoptotic 
proteins contain up to four homologous regions in their structure, termed Bcl-2 homology 
domains (BH1-4).104 The pro-apoptotic proteins can be further divided into subgroups of the 
multi-domain members Bak and Bax consisting BH1-BH3 domains, Bcl-xs consisting BH3 and 
BH4 domains, and the BH3-only members Bid, Bik, Bim, Bad, Puma and Noxa (Figure 1.21). 
The anti-apoptotic Bcl-2 proteins (Bcl-xL and Bcl-2), additionally are able to bind BH-3 
domains of pro-apoptotic proteins due to a distinct hydrophobic cleft in their protein 
structure.105,106 Therefore, the relative concentration of both pro-apoptotic and anti-
apoptotic members determine the cells survival. 
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Figure 1.21: Schematic domain structure of Bcl-2 family, also showing the 
trans-membrane domain(TM) at the C-terminus in red. 
 
1.5.3 Extrinsic pathway 
The extrinsic pathway is activated by the binding of ligands (Fas, Tumour necrosis factor TNF 
and TNF-related apoptosis-inducing ligand TRAIL) to cell surface receptors. Once activated 
conformational changes occur in these signalling receptors leading to the binding of adaptor 
molecules such as Fas-associated death domain (FADD). In Type I cells (independent of 
mitochondria) the adaptor domains recruit of pro-caspase-8, resulting in the formation of 
the death-inducing signalling complex (DISC, Figure 1.22). DISC causes the activation of pro-
caspase-8 to caspase-8 via auto-proteolytic cleavage. Caspase-8 directly activates casapse-3 
and caspase-7 which induce the morphological changes associated with apoptosis.18 Type II 
cells (mitochondria-dependent) have reduced DISC formation due to low levels of localised 
caspase-8, therefore activation of caspases-3 and 7 does not proceed directly, rather the 
BH3-interacting domain death antagonist (Bid) is cleaved to its truncated form (tBid), which 
then translocates to the mitochondrial outer membrane and initiates the intrinsic pathway 
(Figure 1.22), with executioner caspase-3 activation instead occurring through caspase-9.98 
  
TM BH3 
Anti-apoptotic 
Pro-apoptotic 
Bcl-2 Bcl-xL Mcl-1  BH4 BH3 BH2 BH1 TM 
Bak Bax  BH3 BH2 BH1 TM 
BH3 BH4 
Bim, Bik 
Bid Bad Noxa Puma 
TM Bcl-xS 
BH3 
Chapter 1: Introduction 
 
 
25 
 
 
 
 
Figure 1.22: The extrinsic pathway of apoptosis in type I cells through Caspase-8 auto-catalytic activation at the 
DISC. Initiation of type II cells is through proteolytic cleavage of Bid by caspase-8, which then activates the 
intrinsic pathway. 
 
1.5.4 Intrinsic pathway 
The intrinsic pathway can be activated by oxidative stress, DNA damage, UV-exposure or 
chemo-toxic substances. It is regulated by interactions between the pro-apoptotic and anti-
apoptotic Bcl-2 family of proteins. The BH3-only proteins: Bid, Bim, Bad, Bik, PUMA, Noxa 
can bind to the anti-apoptotic proteins, therefore an increase in their effective 
concentration either through up-regulation of their transcription by p53 or, as described 
above for Bid, cleavage of a passive to an active form can result in sequestering sufficient 
anti-apoptotic protein for Bak and Bax to homo-oligomerise and form pores leading to the 
mitochondrial outer-membrane permeabilisation (MOMP). MOMP allows the release of 
cytochrome c and Smac I (second mitochondria-derived activator of caspases, also known as 
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DIABLO) into the cytosol, the first committed step in the intrinsic apoptosis pathway (Figure 
1.24). Smac I binds to IAP (apoptosis inhibitor) and inactivates it99 whilst cytochrome c 
released from the mitochondria forms a complex with Apaf-1, a cytosolic protein that 
oligomerises in the presence of dATP and forms a protein complex known as the 
apoptosome (Figure 1.23), containing multiple caspase-recruitment domains (CARD) which 
activate caspase-9.  
 
 
Figure 1.23: Apoptosome assembly in the extrinsic pathway of apoptosis. Cytochrome c (green, round), CARD 
(black, round), and WD40 domain (black, square) are illustrated. 
 
1.5.5 Granzyme pathways 
Cytotoxic T-cells are tasked with killing tumours or virus infected cells, for which purpose 
they employ Granzymes-A and -B. Granzymes are serine proteases that are delivered into 
target cells with the assistance of perforin, a transmembrane pore forming molecule.100 The 
exact mechanism of entry into the cell is still a matter of debate with the strongest 
candidates being entry through the mannose-6-phosphate receptor or endocytosis during 
membrane repair processes triggered by calcium-loss. What is known is that their ability to 
induce apoptosis in human cells is strongly dependent on Bid, which granzymes truncate,101 
activating the downstream elements of the intrinsic apoptosis pathway; i.e. via capsase-9 
(Figure 1.24).  
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Figure 1.24: Schematic representation of important apoptosis signalling interactions. The nucleus is in cyan and 
the mitochondrion above nucleus, showing the release of cytochrome c (green, round). 
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1.6 Overview and Hypothesis 
LOV based optogenetics tools have so far proven to be successful in controlling cellular 
functions as seen with LOV-Rac,54-56 TULIPs,57 and YF1/YHF.59,60 As discussed earlier, Mills et 
al. have already demonstrated activation of apoptosis using an AsLOV-J-caspase-7 
hybrid.58 However, executioner caspases such as caspase-7 rely on internal cleavage by 
upstream initiator caspases (caspase-8 and -9), which are activated allosterically on 
platforms such as the apoptosome, which is regulated by the Bcl-2 family of proteins. Since 
the Bcl-2 family consists of anti-apoptotic proteins that can inhibit executioner caspase 
activation, as seen with AsLOV-J-caspase-7 and Bcl-2 overexpression,58 apoptosis can be 
better regulated by targeting Bcl-2 proteins from further upstream of the apoptosis 
pathway. Limitations of optogenetics tools lay within the design concepts, as seen with LOV-
DHFR.53 This work tests the hypothesis that if various designs are produced and optimised 
using examples of successful LOV-based photo-switches then regulation of cellular 
pathways, such as apoptosis further upstream of caspase execution, can be conducted 
through fusions between LOV-J and catalytic domains such as the BH3 domain of 
proapoptotic Bcl-2 family of proteins.  
1.7 Aim of the Investigation 
The aim of this investigation is to develop and engineer a new optogenetic tool to control 
apoptosis. Bcl-xL protein is a major regulator of apoptosis by binding and sequestering BH3 
domains of pro-apoptotic proteins. Here we firstly aim to develop fusions of the AsLOV2 
domain to pro-apoptotic BH3 domains such that the BH3 domains are only available for 
interacting with anti-apoptotic proteins when illuminated with blue light. The second part of 
this research is to study and develop possible fusions using the YtvA-LOV domain, as this 
photo-receptor encompasses longer photo-recovery time and will allow longer duration for 
signalling in vivo. However, this second objective is complicated by the homodimeric form of 
the parent protein and therefore requires further investigation using mutational studies in 
order to understand the importance of specific amino acid residues on its homodimeric 
form. 
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2.1 Materials 
Chemicals were purchased from Chemodex, Fisher, Fluka, GE Healthcare, Merck, New 
England Biolabs, NovaBiochem, QIAGEN or Sigma-Aldrich. DNA primers (oligonucleotides) 
were purchased from Operon or Sigma-Aldrich. 
A pNCO-Hisact plasmid containing the gene encoded for Avena sativa LOV2 fused to the C-
terminus of hisactophilin was provided by from Prof. G. Richter (Cardiff University).  YtvA-
LOV-STAS (encoding both the single LOV domain and STAS domain) was cloned from Bacillus 
subtilis. A pET 21a plasmid containing a gene encoding for loop truncated (1-209 Δ45-84, 
Δ210-233) Bcl-xL was obtained from Dr. M. Crump (Bristol University) 
2.1.1 Rich culture media 
2.1.1.1 Luria Bertani (LB) medium 
Bacto tryptone (10 g/L), yeast extracts (5 g/L) and sodium chloride (10 g/L) was dissolved in 
deionised water (dH2O). The medium was transferred to bottles or flasks and autoclaved for 
1 hour and 30 minutes at 15 lb/In2. 
2.1.1.2 Terrific broth (TB) medium 
Bacto tryptone (12 g/L), yeast extracts (24 g/L) and glycerol (4 mL/L) was mixed in 900 mL of 
deionised water (dH2O) and the medium was transferred to flasks. Monopotassium 
phosphate (2.31 g) and dipotassium phosphate (12.54 g) were dissolved in distilled water 
(100 mL) and autoclaved alongside the medium for 1 hour and 30 minutes at 15 lb/In2. Once 
both solutions had cooled to room temperature they were mixed. 
2.1.2 Agar plates 
Agar plates were prepared using autoclaved LB medium containing agar (15 g/L) and a 
magnetic stirring bead. After the media had cooled to approximately 40 °C the appropriate 
concentration of antibiotic added and the mixture was stirred. The solution was then 
poured in to 90 mm Petri dishes using aseptic techniques. Once set, the agar plates were 
stored inverted at 4 °C. For cell growth a solution of bacterial culture was spread over the 
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agar plate using a sterile glass rod. The plates were then incubated inverted at 37 °C 
overnight (15-16 hours). 
2.1.3 Preparation of antibiotic solutions 
An ampicillin stock solution in distilled water (50 mg/mL) was used to create a final 
concentration of 100 μg/mL in media. A stock solution of kanamycin in distilled water (25 
mg/mL) was used to create final concentration of 50 μg/mL. 
2.1.4 Escherichia coli strains 
E. coli BL21 (DE3) and BL21 (DE3) star strains were used for expression of plasmids (Table 
2.14). They contain the λDE3 lysogen carrying the gene for T7 RNA polymerase under the 
control of lacUV5 promoter allowing induction of the expression of recombinant proteins 
with isopropyl-1-thio-β-D-galactopyranoside (IPTG). The BL21 (DE3) star cells exhibit 
enhanced mRNA stability due to a mutation in the RNaseE gene (rne131), which reduces 
levels of endogenous RNases and mRNA degradation, increasing the stability of mRNA 
transcripts and increasing protein yield. Protein expression is further enhanced by the 
absence of the lon and outer membrane (OmpT) proteases, which reduces degradation of 
heterologous proteins. The XL-1 Blue strain was used as a host for optimal propagation of 
plasmids and was used for cloning where high transformation efficiencies were required. 
 
Strain Genotype 
BL21(DE3) F– ompT hsdSB (rB- mB-) gal dcm (DE3) 
BL21(DE3)* F– ompT hsdSB (rB– mB–) gal dcm rne131 (DE3) 
XL1-Blue endA1 recA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F’ proAB laclqZΔM15 
Tn10 (Tetr)] 
Table 2.1: Genotype of the Escherichia coli strains used in this study. 
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2.1.5 Oligonucleotides (Primers)  
Oligonucleotide sequences used for Bcl-xL and in the cloning of AsLOV-BID proteins and 
YtvA-LOV are listed below. 
 Name Sequence (5’ – 3’) 
1 Hisact-AsLOV2-
V416I 
For: GAACGTATTGAGAAGAACTTTATTATTACTGACCCACGTTTGCC 
Rev: GGCAAACGTGGGTCAGTAATAATAAAGTTCTTCTCAATACGTTC 
2 Hisact-AsLOV2-
V416I-BID 
LOVBID F1: 
CGAACATGTCCGTGATTGCGCCGAGGATTGGTGTCAACATCGCGCGTCATCTGGC
ACAGGTGGGTGAT 
LOVBID F2: 
AGCATTGATAGCCGTATTCCAGATGCTAATCTGCGTCCAGAGGATTTGTGGGCTA
ACTA 
LOVBID R1: 
AGCTTAGTTAGCCCACAAATCCTCTGGACGCAGATTAGCATCTGGAATACGGCTA
TCAATGCTATCACCCACCTGTGC 
LOVBID R2: 
CAGATGACGCGCGATGTTGACACCAATATCCTCGGCGCAATCACGGACATGTTCG
GTAC 
3 Hisact-AsLOV-
V416I-BID-
PD547C_ 
For: GATAGCATTGATAGCCGTATTTGCTAAGCTAATCTGCGTCCAGAGG 
Rev: CCTCTGGACGCAGATTAGCTTAGCAAATACGGCTATCAATGCTATC 
4 YtvA-LOV-STAS-
pET19b 
YtvA F: ATCTCGCGCATATGGCTAGTTTTCAATCATTTGG 
YtvA R: GGAGGATCCTTACATAATCGGAAGCACTTTAACG 
5 YtvA-LOV YtvALOV F: CTGCACTTTCAACTTAATAACCTATTGTCCCGATTCGC 
YtvALOV R: GCGAATCGGGACAATAGGTTATTAAGTTGAAAGTGCAG 
6 YtvA-LOV-V27D V27D F: CACGTGCGAGTCGGTGATGTAATTACAGATCCCG 
V27D R: CGGGATCTGTAATTACATCACCGACTCGCACGTG 
7 YtvA-LOV-I113D I113D F: GATCCAATGGAAGATGAGGATAAAACG 
I113D R: CGTTTTATCCTCATCTTCCATTGGATC 
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8 AsLOV-BID1 
(pET28a) 
LB-Pet F: TATATACATATGTTTCTTGCTACTACACTTGAACG 
LB-Pet R: AATTAAGGATCCTTAAGCTTAGTTAGCCCACAAATC 
9 AsLOV-BID2 For 1: CGAACATGTCCGTGATGCGGCCGAGCGTGAGGGTGTC 
LOVBID2 F2: ATGCTGATTAAGGATATTGCACGTAATATTGATCGTGCG 
LOVBID2 F3: CTGGCGGAAGTGGGTGATAGCATTGATCGTAGCATTTA 
LOVBID2 R1: AGCTTAAATGCTACGATCAATGCTATCACCCAC 
LOVBID2 R2: TTCCGCCAGCGCACGATCAATATTACGTGCAATATCCTT 
Rev 3: AATCAGCATGACACCCTCACGCTCGGCCGCATCACGGACATGTTCGGTAC 
10 AsLOV-BID3 For 1: CGAACATGTCCGTGATGCGGCCGAGCGTGAGGGTGTC 
LOVBID3 F2: ATGCTGATTAAGAAAACTGCAGATATTATTGATAACGCGGCACGT 
LOVBID3 F3: GAACTTGCACAGGTGGGTGATAGCATTGATCGTAGCATTTA 
LOVBID3 R1: AGCTTAAATGCTACGATCAATGCTATCACCCAC 
LOVBID3 R2: 
CTGTGCAAGTTCACGTGCCGCGTTATCAATAATATCTGCAGTTTTCTT 
Rev 3: AATCAGCATGACACCCTCACGCTCGGCCGCATCACGGACATGTTCGGTAC 
11 AsLOV-BID4 For 1: CGAACATGTCCGTGATGCGGCCGAGCGTGAGGGTGTC 
LOVBID4 F2: ATGCTGATTAAGAAAACTGCAGAAAATGATATTGCGCGTAATATC 
LOVBID4 F3: 
GCGCGTCATCTGGCACAGGTGGGTGATAGCATTGATCGTAGCATTTA 
LOVBID4 R1:  
AGCTTAAATGCTACGATCAATGCTATCACCCACCTGTGC 
LOVBID4 R2: 
CAGATGACGCGCGATATTACGCGCAATATCATTTTCTGCAGTTTTCTT 
Rev 3: AATCAGCATGACACCCTCACGCTCGGCCGCATCACGGACATGTTCGGTAC 
12 AsLOV-BID5 For 1: CGAACATGTCCGTGATGCGGCCGAGCGTGAGGGTGTC 
LOVBID5 F2: ATGCTGATTAAGAAAACTGCAGAAAATATTGATGAGGCG 
LOVBID5 F2.5: GCAAAAGAACTTGATATTATTCGTAATATCGCGCGTCATCTG 
LOVBID5 F3: GCACAGGTGGGTGATAGCATTGATCGTAGCATTTA 
LOVBID5 R1: AGCTTAAATGCTACGATCAATGCTATC 
LOVBID5 R2: ACCCACCTGTGCCAGATGACGCGCGATATTACGAATAATATCAAG 
LOVBID5 R2.5: TTCTTTTGCCGCCTCATCAATATTTTCTGCAGTTTTCTT 
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Rev 3: AATCAGCATGACACCCTCACGCTCGGCCGCATCACGGACATGTTCGGTAC 
13 Bcl-xL-S2C For: GGAGATATACATATGTGCCAGTCTAACCGTG 
Rev: CACGGTTAGACTGGCACATATGTATATCTCC 
Table 2.2: DNA sequences of oligonucleotides used for cloning and site-directed mutagenesis of engineered 
proteins. 
 
2.1.6 Preparation of reagents and buffers 
2.1.6.1 TFB I buffer for super-competent cells 
30 mM  Potassium acetate 
100 mM  Rubidium chloride 
10 mM  Calcium chloride 
50 mM  Manganese chloride 
15 % (v/v)  Glycerol 
The solids were dissolved in distilled water and the pH was adjusted to 5.8 using acetic acid. 
The resulting solution was stored at 4 °C. 
2.1.6.2 TFB II buffer for super-competent cells 
10 mM  3-(N-morpholino)propanesulfonic acid (MOPS) 
75 mM  Calcium chloride 
10 mM  Rubidium chloride 
15 % (v/v)  Glycerol 
The solids were dissolved in distilled water and the pH was adjusted to 6.5 using sodium 
hydroxide. The solution was stored at 4 °C. 
2.1.6.3 P1 buffer for QIA DNA isolation protocol 
50 mM  Tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl)  
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10 mM  Ethylene diaminotetracetic acid (EDTA) 
The solids were dissolved in water and the pH was adjusted to 8.0 then 50 μg/ml RNase A 
was added to the buffer. 
2.1.6.4 P2 buffer for QIA DNA isolation protocol 
200 mM  Sodium hydroxide 
1 % (w/v) Sodium dodecyl sulfate (SDS) 
2.1.6.5 N3 buffer for QIA DNA isolation protocol 
4 M Guanidine hydrochloride 
500 mM  Potassium acetate 
Once dissolved in water, the pH was adjusted to 4.2 using acetic acid. 
2.1.6.6 PB buffer for QIA DNA isolation protocol 
5 M  Guanidine hydrochloride 
20 mM  Tris HCl 
38 % (v/v)  Ethanol 
Once the solids were dissolved in water, the pH was adjusted to 6.6 and then ethanol was 
added to the final volume. 
2.1.6.7 PE buffer for QIA DNA isolation protocol 
20 mM  Sodium chloride 
2 mM  Tris(hydroxymethyl)aminomethane  (Tris base) 
80 % (v/v)  Ethanol 
Once the solids were dissolved in water, the pH was adjusted to 7.5 and then ethanol was 
added. 
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2.1.6.8 TAE 50x (Tris-acetate/EDTA) agarose gel electrophoresis buffer 
2 M  Tris base 
6 % (v/v)  Glacial acetic acid 
0.5 M  EDTA 
Once the solids were dissolved in water, the pH was adjusted to pH 8.0. 
2.1.6.9 Gel loading buffer for agarose gel electrophoresis 
0.25 % (w/v)  Bromophenol blue 
15 % (v/v)  Glycerol 
2.1.6.10 Resolving-gel buffer for SDS-PAGE 
1.5 M  Tris base 
The solution was adjusted to pH 8.8 using hydrochloric acid and the buffer was stored at 4 
°C. 
2.1.6.11 Stacking-gel buffer for SDS-PAGE 
0.5 M  Tris base 
The solution was adjusted to pH 6.8 using hydrochloric acid and the buffer was stored at 4 
°C. 
2.1.6.12 10x SDS-PAGE running buffer 
250 mM  Tris base 
1.9 M  Glycine 
1 % (w/v)  SDS 
Once the solids were dissolved in water, the pH was adjusted to pH 8.3. 
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2.1.6.13 SDS-PAGE gel-loading buffer 
1.25 mL  Stacking-gel buffer 
2 mL SDS solution (10% w/v) 
0.2 mL Bromophenol blue 
2.5 mL  Glycerol 
0.5 mL  β-Mercaptoethanol 
Volume made up to 10 mL with distilled water. 
2.1.6.14 Staining solution for SDS-PAGE 
0.25 % (w/v) Comassie brilliant blue 
45 % (v/v)  Methanol 
10 % (v/v)  Glacial acetic acid 
2.1.6.15 De-staining solution for SDS-PAGE 
10 % (v/v) Glacial acetic acid 
40 % (v/v) Ethanol 
2.1.6.16 0.1 M Isopropyl β-D-1-thiogalactopyranoside 
0.24 g  Isopropyl β-D-1-thiogalactopyranoside  (IPTG) 
IPTG was dissolved in distilled water, the volume was then made up to 10 mL and the 
solution was sterilized by passing it through a 0.2 μm syringe filter. 
2.1.6.17 0.5 M Phenylmethylsulfonyl fluoride 
0.87 g  Phenylmethylsulfonyl fluoride (PMSF) 
1 mL  Isopropanol 
PMSF was dissolved in isopropanol and stored at 4 °C. 
Chapter 2: Materials and Methods 
 
 
38 
2.1.6.18  Phosphate buffered saline (1x PBS) 
137 mM Sodium chloride 
2.7 mM Potassium chloride 
10 mM  Disodium phosphate 
1.8 mM  Monopotassium phosphate 
The solids were dissolved in distilled water; then the solution was adjusted to pH 7.4 using 
hydrochloric acid and made up to the required volume with distilled water.. 
2.1.6.19 Buffer for fluorescent labelling 
50 mM  Tris base 
100 mM  Sodium chloride 
2 mM  Tris(2-carboxyethyl)phosphine (TCEP) 
The solids were dissolved in distilled water; then the solution was adjusted to pH 8.3 using 
sodium hydroxide and made up to the required volume with distilled water. 
2.1.6.20 LOV protein purification buffers 
1.7.1.1.1 Cell lysis buffer 
50 mM  Disodium phosphate 
300 mM  Sodium chloride 
10 mM  Imidazole 
0.02 % (w/v) Sodium azide 
The solids were dissolved in distilled water and the pH was adjusted to 8.0 using 
hydrochloric acid. PMSF from a stock solution in isopropanol was added separately to cell 
suspension (final concentration 0.1 M) immediately prior to lysis. 
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2.1.6.20.1 Ni-NTA affinity chromatography: Ni- NTA binding buffer 
50 mM  Disodium phosphate 
300 mM  Sodium chloride 
10 mM  Imidazole 
0.02 % (w/v) Sodium azide 
Once the solids were dissolved in distilled water the solution was adjusted to pH 8.0 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.20.2 Ni-NTA affinity chromatography: wash buffer 
50 mM  Disodium phosphate  
300 mM  Sodium chloride 
40 mM  Imidazole 
0.02 % (w/v)  Sodium azide 
Once the solids were dissolved in distilled water the solution was adjusted to pH 8.0 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.20.3 Ni-NTA affinity chromatography: Elution buffer 
50 mM  Disodium phosphate  
300 mM  Sodium chloride 
500 mM  Imidazole 
0.02 % (w/v)  Sodium azide 
Once the solids were dissolved in distilled water the solution was adjusted to pH 8.0 using 
hydrochloric acid and made up to the required volume with further distilled water. 
Chapter 2: Materials and Methods 
 
 
40 
2.1.6.20.4 Size-exclusion chromatography purification buffer A 
50 mM  Disodium phosphate 
100 mM  Sodium chloride 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. The 
buffer was degassed under reduced pressure before use. 
2.1.6.21 UV spectroscopy buffer 
50 mM  Disodium phosphate  
100 mM  Sodium chloride 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.22 CD spectroscopy buffer 
50 mM  Disodium phosphate 
10 mM  Sodium chloride 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.23 Fluorescence anisotropy assay buffer 
50 mM  Disodium phosphate  
10 mM  Sodium chloride 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. The 
buffer was filtered before use. 
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2.1.6.24 Unfolding buffer 
50 mM  Disodium phosphate 
300 mM  Sodium chloride 
10 mM  Imidazole 
0.02 %  Sodium azide 
4.5 M  Guanidinium thiocyanate 
Once the solids were dissolved in distilled water the solution was adjusted to pH 8.0 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25 Bcl-xL protein purification buffers 
2.1.6.25.1 Buffer A1 
100 mM  Disodium phosphate 
500 mM  Sodium chloride 
5 mM  Imidazole 
1 mM PMSF (added immediately prior to use) 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25.2 Buffer A2 
100 mM  Disodium phosphate 
500 mM  Sodium chloride 
5 mM  Imidazole 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
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2.1.6.25.3 Buffer B 
100 mM  Disodium phosphate 
500 mM  Sodium chloride 
50 mM  Imidazole 
The buffer was adjusted to pH 7.5. 
2.1.6.25.4 Buffer C1 
100 mM Disodium phosphate  
500 mM Sodium chloride 
100 mM Imidazole 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25.5 Buffer C2 
100 mM  Disodium phosphate 
500 mM  Sodium chloride 
150 mM  Imidazole 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25.6 Buffer C3 
100 mM Disodium phosphate  
500 mM Sodium chloride 
200 mM Imidazole 
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Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25.7 Buffer D 
100 mM  Disodium phosphate 
500 mM  Sodium chloride 
500 mM  Imidazole 
Once the solids were dissolved in distilled water the solution was adjusted to pH 7.5 using 
hydrochloric acid and made up to the required volume with further distilled water. 
2.1.6.25.8 Size-exclusion chromatography purification buffer B 
50 mM  Disodium phosphate 
100 mM  Sodium chloride 
5 mM β-Mercaptoethanol  
The buffer was adjusted to pH 7.5 with hydrochloric acid and the buffer was filtered and 
degassed before β-mercaptoethanol addition. 
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2.2 Methods 
2.2.1 Preparation of competent cells 
The calcium chloride method was used to prepare competent cells.111 LB medium (100 mL) 
was aseptically inoculated with the desired E. coli strain. The culture was incubated 
overnight at 37 °C with vigorous shaking. The following day a sample (1 mL) of the culture 
was used to inoculate fresh LB media (100 mL) and the flask was incubated at 37 °C with 
vigorous shaking. Upon reaching an OD600 of 0.6 the flask was cooled on ice (or 4 °C) for 20 
min and then centrifuged at 4000 rpm for 10 min at 4 °C. The supernatant was discarded 
and the pellet was re-suspended in calcium chloride solution (20 mL, 100 mM CaCl2 pH 7.0; 
sterilised by autoclaving or with a syringe filter) and cooled on ice for 20 min, and then 
centrifuged again. The pellet was re-suspended in calcium chloride solution (6 mL, 100 mM 
CaCl2 with 15 % glycerol (w/v), pH 7.0; sterilised using syringe filter) and cooled on ice for 20 
min. Aliquots (100 μL) were flash frozen in liquid nitrogen and stored at -80 °C. 
2.2.2 Preparation of super-competent cells 
The rubidium chloride method111 was used to prepare super-competent cells. The desired E. 
coli strain (1 mL) was used to inoculate LB media (100 mL). The culture was incubated 
overnight at 37 °C with vigorous shaking. The following day a sample (1 mL) of the culture 
was used to inoculate fresh LB media (100 mL) and the flask was incubated at 37 °C with 
vigorous shaking. Upon reaching an OD600 of 0.6 the flask was cooled on ice (or 4 °C) for 15 
min and then centrifuged at 5000 rpm for 5 min at 4 °C. The supernatant was discarded and 
the pellet was re-suspended in TFB I buffer (40 mL, sterilised by autoclaving or with a 
syringe filter) and cooled on ice for 15 min, and then centrifuged again. The pellet was re-
suspended in TFB II buffer (4 mL) and cooled on ice for 15 min. Aliquots (100 μL) were flash 
frozen and stored at -80 °C. 
2.2.3 Transformation 
Plasmid DNA (1-5 μL) was mixed with competent (or super-competent) cells (100 μL) in a 1.5 
mL Eppendorf tube and incubated on ice (4 °C) for 30 min. The cells were subjected to a 
heat shock in a 42 °C water bath for 45 sec and then placed on ice for 2 minutes. LB medium 
(0.75-1 mL) was added to the cells and incubated at 37 °C for 1 hr. The solution was then 
centrifuged at 10,000 rpm for 30 sec on a bench top microcentrifuge. The supernatant was 
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discarded and the pellet was re-suspended in fresh LB medium (100 μL). The solution was 
spread on an agar plate containing the appropriate antibiotic(s) and then incubated 
overnight at 37 °C. 
2.2.4 DNA isolation, purification and storage 
2.2.4.1 QIAprep spin miniprep kit 
Plasmid DNA was prepared from overnight cultures of E. coli in LB medium (5 mL) according 
to the manufacturer’s instructions. 
2.2.4.2 Agarose gel electrophoresis 
Agarose gels were used for analysis and isolation of DNA fragments.  For 1% agarose gels 
1× TAE buffer (50 mL) was used to dissolve agarose (0.5 g) by heating the suspension in a 
microwave oven until homogeneous. The mixture was then poured into the minigel kit and 
left to set. Samples were mixed with the gel-loading buffer and loaded into the gel and run 
in 1× TAE buffer at 100 V for 60 minutes after which time the gel was stained with ethidium 
bromide and DNA visualised using an UV lamp at 254 nm. DNA fragments were extracted 
from the agarose gel with a clean, sharp scalpel. The QIAquick Gel Extraction Kit was used 
according to the manufacturer’s instructions (QIAGEN). 
2.2.4.3 Alcohol precipitation 
Alcohol precipitation was used to adjust DNA concentrations, for purification and as a 
method of storing DNA over long periods. The DNA sample was gently mixed with 
ammonium acetate (to a final concentration of 2-2.5 M), then absolute ethanol (2.5 
volumes) was added and the sample was incubated at 25 °C for 10 min. The solution was 
then centrifuged at 13,500 rpm for 15 min on a bench top microcentrifuge. The supernatant 
was discarded and the pellet was gently washed with 80 % (w/v) ethanol, and then 
centrifuged for 10 min. The supernatant was discarded and the pellet was allowed to dry for 
20 min. The sample was then stored at -20 °C or diluted to the required concentration. 
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2.2.4.4 Glycerol stocks 
Samples from an overnight culture of XL-1 Blue cells harbouring the desired plasmid (0.6 
mL) were aseptically mixed with sterile 50 % glycerol (0.6 mL). The stocks were stored at -80 
°C until used to inoculate LB medium for preparation of overnight cultures. 
2.2.5 Quantification of DNA and oligonucleotides in solution 
The concentration of nucleic acids was determined using a Thermo Scientific NanoDrop 
1000 photospectrometer, by measuring the optical density (OD) of a solution of DNA or 
oligonucleotide at 260 nm. 
2.2.6 Digestion with restriction enzymes 
Digestion reactions were performed with plasmid DNA (10 μL of 200 ng/μL DNA) and the 
appropriate restriction endonuclease (1 μL, 20,000 units/mL) in their recommended buffers 
(New England Biolabs). Reactions were incubated for 3-4 hours at 37 °C. For double 
digestions the buffer used was the recommended one that gave the highest digestion 
efficiency for both enzymes. The DNA product for the digestion was analysed by agarose gel 
electrophoresis. 
2.2.7 Dephosphorylation of DNA fragments 
Following digestion with a single restriction enzyme, the vector was dephosphorylated at 
the 5’ end with Antarctic Phosphatase to avoid self-ligation. DNA (10 μL-1 from 0.5 μg stock) 
was suspended in 1× Antarctic Phosphatase buffer (New England Biolabs) and 5 units of 
Antarctic Phosphatase were added to the mixture. The solution was incubated for 15 
minutes at 37 °C. The enzyme was heat inactivated (at 65 °C) for 5 minutes, and DNA 
purified using the QIAquick PCR purification protocol according to the manufacturer’s 
instructions. 
2.2.8 Phosphorylation of DNA fragments 
Oligonucleotide stock solutions (100 pmol/ mL) were diluted to 50 pmol/ mL with deionised 
water. Equal volumes of all forward oligonucleotides were combined to a total of 50 pmol, 
prior to phosphorylation. The same procedure was also applied to reverse oligos. The 
phosphorylation of forward and reverse mixtures were carried out in separate Eppendorf 
tubes; the combined oligonucleotides were phosphorylated at the 5’-end with 0.5 μL of 
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20,000 units/mL of T4 polynucleotide kinase (New England Biolabs) in T4 ligase buffer (50 
mM Tris pH 7.5, 10 mM magnesium chloride, 10 mM dithiothreitol, 1 mM adenosine 
triphosphate, 25 μg/mL bovine serum albumin). The solutions were incubated at 37 °C for 
30 minutes, and subsequently purified using the QIAquick PCR purification protocol and 
stored at -20 °C for future use.  
2.2.9 Annealing oligonucleotides 
Equimolar quantities of oligonucleotides were mixed in deionised water in an Eppendorf 
tube that was placed in a thermal cycler at 95 °C. The temperature gradually was reduced to 
15 °C over a period of 15 hours. The annealed oligonucleotides were stored at -20 °C. 
2.2.10 Ligation reaction 
Ligation reactions were carried out to insert desired genes into an expression vector. 
Digested plasmid (50 ng/μL) and the annealed oligonucleotides (50 ng/μL) or digested DNA 
fragments (50 ng/μL) were mixed together to a 1:3 or 1:5 ratio with 1 μL T4 DNA ligase (10 
units/μL) and 1 μL 10× T4 DNA ligase buffer (400 mM Tris, pH 7.8, 100 mM magnesium 
chloride, 100 mM dithiothreitol, 5 mM ATP). The solution was then incubated at 4 °C 
overnight (in polystyrene box to allow gradual cooling) or at 16 °C for 4 hours. Ligation 
products were stored at -20 °C. 
2.2.11 Polymerase chain reaction (PCR) 
Each reaction was prepared in a 0.5 mL thin-walled PCR tube to a final volume of 50 L 
containing 50 ng/μL DNA (0.3 L, 0.5 L or 0.8 L), Pfu polymerase buffer (5 L 10x), 
mutagenic primers (2 L from 10 pmol/ μL stock of each forward and reverse primers), 
deoxynucleotide triphosphates (1 μL, 0.2 mM each of dATP, dCTP, dGTP and dTTP), 
magnesium sulfate (1 L, 25 mM) and Pfu polymerase (0.5 μL, 2.5U/ μL).  
The temperatures were adjusted in each case according the melting temperatures of the 
primers being used. A typical cycle was as follows: 1 min at 95 °C (denaturation), 1 min at 55 
°C (annealing) and 1 min/1000 base-pairs at 72 °C (extension). This cycle was repeated 30 
times. 
Amplification of the desired DNA fragment was confirmed by agarose gel electrophoresis 
and PCR products were stored at -20 °C. 
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2.2.12 Mutagenesis 
The mutagenic primers were designed using PrimerX (Web-based program: Automated 
design of mutagenic primers for site-directed mutagenesis) using the following parameters: 
70-85 °C melting temperature, 35-60 % GC content and termination in G or C residues. PCR 
was carried out on the sample using temperatures considering the melting temperature of 
the primers being used. Once the reaction was complete DpnI (1 L, 20 units) was added to 
each of the samples which were then incubated for 1.5 hours at 37°C. The products were 
stored at -20 °C. 
2.2.13 DNA Sequencing 
All sequencing reactions were carried out by Cardiff University sequencing services or 
Eurofins MWG Operon DNA sequencing service. 
2.3 General Methods for Protein Preparation and Analysis 
2.3.1 Growth of bacterial cultures 
Overnight cultures were grown in sterile conditions by inoculating from glycerol stock or a 
single colony from an agar plate into LB medium (5 mL) containing the appropriate 
antibiotic. The cultures were incubated overnight at 37 °C with constant shaking at 150 rpm 
(Innova 43/44 incubator shaker). 
2.3.2 Protein expression using the T7 system 
Chemically competent cells were transformed with plasmid DNA, plated onto selective 
media and grown overnight at 37 °C.  Individual colonies were then picked and grown 
overnight in LB medium (100 mL) containing the appropriate antibiotic. Samples from the 
overnight culture were transferred to fresh LB or TB (for LOV protein expression) medium (5 
mL inoculum per 500 mL) containing the appropriate antibiotic in 2 L conical flasks, and 
incubated until they reached an OD600 of 0.6-0.8. The cells were then induced by the 
addition of IPTG to a final concentration of 1 mM, and left to grow for 4 to 6 hours (Bcl-xL) or 
overnight at 20 °C (LOV proteins). Samples (0.5 mL) were taken from each flask (including a 
sample prior to induction) and a SDS-PAGE was used to assess the extent of the expression 
of the target protein. The cells were then centrifuged at 6,000 g (Sorvall RC6 Plus) for 30 
minutes at 4 °C and pellets were stored at -20 °C. 
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2.3.3 Purification of LOV proteins 
2.3.3.1 Cell lysis 
Frozen pellets were thawed on ice and re-suspended by vortexing in cell lysis buffer. The 
suspension was sonicated for 6 minutes (3 s on, 5 s off) on ice using a Sonicator W-37 (Heat 
Systems Ultrasonics Inc.). The resulting lysate was centrifuged at 12,000 g for 30 minutes. 
The supernatant was transferred to a separate tube and a sample was taken for SDS-PAGE 
analysis. The remainder of the supernatant was purified immediately and the pellet was 
kept for analysis. 
2.3.3.2 Purification by Ni-NTA affinity chromatography 
The supernatant containing the protein was loaded onto a Ni-NTA agarose (QIAGEN) packed 
column pre-washed in Ni-NTA binding buffer. After loading the protein on to the column, it 
was washed with 1.5 column volumes of wash buffer. The bound protein was then eluted 
from the column with the elution buffer and the sample was kept at 4 °C until further 
purification. Samples (10 μL) of each of the flow-through, washed solution and eluted 
protein sample were kept for analysis by SDS-PAGE. 
2.3.3.3 Thrombin cleavage of LOV2 protein 
The protein sample was dialysed against a large volume (4 L) of PBS buffer pH 7.4 (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4) for 4 hours.  Calcium chloride (4.5 L, 
25 mM) and thrombin protease (50 L, ~50 units = 10 NIH units) was added and the sample 
was incubated overnight at 20C. The following day the protein was purified using Ni-NTA 
affinity chromatography. The cleaved sample was allowed to flow through the pre-washed 
column with AsLOV2 protein recovered from the flow-through solution. The resin was 
eluted with elution buffer and each sample was analysed using SDS-PAGE. 
2.3.3.4 Purification by size-exclusion chromatography (SEC) 
The eluted protein sample (up to 10 mL) was loaded onto a Superdex-75 10/300 GL (GE 
Healthcare) column pre-equilibrated with the size-exclusion chromatography Buffer A. The 
column was run at 2.5 mL/min and 10 mL fractions were collected. The eluted protein 
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fraction was wrapped in foil and stored at 4 °C. A sample (10 μL) was retained for SDS-PAGE 
analysis. 
2.3.4 Purification of Bcl-xL 
2.3.4.1 Cell lysis 
Frozen pellets were thawed on ice and re-suspended by vortexing in buffer A1. The 
suspension was sonicated for 5 minutes (5 s on, 10 s off) on ice using a Sonicator W-37 (Heat 
Systems Ultrasonics Inc.). The resulting lysate was centrifuged at 15,000 g for 30 minutes. To 
the supernatant was transferred to a separate tube. A sample (10 μL) was retained for SDS-
PAGE analysis and the remainder of the protein was purified immediately. The pellet was 
also kept for analysis. 
2.1.1.1 Purification by Ni-NTA affinity chromatography 
The supernatant containing the protein was loaded onto a Ni-NTA agarose (QIAGEN) packed 
column pre-washed in buffer A2. After passing the solubilised protein through the column, it 
was washed with 1.5 column volumes of buffer B. The bound protein was then eluted using 
a step gradient elution using buffers C1-C3 (3 mL of each) collecting fractions (1.5 mL) then 
finally buffer D (10 mL). The sample was kept at 4 °C until further use.  
2.3.4.2 Purification by size-exclusion chromatography (SEC) 
Protein samples (up to 10 mL) were loaded onto a Superdex 75 10/300 GL (GE Healthcare) 
column pre-equilibrated with buffer B. The column was run at 2.5 mL/min and fractions (10 
mL) were collected. The eluted protein fraction was stored at 4 °C. 
2.3.5 Dialysis of pure proteins 
In order to remove undesired components, the protein was dialysed using Medicell 
International Ltd. dialysis membrane (12,000-14,000 MWCO) in the appropriate buffer with 
stirring at 4 °C. The dialysis was carried out overnight in 5 L of buffer for large volumes of 
protein solution, or in 500 mL to 1 L, exchanging to fresh buffer every 1 hour in 3-5 intervals 
for smaller volumes of protein solution. 
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2.3.6 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Precursor solutions for 12 % resolving gels were created by mixing degassed deionised 
water (3.4 mL), acrylamide/bisacrylamide (4 mL, 30 %), Tris buffer (2.5 mL, 1.5 M, pH 8.8), 
sodium dodecylsulfate solution (SDS, 0.1 mL, 10 % w/v) with polymerising agents 
ammonium persulfate (APS, 100 μL, 10 % w/v in water) and tetramethylethylenediamine 
(TEMED, 15 μL). The solution was immediately poured between assembled glass plates with 
integrated 0.75 mm spacers and left to polymerise under a layer of isopropanol at room 
temperature. A 5 % stacking gel was created by mixing deionised water (5.7 mL), degassed 
acrylamide/bisacrylamide (1.7 mL 30 %), Tris buffer (2.5 mL, 0.5 M, pH 6.8), SDS (0.1 mL, 10 
% w/v) containing was mixed with APS solution (100 μL, 10 %) and TEMED (10 μL) and 
pipetted on top of the resolving gel. A comb was immediately inserted between the plates 
and the stacking gel was left to polymerise at room temperature. The comb was then 
removed and the wells rinsed with 1× SDS running buffer. Samples, mixed with 1× SDS gel-
loading buffer, were loaded into the gel (15 μL in the 10-well gels and 8 μL in the 15-well 
gels) and subjected to 160 V potential for 60 minutes. After electrophoresis, the gel was 
stained and destained using the corresponding solutions, followed by visualisation of the 
protein bands on a light box equipped with a UV lamp. 
2.3.7 Measurement and calculation of protein concentration 
2.3.7.1 Determination of protein concentration 
The concentrations of proteins were determined spectrophotometrically using a Jasco V-660 
UV/Vis spectrophotometer. The measurements were taken three times for accuracy and the 
following equation was used to calculate the concentration:  
  
 
  
 
Where C is the concentration in mg/mL, A is the absorbance; ε is the extinction co-efficient 
and l is the pathlength in cm. 
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2.3.7.1.1 LOV proteins 
The concentration of LOV proteins was determined using an extinction co-efficient of 12,550 
M-1cm-1 at 407 nm (an isosbestic point) using a clean quartz cuvette subtracting a blank 
measurement of buffer alone. 
2.3.7.1.2 Bcl-xL 
The concentration of Bcl-xL was determined using an extinction co-efficient value of 41,940 
M-1cm-1 at 280 nm (isosbestic point) using a clean quartz cuvette subtracting a blank 
measurement of buffer alone.  
2.3.7.1.3 Labelled protein 
To determine the concentration of tetramethylrhodamine-5-maleimide labelled protein an 
extinction coefficient of 91,000 M-1cm-1 at 550 nm was used using a clean quartz cuvette 
subtracting a blank measurement of buffer alone.  
2.3.8 Mass spectrometry (MS) 
2.3.8.1 MALDI-TOF MS 
Matrix assisted laser desorption/ionisation-time of flight (MALDI-TOF) mass spectrometry 
was performed to identify the purified proteins and peptides. α-Cyano-4-hydroxycinnamic 
acid in 1:1 MeCN/H2O was used as the matrix. 
2.3.8.2 ESI-TOF MS 
Electrospray ionisation-time of flight (ESI-TOF) mass spectrometry was preformed to identify 
the purified proteins. The sample was prepared in deionised water and concentrated to 
200-250 μM using a spin concentrator (10,000 MWCO). 
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2.4 General Method for Peptide Synthesis and Purification 
2.4.1 Peptide synthesis 
All peptides were synthesized according to standard fluorenylmethylcarbamoyl (Fmoc) solid 
phase synthesis protocols using a CEM Liberty microwave-assisted peptide synthesizer. The 
amino acids were protected with trityl (Trt), tert-butyl (tBu), butoxycarbonyl (Boc) or 
2,2,4,6,7- pentamethyldihydrobenzofuran (Pbf) sidechain protecting groups as required, O-
benzotriazole-N,N,N',N'-tetramethyl-uronium-hexa-fluorophosphate (HBTU), hydroxyl-
benzotriazole (HOBt), N- methylpyrrolidinone (NMP) and dimethylformamide (DMF) were 
purchased from AGTC Bioproducts. Dichloromethane (DCM), trifluoroacetic acid (TFA) and 
diethyl ether were sourced from Fisher. Piperidine, acetic anhydride, triisopropylsilane (TIS), 
N,N-diisopropylethylamine (DIEA), 4-(2-hydroxyethyl)-1-piperizineethanesulfonic acid 
(HEPES) and triscarboxyethylphosphine (TCEP) were purchased from Sigma Aldrich. Rink 
Amide resin (0.72 mmol/g) was purchased from NovaBioChem. The procedure used for the 
synthesis of all peptides was as described by Wysoczanski et al.107 
Steps Solutions 
Activator 0.45 M HBTU in DMF 
Deprotection mix 20% piperidine, 0.1 M HOBt in DMF 
Activator base 2 M DIEA in NMP 
Capping solution 20% acetic anhydride in DMF  
Amino acid solutions 
0.1 M solutions of Fmoc-protected amino acids in DMF: 
Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asn(Trt)-OH, 
Fmoc-Asp(tBu)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-
OH, Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-
Phe-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH 
Cleavage cocktail 95% TFA, 2.5% TIPS, 2.5% water 
Table 2.3: The solutions that were used for peptide synthesis. 
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Peptide Sequence 
LOVBid DCAEDIGVNIARHLAQVGDSIDRSI-NH2 
Ac-Bak wt Ac-GQVGRQLAIIGDDINR-NH2 
CG_Bid wt CGDIIRNIARHLAQVGDSIDRSI-NH2 
Table 2.4: Peptides synthesized for fluorescence anisotropy studies (Ac-Bak peptide was provided by Dr. Robert 
Mart from Cardiff University). 
 
2.4.2 Peptide purification and identification 
The peptide samples were purified by reverse phase HPLC (Dionex) using a Phemonenex 
Gemini C18 column (10 μm, 110 A, 10×250 mm) with an water/gradient from 0 % to 100 % 
acetonitrile (0.1 % TFA) containing in water (0.1 % TFA) over 50 min at a flow rate of 5 
mL/min (Figures 10 and 15), peaks were collected, identified by MALDI-TOF MS (Matrix: α-
cyano-hydroxy-cinnamic acid in 1:1 ratio of CH3CN/H2O) and the samples were freeze-dried 
and kept at -20 °C until further use.  
The purity of peptides was confirmed using analytical HPLC using an Acclaim Dionex 
Ultimate-3000 equipped with a Acclaim C18 column (3 μm, 120 A, 4.6×150 mm) with a 
gradient from 100% water (0.1% TFA) to 100% acetonitrile (0.1% TFA) over 50 minutes at a 
flow rate of 1 mL/minute. Peptides were identified using MALDI-TOF MS.  
2.4.3 Determination of peptide concentration 
The extinction coefficient of the fluorescent dye was used to determine the concentration 
of labelled peptides using the Thermo Scientific NanoDrop 1000 spectrophotometer. The 
following labelling dyes were used: Fluoresceinamide (FAM) with extinction coefficient of 
72,000 M-1 cm-1 at 494 nm, Tetramethylrhodamin-5-maleimide (TMR) with extinction co-
efficient of 91,000 M-1 cm-1 at 550 nm. 
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2.5 Fluorescent Labelling 
For fluorescent labelling, protein samples were dialysed or peptide freeze-dried samples 
were dissolved in Tris (50 mM, pH 8.3) buffer containing sodium chloride (100 mM) with 
TCEP (2 mM, added from 100 mM stock) reducing agent and incubated with 
maleimidofluorescein or maleimidotetramethylrhodamine at 15 °C overnight for proteins 
(at 300 rpm, using Eppendorf Thermo Mixer Comfort), and 4 °C overnight for peptides. The 
protein samples were dialysed into 50 mM disodium phosphate buffer pH 7.5 to remove 
excess dye, and size exclusion chromatography was carried out for further purification. The 
peptide samples were purified and their identities were confirmed by reverse phase HPLC 
and MALDI-TOF MS. Peptide samples were freeze-dried and redissolved in buffer for 
fluorescent anisotropy experiments. 
2.6 Photoswitching  
2.6.1 Dark state 
Dark state measurements of LOV proteins were recorded after the sample was kept in a 
dark bottle, covered in foil for a minimum of 2 hours at 4 °C.  
2.6.2 Light state 
A royal blue (455 nm peak wavelength) Luxeon K2 LAMRT Light emitting diode (LED) was 
used to photoswitch proteins. For CD spectroscopy and fluorescence anisotropy 
measurements samples were irradiated for 30 sec before taking measurements, for all 
UV/Vis spectroscopic measurements samples were directly irradiated in spectrometer. 
2.7 UV/ Visible Absorption Measurements 
UV/Visible absorption experiments were carried out using a JASCO V-660 UV/Vis 
Spectrophotometer with a 1 cm path length quarts cuvette. Single wavelength kinetics 
measurements were carried out at 447 nm and the half-life (t½) of LOV proteins was 
calculated using the following equation: 
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Where k is the first order rate constant for the relaxation process, which was calculated by 
plotting the natural logarithm of the absorbance at 447 nm versus time 
2.8 Circular Dichroism (CD) Spectroscopy 
CD spectra were recorded on a Applied Photophysics ChiraScan spectrometer. 
Measurements were recorded at 20 °C using a 0.1 cm path length quartz cuvette. 
Temperature dependent measurements of protein structure were carried out over a 
temperature range of 4–96 °C. The mean residue ellipticities [Θ]r (deg cm2 dmol-1) of 
different states of LOV2 proteins were calculated according to the equation: 
      
 
          
 
Where, Θ is the measured ellipticity in mdeg, n is the number of backbone amide bonds, c is 
the concentration and l is the pathlength (0.1 cm). 
The percentage change in -helical content at 222 nm of LOV2 proteins from dark to light 
states were calculated from the following equations: 
              
       
       
      
                          
2.9 Binding Assay using Fluorescence Anisotropy 
Fluorescence anisotropy measurements were performed at 15 °C on a Perkin Elmer LS55 
luminescence spectrometer arranged in L format (FAM: 492 nm excitation, 520 nm emission 
TMR: 545 nm excitation, 573 nm emission). A quartz fluorescence cuvette (4 mL) contained 
labelled protein or peptide (2.5-10 nM) in sodium phosphate buffer (3 mL, 50 mM, pH 7.5) 
containing sodium chloride (10 mM). Bak peptide, Bcl-xL or LOV2 proteins at concentrations 
of 0-5000 nM were successively added to cuvette. For peptide-peptide or peptide-protein 
assays each anisotropy value was from twenty single measurements were taken using an 
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integration time of 1 sec. For protein-protein binding assays each anisotropy value was from 
ten single measurements taken using an integration time of 5 sec. 
The G factor (ratio of sensitivities of the monochromator for horizontally and vertically 
polarised light) can be calculated using the equation:108 
  
   
   
 
Where, IHH and IHV are the intensities of the fluorescent emissions in parallel and 
perpendicular planes, respectively to the excitation plane. The G factor value was always 
close to 1.16 for FAM-labelled peptides and 0.85 for TMR-labelled proteins. Values for 
fluorescence anisotropy (A) were then determined from the equation:109 
      
    
   
        
The data were fit to the Langmuir isotherm: 
     
 
   
  
 
    
 
 
Where,      denotes the fraction of bound labelled-ligand, KD is the apparent dissociation 
constant, [P] is the concentration of protein and n is the number of binding sites.  
All binding curves were acquired independently at least three times and the resulting KD 
values averaged. Errors are the standard errors of the mean for each concentration point. 
Fluorescence anisotropy data were normalised and expressed as: 
  
      
         
 
Where, A denotes the fluorescence anisotropy in the presence of the indicated 
concentration of protein, AD denotes the fluorescence anisotropy in the absence of protein, 
and Amax denotes the fluorescence anisotropy at saturation.
110 
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3.1 Aim 
The aim of this project was to create modified versions of the second LOV domain of 
phototropin 1 from the plant Avena sativa to improve its properties for use as a photo-
switch that can be further developed to control and regulate protein-protein interactions of 
important regulatory proteins.  
3.2 Introduction 
As previously described (Section 1.4.4), AsLOV2 contains a five stranded anti-parallel -
sheet (2 4 3) (Figure 3.1). Upon formation of the FMN-cysteinyl adduct, rapid structural 
changes take place to amino acids of the G, H, I strands and E helix18 that affect the J 
helix. The J is initially docked to the -sheet of the LOV2 core (G, H and I strands), but 
the conformational changes result in disruption of the hydrophobic interactions that hold 
the J in the docked position.112,30 Harper and co-workers18 created a series of point 
mutations along the J to disrupt its hydrophobic interface in the absence of light. Using 
partial proteolysis and NMR spectroscopy they demonstrated that several of these 
mutations caused displacement and unfolding of the J helix. The photo-activated 
undocking mechanism of the wild type LOV domain will allow protein-protein binding using 
modified Jfusions in the absence of the C-terminal kinase domain. 
 
Figure 3.1: Structure of AsLOV2 showing residue I532 (green) on the J helix, residue Q513 (blue) from the I 
strand and residues L493 and H495 (gray) from the H strand (PDB: 2V1B). 
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A combination of crystallography and NMR spectroscopy of AsLOV218,112,30 provided 
structural information that identified the residues responsible for the hydrophobic 
interaction between the -sheet of the LOV core and the J helix (Figure 3.2). The side chain 
of I532 of the J helix packs between the side chains of L493 and H495 of the H strand, 
holding the helix to the LOV core (Figures 3.1 and 3.2A). Residues K533 and T535 also 
anchor the J to the -sheet through hydrogen bonding112,30 with K533 forming a hydrogen 
bond network with E475, T477, H495 and Q497 (Figure 3.3A). The side chain of T535 forms a 
single hydrogen bond with K413 (Figure 3.3B). Residues I539, A542 and A543 are highly 
conserved hydrophobic residues at the C-terminal open-end of the J helix112,30 suggesting 
that these are important residues for the docking of the J helix. 
 
 
 
Figure 3.2: Structures of AsLOV2 showing A) residues in the J helix and residues L493 and H495 from the H 
strand (PDB: 2V1B), B) J helix from its N-terminal end representation C) J helix from C-terminal end. 
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Figure 3.3: The hydrogen bonding network between A) amino acid residues T477, H495, 
E475, and Q479 located in the hydrophobic core of LOV2 and K533 of the J helix. B) 
Hydrogen bond between residues K413 located in the hydrophobic core of LOV2 and T535 
from the C-terminal end of J helix. 
 
The short photo-recovery time of AsLOV2 has rendered it difficult to crystallise in the open 
form, therefore structural information available on the light state of AsLOV2 is limited to 
irradiated crystals as opposed to a definite light state structure. The results from blue light 
irradiated crystals of LOV2 reveal that the FMN isoalloxazine ring is tilted towards the side 
chain of a highly-conserved glutamine residue (Q513) on the I strand (Figure 3.4A and B) 
which forms hydrogen bonds with the O4 and N5 of the FMN isoalloxazine ring30,37,113,115 
(Figure 3.4C). Formation of a secondary hydrogen bond at N5 of FMN causes slight 
displacement of residue Q513, changing the structure of the FMN binding pocket and 
increasing I strand dynamics and therefore disrupting the hydrophobic docking site for J 
helix as residue Q513 is located close to I532 (Figure 3.4B).30,113  
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Figure 3.4:  Structures showing the connection between residue I532 (green) on the Jhelix and residue Q513 
(blue) on the Istrand (remaining residues in gray) A) within the FMN binding pocket of AsLOV2 B) and also a 
schematic representation (shown by black arrows) of the possible conformational changes to the protein, C) 
due to formation of a secondary hydrogen bond (dashed lines) between Q513 and the N5 position of FMN upon 
light absorption (PDB: 2V1B). 
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3.3 Results and Discussion 
3.3.1 Expression and purification of AsLOV2 proteins 
LOV proteins were expressed and purified by adapting the procedure of Kay et al.120 (Section 
2.3). E. coli BL21 (DE3) cells harbouring a pNCO-Hisact-AsLOV2, containing a gene encoding 
the LOV2 domain of phototropin from Avena sativa  fused to the hisactophilin protein from 
Dictyostelium discoideum were grown in LB medium. Over expression was induced by the 
addition of IPTG and after 5 hours SDS-PAGE showed copious amounts of the fusion protein 
(Figure 3.5) producing a luminous yellow protein solution. Histidine residues at the surface 
of the fused hisactophilin protein allowed purification by affinity chromatography using a 
nickel-nitrilotriacetic acid (Ni-NTA) resin and the eluted fractions were analysed using SDS-
PAGE (Figure 3.6). Lane 5 of figure 3.6 shows vertical streaking of bands which may be as a 
result to high imidazole concentration in sample. 
 
 
 
Figure 3.5: SDS-PAGE analysis of Hisact-AsLOV2 expression. M: protein marker, lane 1: 
total cellular protein before induction, lane 2: total cellular protein 5 hours after induction. 
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Figure 3.6: SDS-PAGE analysis of Hisact-AsLOV2 at various stages of purification. M: 
protein marker, lane 1: supernatant after sonication of total cellular protein, lane 2: flow 
through from affinity column (10 mM imidazole), lane 3: wash (40 mM imidazole), lane 4: 
elution fraction 1 (200 mM imidazole), lane 5: elution fraction 2 (500 mM imidazole), lane 
6-8: elution fractions after dialysis. 
Wild-type LOV2 has a relatively short lived light-state of 59.5 ± 3.2 seconds (Section 3.2.4), 
therefore a valine to isoleucine mutation that is known to stabilise the cysteinyl-FMN 
adduct116 was introduced to generate a protein with a longer light-state half-life. Site-
directed mutagenesis using Pfu polymerase to perform a V416I alteration generated the 
pNCO-Hisact-AsLOV2-V416I plasmid and successful mutation of the codon was confirmed by 
sequencing (Appendix B). The protein was then expressed without any difficulty as before 
and MALDI-TOF MS was used to determine the protein mass of 32123.3 (without FMN) 
(Figure 3.7), this corresponded well to the calculated mass of 32700 which includes the FMN 
(456.34 for FMN). 
 
 
Figure 3.7: MALDI-TOF spectrum of Hisact-AsLOV2-V416I (positive mode). 
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In order to remove the fused hisactophilin, proteins were cleaved by thrombin at the target 
site (LVPR-GS) between the two domains. SDS-PAGE suggested incomplete cleavage by the 
continued presence of band at the correct size for Hisact-AsLOV2-V416I (32.7 kDa). Bold 
bands at the lower region suggest that the hisactophilin (14.3 kDa) and LOV2 (18.4 kDa) 
have been cleaved successfully (Figure 3.8). Collection of the protein fraction that no longer 
bound to the Ni-NTA column was followed by size-exclusion chromatography which 
separated LOV2 from thrombin. The peak at approximately 110 mL is expected to be 
thrombin (36 kDa) as it is a colourless solution (Figure 3.9). LOV2 eluted at 190 mL (bright 
yellow solution), suggesting that there was mostly monomeric protein (Figure 3.9), as 
observed in previous studies.33,120  
 
 
 
Figure 3.8: SDS-PAGE analysis of AsLOV2-V416I through the stages of purification after 
thrombin cleavage. M: protein marker, lane 1: Hisact-AsLOV2-V416I before thrombin 
cleavage, lane 2: after overnight cleavage with thrombin, lane 3: flow through fraction 
after loading on Ni-NTA affinity column, lane 4: sample after dialysis, lane 5: concentrated 
sample. 
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Figure 3.9: Superdex-75 size-exclusion chromatogram of AsLOV2-V416I. 
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3.3.2 UV/Vis spectroscopic characterisation of AsLOV2 proteins 
As expected, UV/Vis spectra of dark adapted wild-type Hisact-AsLOV2 showed an FMN 
absorption maximum at 447 nm with side bands at 427 nm and 474 nm32,35,62 (Figure 3.10) 
due to vibronic coupling resulting in changes to the electronic and vibrational energy of the 
isoalloxazine ring within the environment of the FMN binding pocket.125 After broad band 
UV irradiation using GG 455 band pass filter, the UV/Vis spectra of wild-type LOV2 reflected 
a photo-stationary equilibrium consisting of 80-90 % of LOV2 in the dark state, with the 447 
nm maximum still clearly evident (Figure 3.10).  Prolonged irradiation intervals with UV light 
passed through a WG 360 filter to remove < 360 nm light still did not completely diminish 
the 447 nm maximum, however after several hours a change in dark state spectra (red) was 
seen, likely due to protein degradation (Figure 3.10).  
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Figure 3.10: UV/Vis absorption spectra of Hisact-AsLOV2 in the dark (black) immediately 
after irradiation for 1 min (green) and 10 min (blue), using UV lamp and filter WG 360. The 
relaxation of same sample after 6 hours is shown in red. 
 
Careful investigation of the cause of this lack of switching revealed a discrepancy between 
samples that had been purified by size exclusion chromatography and those purified by 
dialysis alone. Residual imidazole was speculated to be present from insufficiently stringent 
dialysis; imidazole, which resides in its basic form at pH 7.5-8, has previously been reported 
to enhance relaxation to dark state or cause incomplete conversion to light state. Alexandre 
et al. observed this effect and ascribed it to an imidazole ‘base-catalysed’ mechanism 
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(Figure 3.11) which prevents the hydrogen bond formation between Q513 and the FMN 
N(5)-H in the light state, thus detaching the proton from the N(5) position and therefore 
disrupting the FMN-cysteine covalent adduct.30 Using a royal blue LED (Wavelength maxima 
at 455 nm) for irradiation did not improve switching for protein in the presence of imidazole 
(Figure 3.12) 
 
Figure 3.11: Imidazole mediated ‘base-catalysed’ mechanism (ionic) of enhancing the FMN 
dark state relaxation. 2D Graph 2
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Figure 3.12: UV/Vis absorption spectra of AsLOV2 (solution containing 500 mM imidazole) 
in the dark (black) immediately after irradiation for 1 min (green) and after 20 sec in the 
dark (red) using a Luxeon Rebel royal blue LED. 
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However, LED irradiation after removing residual imidazole from the protein solution by 
extensive dialysis (Figure 3.6), allowed complete conversion to light state (Figure 3.13). 
Irradiated LOV2 domains recover to the dark state in a non-photochemical process. The 
sample was irradiated for 30 sec and the absorbance spectra was recorded every 2 min for 
20 min (Figure 3.13). Isosbestic points for AsLOV2-V416I at 330 nm, 380 nm and 407 nm 
(Figure 3.13) suggests that there is equilibrium between two chemical species. Absorbance 
at 407 nm was used to calculate protein concentration using an extinction-coefficient of 
12,550 M-1cm-1 which was derived from the published extinction coefficient for the dark 
state protein of 13,800 M-1 cm-1 at 447 nm.39  
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Figure 3.13: UV/Vis absorption spectra of AsLOV2-V416I relaxation (reading at every 2 
min) from light state (green) to dark state (black), the FMN absorption maximum visible at 
447 nm (blue arrow) and three isosbestic points are seen at 330 nm, 380 nm and 407 nm 
(black arrows). 
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3.3.3 Half- life measurements 
UV/Vis absorption spectroscopy was used to perform time-course measurements at 447 
nm, which enabled calculation of the half-life of the cysteinyl-FMN adduct in wild-type and 
various mutant LOV2 domains. The samples where irradiated for 30 sec and the absorbance 
measured every second for Hisact-AsLOV2 and every 1 min for Hisact-AsLOV2-V416I and 
AsLOV2-V416I. The half-life of AsLOV2 has been recorded between 27 and 81 seconds in 
previous studies.32,35,116 In this study, the half-life of wild-type Hisact-AsLOV2 at 20 °C, pH 
7.5 was calculated to be 59.5 ± 3.2 seconds, whereas that of the Hisact-AsLOV2-V416I 
mutant was extended to 461.3 ± 6.4 seconds and again to 684 ± 6 seconds for AsLOV2-V416I 
(Figure 3.14).  
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Figure 3.14: UV/Vis absorption time-course measurements at 447 nm of Hisact-AsLOV2 
(black) and Hisact-AsLOV2-V416I (red) and AsLOV2-V416I (blue). 
 
Valine 416 is located within the FMN pocket (Figure 3.15) and substitution to isoleucine 
(addition of a methyl group) sterically alters FMN dynamics and increases the light-state 
stability, therefore increasing the relaxation half-life. It has already been shown that 
imidazole (side chain in histidine residues) disrupts the FMN-cysteine adduct,30 thus removal 
of the hisactophilin protein from the N-terminus of LOV2 may have altered the redox 
potential and light-state stability of FMN as the large numbers of histidine residues are no 
longer present. This would explain why AsLOV2-V416I protein has a longer relaxation half-
life than Hisact-AsLOV2-V416I. Although, in comparison to the half-life determined by 
Chapter 3: Avena sativa LOV2 
 
 
71 
Zoltowski, et al. (821 sec) AsLOV2-V416I in this case has a faster relaxation half-life by 137 ± 
6 seconds. However the half-life for V416I mutants is still significantly slower in comparison 
to wild-type LOV2, making it ideal to use as an optogenetics tool as prolonged irradiation 
periods will be illuminated and the risk of protein denaturation caused by heat from the 
light source will  be reduced. 
 
     
Figure 3.15: Structure of AsLOV2 showing C450 (green), V416 (orange) and the FMN (yellow) within the FMN 
binding pocket. 
 
3.3.3.1 The effect of temperature on relaxation rates 
The effect of temperature on Hisact-AsLOV2 and Hisact- AsLOV2-V416I was determined by 
repeating the time course measurements at temperatures between 10 °C and 37 °C at pH 
7.5. The results show an increase in temperature causes an increase in rate of relaxation for 
both wild-type Hisact-AsLOV2 (Figure 3.16) and Hisact-AsLOV2-V416I (Figure 3.17). At 10 °C 
wild type LOV2 has a half-life of 142 seconds which decreases to 16 seconds as the 
temperature was increased to 37 °C. In contrast the mutant Hisact-AsLOV2-V416I has a 
much longer half-life of 1385 seconds at 10 °C decreasing to 138 seconds as the 
temperature is increased to 37 °C.  
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Figure 3.16: UV/Vis absorption time-course measurements at 447 nm of irradiated Hisact-
AsLOV2 at 10 °C (pink), 15 °C (yellow), 20 °C (blue), 25 °C (green), 30 °C (red) and 37 °C 
(black). 2D Graph 1
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Figure 3.17: UV/Vis absorption time-course measurements at 447 nm of irradiated Hisact-
AsLOV2-V416I at 10 °C (pink), 15 °C (yellow), 18 °C (blue), 20 °C (green), 25 °C (red), 30 °C 
(black) and 37 °C (cyan). 
 
The time-course measurements were performed in triplicate for each temperature. The 
data was used to determine the activation energies in the thermal-relaxation of Hisact-
AsLOV2 and Hisact-AsLOV2-V416I (Tables 3.1) using Arrhenius plots (Ln k versus 1/T) (Figure 
3.18). Ln A is the intercept, where A is called the pre-exponential factor and the slope is 
equivalent to –Ea/R, where R is the gas constant and Ea is the activation energy. Reactions 
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that obey this equation show Arrhenius behaviour; LOV domains generally show linear 
Arrhenius behaviour for the temperature dependence for adduct relaxation.127,129 In this 
case both wild type and mutant exhibited linear Arrhenius behaviour, as expected (Figure 
3.18).  Large activation energies signify that the rate is sensitive to the changes in 
temperature. The activation energies for Hisact-AsLOV2 (57.3 kJ mol-1) and Hisact-AsLOV2-
V416I (69.5 kJ mol-1) differ slightly (Table 3.2), where Hisact-AsLOV2-V416I has 12.2 kJ mol-1 
higher activation barrier than wild type Hisact-AsLOV2, suggesting that the mutant is slightly 
more sensitive to changes in temperature than wild type LOV2. This increase in activation 
energy has also been observed with other slow-cycling LOV mutants128 and may be as a 
result of steric hindrance to the FMN-cysteine adduct formation, solvent accessibility or 
perturbation to the hydrogen bonding network of the isoallozaxine ring at N1, O2 and N3 
positions. These factors all affect proton transfers within protein complexes; previous 
studies have determined that the rate limiting step for thermal recovery in LOV domains, 
are due to the proton transfer to the N5 of FMN,30,35,129,130 and the activation energy barrier 
for the proton transfer step has been determined as 55 kJ mol-1.129 
 
Temperature 
Hisact-AsLOV2 Hisact-AsLOV2-V416I 
Half-life (sec) Half-life (sec) 
10 °C 142.4 ± 29.9 1924.0 ± 12.5 
15 °C 104.1 ± 2.4 1164.2 ± 10.6 
18 °C - 725.0 ± 37.7 
20 °C 59. 5 ± 3.2 461.3 ± 6.4 
25 °C 53.2 ± 3.5 273.0 ± 10.5 
30 °C 32.7 ± 2.0 156.0 ± 14.1 
37 °C 15.9 ± 1.3 137.6 ± 2.8 
Table 3.1: Half-life measurements of irradiated samples of Hisact-AsLOV2 and Hisact-
AsLOV2-V416I; listing the average half-lives from three independent experiments and their 
standard deviation. 
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Figure 3.18: Arrhenius plot of the relaxation rates of light state to dark state Hisact-
AsLOV2 (black) and Hisact-AsLOV2-V416I (red). 
 
 
EA (kJ mol
-1) A (s-1) 
Hisact-AsLOV2 57.3 2.86 x 106 
Hisact-AsLOV2-V416I 69.5 5.45 x 107 
Table 3.2:  Arrhenius parameters for the thermal relaxation of Hisact-AsLOV2 and Hisact-
AsLOV2-V416I. 
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3.3.3.2 The effect of pH on relaxation rates 
The effect of pH on the relaxation of light-state Hisact-AsLOV2-V416I was examined by 
recording time-courses monitoring absorbance at 447 nm over time at pH 6.5, 7.9, 7.5 and 
8.0 (Figure 3.19). At each pH the average half-life differed by only a maximum of 31 sec 
(Table 3.4) however, all except pH 6.5 and pH 8.0 are within the errors. The protein samples 
at pH 6.5 showed precipitation after 8-12 hours and after 16-24 hours at pH 7.0, whereas 
samples at pH 7.5 and 8.0 lasted up to two weeks without precipitation of the protein. The 
results obtained correspond to preceding studies. Bogomolni et al., used absorption 
difference spectroscopy to monitor proton transfers where light-induced adduct formation 
was found pH independent between pH 6.3 and pH 9.5.129 Amino acid residues such as 
lysine, tyrosine, glutamate, aspartate and arginine have side chain groups with acid 
dissociation (pK) values outside the range for pH 6.3-9.5, suggesting that these groups do 
not interact with FMN and/ or that their ionisation energies are insignificant. Studies on the 
triplet state decay however was found to have a small change between pH 3.7 and pH 9.5, 
where slow chromophore release was monitored below pH 5,129 this also corresponds to 
earlier studies that showed the same effect as the pK of cysteine in LOV2 is less than 4.35 
The theoretical isoelectric point (pI) for Hisact-AsLOV2-V416I is 6.41, at which there is no net 
electrical charge. Lowering the pH will affect the ionic bonds within the proteins, and alter 
their 3D structure causing protein denaturation. pH 7.5 and pH 8 were optimum for the LOV 
protein. pH 7.5 has a slightly higher average relaxation half-life than pH 8.0 therefore, all 
experiments from this point forward were conducted at pH 7.5 unless otherwise stated. 
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Figure 3.19: pH dependant time course absorption measurements of Hisact-LOV2-V416I at 
pH 6.5 (black), pH 7.0 (red), pH 7.5 (green) and pH 8 (blue). 
 
 
 
pH Half-life (sec) 
6.5 730.6 ± 19.5 
7.0 700.0 ± 44.2 
7.5 725.0 ± 37.8 
8.0 711.4 ± 11.2 
Table 3.3: Half-life measurements of Hiscat-LOV2-V416I at 18 °C at varying pH values 
showing the average half-life and the standard deviation. 
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3.3.4 Circular Dichroism spectroscopy 
Circular dichroism (CD) spectroscopy was carried out on purified proteins to assess the 
change in secondary structure upon photo-adduct formation. The rapidly relaxing Hisact-
AsLOV2 rendered it difficult to get an accurate light CD state spectra in the far UV region, 
however the dark spectra was recorded (Figure 3.20A), which is in agreement to existing 
literature37,129 showing a CD spectrum typical of a protein containing considerable fractions 
of both -helical and -sheet structure.  The maximum signal at approximately 190 nm and 
double minimum signal at 208 nm and 222 nm are features of helical secondary structure 
and represent the  -(~190 nm and 208 nm) and n-(222 nm) electronic transitions of 
peptide bonds. In -sheet structures, a maximum signal at around 195 nm ( transitions) 
and a strong minimum signal at 216-218 nm (n- transitions) is observed.123 Hisact-AsLOV2-
V416I has a large -sheet content due to the hisactophilin domain,121,122 resulting in a strong 
negative signal between 210-220 nm (Figure 3.20B). In contrast, AsLOV2-V416I displays 
distinct negative signals at 208 nm and 222 nm characteristic of high α-helical content 
(Figure 3.20C).123   
Undocking and/or disordering of the Jα-helix were observed by the change in mean residue 
ellipticity (MRE) at 222 nm (Table: 3.4). As expected, a decrease in the α-helical content was 
recorded upon irradiation: a 39.2 % decrease in ellipticity in Hisact-AsLOV2, 38.1 % in Hisact-
AsLOV2-V416I and 38.5 % in AsLOV2-V416I. Since the J helix accounts for 38.5 % of -
helical residues in dark state AsLOV2 (25 amino acids of 65) this change in -helicity is likely 
due to J undocking and unfolding.  
 
Protein % Change in [r at 222 nm 
Hisact-AsLOV2 [a] 39.2 
Hisact-AsV183I [a] 38.1 
LOV2-AsV416I [b] 38.5 
Table 3.4: Extent of photo-switching. Length of protein: [a] 288 amino acid residues [b] 160 
residues. 
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Figure 3.20: CD Spectra of A) Hisact-AsLOV2, B) Hisact-AsLOV2-V416I and C) AsLOV2-V416I 
in the dark-state (black) and light state (green). 
 
A 
C 
B 
Chapter 3: Avena sativa LOV2 
 
 
79 
3.3.4.1 Half-life measurements 
The half-life was measured using the MRE at 222 nm (Figure 3.21) to give an estimation of 
the refolding time once the dark state is re-established. Compared with the half-lives of the 
light states measured with the UV/Vis the structural relaxation time was slightly slower than 
that for FMN adduct reversion except for the rapidly relaxing Hisact-AsLOV2 (Table 3.5). It is 
unexpected that the protein relaxation time to be slower than that of the FMN, as decay 
kinetics for CD spectral changes in the far UV region was found to occur at the same rate as 
in the visible region.129 In the case of Hisact-AsLOV2, the faster protein recovery time may 
be due to a systematic error as a result to the short relaxation time of this protein; It is 
important to consider that several seconds (~ 5-10 sec) was required to transfer the sample 
cuvette from the LED light box to the CD sample holder. AsLOV2-V416I relaxation kinetics 
fall within error and Hisact-AsLOV2-V416I, may recover slower due to steric restraints to the 
protein conformation caused by fusion to hisactophilin. However, it likely that the cysteinyl-
FMN adduct decay is faster than the protein relaxation in response to alterations in redox 
potential and light-state stability caused by the histidine residues from hisactophilin.  
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Figure 3.21: CD relaxation curve of Hisact-AsLOV2 (green) Hisact-AsLOV2-V416I (red) and 
AsLOV2-V416I (blue). 
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Protein Half-life (sec) 
 
UV CD 
Hisact-AsLOV2 59.5 ± 3.2 39.7 ± 0.87 
Hisact-AsLOV2-V416I 461.3 ± 6.4 666 ± 162 
LOV2-AsV416I 684 ± 6.0 780 ± 168 
Table 3.5: Half-lives of light states of Hisact-AsLOV2, Hisact-AsLOV2-V416I and AsLOV2-
V416I at 20 °C measured by UV/Vis observation of cysteinyl-FMN adduct reversion at 447 
nm and CD mean residue ellipticity at 222 nm. 
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3.3.4.2 The effect of temperature on AsLOV2 proteins 
It is already investigated that the relaxation half-life of AsLOV2 proteins are temperature 
dependent, therefore to acknowledge the temperature at which the proteins denature at 
will be ideal for when future optogenetics studies are conducted. The CD signal at 222 nm 
represents the n- electronic transitions, which represents the strong hydrogen bonding 
environment of -helices123 within the protein complex, therefore increasing the 
temperature diminishes the hydrogen bonds and a loss in signal at 222 nm is observed. 
Temperature dependent measurements between 4 °C and 96 °C  were conducted at 222 
nm, which gave 56 °C as the melting point for Hisact-AsLOV2, although unfolding of the 
protein can be seen from as low as 30 °C onwards. Hisact-AsLOV2-V416I (melting point: 56 
°C) starts to unfold at higher temperature of 48 °C and AsLOV2-V416I (melting point: 54 °C) 
at 44 °C (Figure 3.22) although the melting point is within the same range of wild-type 
Hisact-AsLOV2. The temperature dependent measurements, suggest that the insertion of 
the mutation did not affect the protein stability any great extent and the absence of the 
Hisact also has relatively small impact on stability. 
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Figure 3.22: Temperature dependent CD Spectra of Hisact-AsLOV2 (red), Hisact-AsLOV2-
V416I (blue) and AsLOV2-V416I (green) at 222 nm. 
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3.4 Conclusion 
LOV domains are very specific to blue light irradiation as seen with the preliminary UV/Vis 
absorption spectroscopic studies that showed limited switching with various UV band pass 
filters. Confirmation on the negative effect of imidazole, known to enhance relaxation to the 
dark state,30 was demonstrated through the use of a blue LED which did not improve the 
switching observed by UV/Vis spectroscopy in the presence of imidazole. The ‘base-
catalysed’ effect of imidazole suggests that the FMN binding pocket is solvent accessible, 
this is supported by the evidence from previous studies where, deuterium (D2O) exchange at 
N3 and N5 positions of FMN was observed by Fourier transform infrared spectroscopy37 and 
through pH and isotope effects.35,129 Solvent accessibility of the FMN binding pocket would 
implicate that a change in redox potential, caused by the removal of the histidine 
dominated hisactophilin protein, is a possible explanation for the slower dark state recovery 
for the AsLOV-V416I in comparison to Hisact-AsLOV2-V416I, observed by UV/Vis and CD 
spectroscopy. Full length proteins containing both Arabidopsis thaliana LOV1 and LOV2 but 
with non-switching LOV1 (C39A mutant)20 showed kinetic differences to Avena sativa 
LOV2129 in studies by Bogomolni et al., suggesting that extensions at the N-terminus of LOV2 
may have an impact on light induced protein behaviour. Therefore changes in the half-life 
kinetics caused by the presence of hisactophilin may reflect similar changes in the protein 
secondary structure. UV/Vis and CD half-life values for all except Hisact-AsLOV2-V416I are 
within error, which follow the proceedings in the literature.129 
It was found that AsLOV2 proteins are sensitive to the change in temperature as the half-life 
values for both wild-type and mutant AsLOV2 drastically decrease with increased 
temperatures from 10 °C to 37 °C, this is observed through linear Arrhenius behaviour in 
both this study and previous studies.127,128 It was observed that elevated temperature also 
affects protein folding and stability demonstrated by CD temperature dependent 
measurements. Although no significant changes in protein melting point were observed 
between Hisact-AsLOV2, Hisact-AsLOV2-V416I and AsLOV2-V416I, the slightly higher 
unfolding temperatures for the V416I mutants renders it ideal to use as an optogenetics tool 
at 37 °C for in vivo assays. 
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The effect of pH in the range of pH 6.5 to pH 8 had a minimal effect as no substantial change 
was observed in the relaxation half-life measured using UV/Vis absorption at 447 nm. This 
suggests that important residues involved in the rate-limiting step have pKa values outside 
the pH range investigated. A broader range of pH was not tested due to protein 
precipitation that occurred at extreme pH ranges. For this reason, future experiments will 
be conducted between pH 7.5 and pH 8.5. 
In conclusion, mutant AsLOV2-V416I has the most extended half-life and will provide a 
longer cysteinyl-FMN adduct yield under reduced irradiation intervals, which will reduce 
damage to protein samples cause by extensive heat from the light source. CD time-course 
measurements at 222 nm also enabled calculation of the % change in -helical content 
which suggests that the change is likely due to the undocking and/or unfolding of J. Future 
hybrid proteins engineered with fusions at the J helix to control cellular apoptotic 
signalling will benefit from the longer undocked period of J to allow any possible binding/ 
interactions to regulatory proteins. 
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4.1 Aim 
The aim is to design and develop an AsLOV2-based photo-switch containing the BH3 domain 
of a pro-apoptotic protein that could be used to initiate apoptosis in response to light. The 
Bid/Bcl-xL complex was selected as a model system because of the abundance of structural 
and functional information available on their interaction. 
4.2 Introduction 
Most cancer cells evade apoptosis either by inactivating mutations to p53 or as a result of 
aberrant over-expression of anti-apoptotic proteins, such as Bcl-xL.
132 In either case the 
molecular machinery needed to conduct apoptosis remains intact, but is in a latent state. 
Introducing BH3 peptides or proteins in sufficient numbers to occupy all anti-apoptotic 
proteins in a cell leads to induction of apoptosis. This makes BH3 structure-based mimicry 
an interesting target for inducing apoptosis in multiple carcinomas.133 Widespread research 
has produced BH3-like small molecule inhibitors and peptides including Obatoclax134 and R-
(-)-gossypol (AT-101)135 which mimic the action of the BH3 region and are antagonists of Bcl-
2, Bcl-xL and Mcl-1. They disrupt the hetero-dimerisation of Bcl-2 with pro-apoptotic 
proteins, making them cytotoxic to drug-resistant cancer cells.136 BH3 peptides also have 
high binding affinities to anti-apoptotic proteins such as, the Bak BH3/Bcl-xL complex
105 
(Figure 4.1), however isolated peptides usually show low α-helicity in aqueous solution.138 
Therefore lactam bridges,139 hydrocarbon staples140 or the use of photo-switchable azo-
benzene staples137 are required for helix stabilisation. Non-peptide foldamer scaffolds have 
also been used to mimic the BH3 α-helix side chains. These scaffolds were found to be more 
stable than isolated α-helices, with correspondingly high binding affinities.141  
Currently there are limited protein-based mimics of BH3 proteins, although the downstream 
proteolytic activity of caspase-7 has been regulated using a LOV domain58 (Section 1.4). 
However as we have discussed earlier, that the activation of executioner caspases are 
dependent on the activities of upstream Bcl-2 family of proteins, in this study we investigate 
the replacement of all or parts of the AsLOV2 J-helix with BH3 helices (Table 4.1) capable 
of directly or indirectly inducing apoptosis.138  
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Figure 4.1: Structure of Bcl-xL (grey) in complex with Bak BH3 peptide (green) situated 
within the Bcl-xL cleft (PDB: 1BXL). A) N-terminal view of Bak peptide showing Important 
interacting amino acid residues (labelled in black) with binding pocket of Bcl-xL 
(hydrophobic residues in orange). B) Illustration of residues in the binding site of Bcl-xL 
(hydrophobic residues in orange, positively charged residues in blue, and negatively 
charged residue in red).  
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4.3 Results and Discussion  
4.3.1 Design of Hisact-AsLOV2-V416I-BID 
Previous designs of AsLOV2 photo-switches included whole domain insertion as seen with 
LOV-DHFR.53 However, most photo-switches were primarily based on introducing 
interacting domains after the Jα-helix, as seen with LOV-TAP.52 More recently, sequences 
have been tested at different positions on the J-helix as seen with LOV-IpaA and LOV-
SsrA.151 Here the initial design concept was to replace or substitute key hydrophobic 
residues in the AsLOV2 Jα-helix for residues key to from a BH3 region of a pro-apoptotic 
peptide (Table 4.1). This will allow photo-control of binding to anti-apoptotic proteins by a 
genetically encoded photo-switch. 
Parent protein BH3 Sequence 
Bad WAAQRYGRELRRMSDEFVDSF 
Bak STMGQVGRQLAIIGDDINRRY 
Bax ASTKKLSECLKRIGDELDSNM 
Bid DIIRNIARHLAQVGDSMDRSI 
Bim RPEIWIAQELRRIGDEFNAYY 
Table 4.1: BH3 regions of pro-apoptotic proteins with important binding residues in bold. 
 
BH3 peptides bind Bcl-xL at the hydrophobic binding pocket formed by the BH1, BH2 and 
BH3 regions of Bcl-xL.
105 Although BH3 peptides are present as random coils in solution,138 it 
is in an -helical conformation when bound to Bcl-xL, as seen with the solution structure of 
Bcl-xL/ Bak  complex in Figure 4.1. The N-terminal amino acid residues of BH3 peptides are 
found to interact with residues from the BH1 region of Bcl-xL (E129, A139, V126, L130 and 
F146) and the C-terminal residues with side chains from the BH2 (Y195) and BH3 (F97 and 
R100) regions of Bcl-xL.
105,106,107 Hydrophobic residues of the BH3 peptides, such as residues 
V74, L78, I81 and I85 of Bak are found to stabilise the complex formation. In addition, 
electrostatic interactions also play an important role in complex formation as seen in figure 
4.1, where residues R76, D83 and D84 of Bak BH3 are located close to oppositely charged 
residues (E129, R139 and R100) of Bcl-xL.
105 Mutations of these hydrophobic and charged 
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residues to alanine are known to weaken there binding affinity to Bcl-xL as the dissociation 
constant (KD) of 0.34 ± 0.03 M for Bak peptide (residue G72-R87) was found to significantly 
increase to 270 ± 90 M for L78A mutant and 93 ± 20 M for D84A mutant.105 From this it 
can be understood that the changes made to BH3 sequences when fused to LOV2, have to 
be carefully considered to avoid completely diminishing binding affinity for Bcl-xL. 
The BH3 domain of Bid (Figure 4.2) was used in this study, since previous research in the 
Allemann group137,145 and elsewhere146,147 showed the BH3 peptide derived from Bid to bind 
strongly to Bcl-xL. Bid derived peptides also bind to Mcl-1, allowing activity against both of 
the sub-branches of the anti-apoptotic protein family in contrast to Bad, BH3 peptides or 
mimics such as, the small molecule inhibitor ABT-737 which is ineffective against cells 
expressing Mcl-1.124 Similar to the hydrophobic contacts of the J-helix to the LOV2 β-core 
(Section 3.2.1) the Bid BH3 region includes residues that make important hydrophobic 
interactions with the Bcl-xL binding pocket (Table 4.1). It is important that these key residues 
are retained in the design of the hybrid protein, as well as residues G528, I532, T535, I539, 
D540 and A542 of AsLOV2 which are important for the Jα helix to correctly dock back to the 
LOV core.144  
 
 
 
Figure 4.2: Structure of human pro-apoptotic Bcl-2 protein, Bid (PDB: 2BID). 
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In the preliminary design of LOV2-Bid (Figure 4.3), the Bid BH3 sequence (residue 81-101) is 
aligned with the Jα helix so that D540 and the conserved aspartate of the BH3 sequence 
overlap, to ensure that the hybrid protein remains able to bind to Bcl-xL. Changes in the J 
sequence are favoured over changes of residues from Bid BH3 sequence, as minor changes 
in the Bid BH3 may eliminate its binding affinity to its target. 
 
 
AsLOV2 GTEHVRDAAEREGVMLIKKTAENIDEAAKELPDANLRPEDLWAN 
Bid BH3           DIIRNIARHLAQVGDSMDRSI 
LOV2-Bid GTEHVRDAAEDIGVNIARHLAQVGDSIDRSIPDANLRPEDLWAN 
Figure 4.3: Amino acid sequences of AsLOV2 Jα-helix (blue), Bid BH3-helix (black, residue 81-101) and LOV2-BID 
hybrid Jα-helix. Important residues involved in hydrophobic interactions are shown in bold. As in previous work, 
isoleucine replaces methionine in the LOV2-Bid sequence to avoid oxidation.
 137,145
 
 
 
4.3.2 Bid BH3 and LOV2-Bid peptides 
In order to ensure that the modified AsLOV2-Bid protein (Figure 4.3) bound to Bcl-xL, 
peptides corresponding to the LOV2-Bid J-helix sequence with a cysteine inserted in place 
of an alanine was synthesised by solid phase synthesis. A wild-type Bid BH3 peptide with an 
additional N-terminal cysteine-glycine pair of amino acids was also synthesised as a control, 
to allow comparison of binding affinities. The additional cysteine residues were included to 
allow the attachment of maleimido-fluorophores to the peptides. The peptides were 
purified via reverse phase HPLC then labelled with a fluorescent dye; LOV2-Bid was labelled 
with maleimido-fluoroscein (FAM) and Bid BH3 with maleimido-tetramethylrhodamine 
(TMR). The rhodamine dye was used for the wild type peptide so that it could be used in the 
presence of a green fluorescent FMN cofactor for displacement assays. Following 
fluorescent labelling, the samples were purified once again, freeze-dried and re-dissolved in 
buffer. Sample purity was assessed by analytical HPLC (Figures 4.4 and 4.5) and the masses 
were determined using MALDI-TOF MS (Table 4.2).  
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Figure 4.4: A) Analytical HPLC of Bid-BH3 peptide. B) MALDI-TOF spectrum of Bid-BH3 peptide 
showing m/z 2521.9 ([M+H]
+
). C) Analytical HPLC showing TMR-Bid BH3 peptide. D) MALDI-
TOF spectrum of TMR-Bid BH3 peptide showing m/z 3004.2 ([M+H]
+
). 
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Figure 4.5: A) Analytical HPLC of LOV2-Bid peptide  B) MALDI-TOF spectrum of LOV2-Bid peptide 
showing a peak at m/z 2666.9 ([M+H]
+
) C) Analytical HPLC of FAM-LOV2-Bid peptide D) MALDI-
TOF spectrum of FAM-LOV2-Bid peptide at 3094.9 m/z ([M+H]
+
). 
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Peptide Sequence Theoretical 
mass  
Observed 
mass ([M+H]+) 
Bid BH3 CGDIIRNIARHLAQVGDSIDRSI-NH2 2520.3 2521.9 
TMR-Bid BH3  3003.4 3004.2 
LOV2-Bid DCAEDIGVNIARHLAQVGDSIDRSI-NH2 2665.0 2666.9 
FAM-LOV2-Bid  3093.4 3094.9 
 
Table 4.2: Theoretical mass and observed mass of Bid-BH3 and LOV2-Bid peptides. 
 
4.3.2.1 Fluorescence anisotropy 
Fluorescence anisotropy experiments measure differences in the plane of excited and 
emitted light to determine rates of rotation during the lifetime of excited dye molecules in 
solution. Since larger molecules tumble more slowly in solution than smaller molecules, 
significant changes are observed in the tumbling rates and therefore fluorescence 
anisotropy values of labelled peptides can be obtained when free in solution and when 
bound in complexes with proteins.  
Bcl-xL was expressed using the T7 expression system as described in Section 2.3 followed by 
purification using Ni-NTA affinity chromatography (section 2.3.4). Bound Bcl-xL was eluted in 
a stepwise addition of imidazole in the same buffer up to 500 mM imidazole (Figure 4.6). 
The elution fractions were pooled and dialysed against 50 mM sodium phosphate buffer (pH 
7.5) containing 100 mM sodium chloride and 5 mM β-mercaptoethanol. The purity of the 
resulting 21.4 kDa protein was analysed by SDS-PAGE (Figure 4.7) with two bands visible; 
one at ~ 22 kDa as expected and also one at ~ 44 kDa. Treatment with strong reducing agent 
dithiothreitol (DTT) diminished this band indicating that the latter corresponded to Bcl-xL 
dimer complexes.  
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Figure 4.6: SDS-PAGE gel showing the purification steps for Bcl-xL using Ni-NTA resin. M: 
protein marker, lane 1: cell pellet, lane 2: supernatant after sonication of total cellular 
protein, lane 3: flow-through fraction, lane 4-6: wash fractions (50 mM imidazole) and lane 
7-12: elution fractions (containing 500 mM imidazole) containing Bcl-xL (band at ~22 kDa). 
 
 
 
Figure 4.7: SDS-PAGE gel of the elution fractions of Bcl-xL: Lane 1 and 3: show visible band 
at ~44 kDa (circled). Lane 2 and 4: D1 and D2 after treatment with reducing agent 
dithiothreitol, there is no visible band at ~44 kDa. 
 
Fluorescence anisotropy measurements were carried out to quantify the binding affinities of 
TMR-Bid BH3 and FAM-LOV2-Bid peptides for Bcl-xL protein. Solutions of TMR-Bid BH3 (2.5 
nM) and FAM-LOV2-Bid (5 nM) were titrated with increasing concentrations of Bcl-xL and 
the resulting anisotropy values were plotted against Bcl-xL concentration (Figure 4.8) and 
fitted to a single site Langmuir binding isotherm. 
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Where,      denotes the fraction of bound labelled-ligand, KD is the apparent dissociation 
constant, [P] is the concentration of protein and n is the number of binding sites.  
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Figure 4.8: Normalised fluorescence anisotropy binding curves of: A) TMR-Bid BH3 B) FAM-
LOV2-Bid peptide. 
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TMR-Bid BH3 peptide has an equilibrium dissociation constant (KD) of 27 ± 5.1 nM in good 
agreement with a literature value of KD 23 ± 7
148 and 27.2 ± 0.5153 measured by isothermal 
calorimetry. The FAM-LOV2-Bid peptide gave a KD of 46 ± 2.6 nM, a relatively small decrease 
in affinity (Table 4.3), therefore the LOV2-Bid hybrid Jα retained a strong enough binding 
affinity for Bcl-xL, which allowed the full-length AsLOV2-BID protein to be engineered. 
 
Peptide 
Sequence 
KD (nM) 
TMR-Bid BH3[a] CGDIIRNIARHLAQVGDSIDRSI-NH2 27 ± 5.1 
FAM-LOV2-Bid[b] DCAEDIGVNIARHLAQVGDSIDRSI-NH2 46 ± 2.6 
Table 4.3: Binding to Bcl-xL: [a] 2.5 nM TMR- Bid peptide, [b] 5 nM FAM-LOV2-Bid peptide 
 
A strong binding affinity of LOV2-Bid peptide for Bcl-xL was expected as minimal changes to 
Bid BH3 sequence was made, retaining key hydrophobic (I86, L90 and V93) and charged 
(D95) residues common in BH3 regions of pro-apoptotic proteins (Table 4.1). Only two 
substitutions to Bid BH3 sequence were made in favour of LOV2 (I83 to G and R84 to V), 
residues A91 and D95 are unchanged as they align in position with A536 and D540 of LOV2. 
However as discussed earlier with the Bcl-xL/ Bak complex formation,105 even a single point 
mutation can cause dramatic change in the binding affinity of BH3 peptides. 
 
4.3.3 Hisact-AsLOV2-V416I-Bid  
The plasmid harbouring the gene encoding Hisact-AsLOV2-V416I contains KpnI and HindIII 
restriction sites (Figure 4.9), which were used to excise the wild-type Jα-helix. The doubly 
cut plasmid was purified by agarose gel electrophoresis (Figure 4.10). Annealed 
oligonucleotides with complementary sticky ends encoding the hybrid Jα (AsLOV2-BID) were 
ligated with the purified linearised pNCO plasmid DNA. E. coli XL-1 Blue cells were 
transformed with the resulting DNA and grown overnight at 37 °C on agar plates containing 
ampicillin. Individual colonies were picked and the plasmid was isolated and sequenced until 
the intended gene was isolated.  
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Figure 4.9: pNCO-Hisact-AsLOV2-V416I vector map. KpnI and HindIII sites are circled in blue. 
 
 
 
Figure 4.10: 1 % Agarose gel showing pNCO-Hisact-AsLOV2-V416I. Lane M: 1 kb DNA marker, 
Lane 1: cut with KpnI. Lane 2: cut with HindIII. Lane 3: cut with KpnI then HindIII. Lane 4: cut with 
HindIII then KpnI. 
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E. coli BL21 (DE3) Star cells were transformed with pNCO-Hisact-AsLOV2-V183I-Bid (Hisact-
AsLOV-Bid) and grown to OD600 0.8. Protein production was induced by the addition of 1 
mM IPTG and expression was allowed to continue overnight at 20 °C. Over-expression of the 
protein was verified by SDS-PAGE (Figure 4.11) which was expected to migrate at a speed 
depending on its mass. Following purification by size-exclusion chromatography the 
resulting protein was analysed by MALDI-TOF MS and a mass of 32497.5 (Figure 4.12), 
compared to the theoretical mass of 32687.3 was established. 
 
 
 
Figure 4.11: Purification of Hisact-AsLOV2-Bid: M: protein marker, lane 1: cell lysate, lane 2: Ni-NTA column 
flow-through, lane 3: wash, lane 4-7: eluted fractions and lane 8-9: fractions from preparative Superdex-75 
column. 
 
 
  
 
Figure 4.12: MALDI-TOF Mass spectra of Hisact-AsLOV2-Bid; m/z 32497.5 
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A cysteine and a stop codon were introduced into the Hisact-AsLOV2-Bid sequence 
(PD547C_) at the C-terminal end of Jα-helix (Figure 4.13) by site-directed mutagenesis to 
facilitate labelling with TMR for fluorescence anisotropy binding studies.  
 
 
GTEHVRDAAEDIGVNIARHLAQVGDSIDRSIC 
 
Figure 4.13: Sequence of the J-helix of Hisact-AsLOV2-V416I-Bid-Cys (Hisact-asLOV2-Bid-cys). 
 
Unbound TMR gives a maximum absorption at 540 nm and once bound to protein a 
bathochromic shift to 551 nm is observed (Figure 4.14). An approximate extinction co-
efficient of 91,000 M-1cm-1 at 551 nm (according to manufacturer’s instructions: Chemodex 
ltd customized molecules) was used to estimate the concentration of labelled protein. 
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Figure 4.14: UV/Vis spectra of free TMR (purple) and Hisact-AsLOV2-V416I-Bid-Cys(TMR) in 
dark (black) and light state (green). 
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4.3.3.1 Fluorescence anisotropy 
Fluorescent Hisact-AsLOV2-V416I-Bid-Cys(TMR) allowed the binding of the full length 
photoswitch hybrid to Bcl-xL to be examined by fluorescence anisotropy. Bcl-xL was titrated 
into a Hisact-AsLOV2-V416I-Bid-Cys(TMR) solution (10 nM) and the anisotropy was 
recorded. The results were fitted to a single site Langmuir binding isotherm (Figure 4.15) 
using the average of 3 sets of readings.  
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Figure 4.15: Normalised fluorescence anisotropy curves of Hisact-AsLOV2-V416I-Bid-
Cys(TMR) in the presence of increasing concentrations of Bcl-xL: dark state (red) and light 
state (green). 
 
The expected result was that there would be no significant binding at the dark state, 
however Hisact-AsLOV2-V416I-Bid-Cys(TMR) bound to Bcl-xL with a KD = 699 ± 65 nM in the 
dark and 266 ± 68 nM in the light state (Table 4.4). The protein bound far less effectively 
than the LOV2-Bid peptide (KD = 46 ± 2.6 nM), which is less hindered and the BH3 domain is 
free to move in solution than when attached to a protein complex. It is imperative to note 
that in the cell, Bid protein is naturally cleaved to t-Bid to allow the BH3 domain binding 
accessibility to its partner.98 
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Protein KD (Dark state) KD (Light State) 
Hisact-AsLOV2-V416I-Bid-Cys(TMR) 699 ± 65 nM 266 ± 68 nM 
Table 4.4: Dissociation constants for binding of Hisact-AsLOV2-V416I-Bid-Cys(TMR) to Bcl-xL. 
 
In comparison to the KD reported in the literature, for t-Bid binding to Bcl-xL (200 ± 20 nM) 
using Fluorescence correlation spectroscopy (FCCS, Bcl-xL was labelled which fluorescent 
dye),147 the KD determined in this investigation (266 ± 68 nM) is in strong agreement. 
Although, this is promising in terms of binding susceptibility with our preliminary LOV2-Bid 
hybrid design, it failed to show a switching on/ off mechanism clearly sought after in this 
project.   
The lack of switching can be correlated to several factors affecting the protein conformation 
and preventing the J-helix from docking properly back to the hydrophobic LOV core, 
therefore allowing the Bcl-xL to effectively bind in dark adapted state. Firstly, the N-terminal 
fusion of hisactophilin, which was previously found to have an effect on the protein 
photoswitching (section 3) and possibly the secondary structure, may have sterically 
hindered photoswitching in addition to the changes made to the J-helix. An additional 
factor could be disruption of the re-docking process caused by the TAMRA dye attached to 
the C-terminus of JFinally it may be that the overall design of the hybrid helix causes 
steric clashes with residues on the hydrophobic surface of LOV2, therefore always remaining 
partially undocked. In order to improve the LOV2-Bid photoswitch, changes were made to 
the Hisact-AsLOV2-V416I-Bid and finally new designs were incorporated and compared 
(outlined in section 4.3.4). 
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4.3.4 Improving the AsLOV2-Bid photoswitch 
4.3.4.1 Cloning AsLOV2-Bid1 
In order to more conveniently isolate the AsLOV2-Bid1 from the hisactophilin domain, NdeI 
and BamHI restriction sites were incorporated at the start and end of the AsLOV-Bid 
sequence via site-directed mutagenesis and then confirmed by sequencing. The gene 
encoding LOV2-Bid (474 bp) was then cut at these sites (Figure 4.16) and the resulting 
sticky-ends were ligated to multiple cloning site of pET28a (previously containing a 2.1 kbp 
calpain gene) singly and doubly cut using the same restriction enzymes and purified by the 
same procedure as Hisact-AsLOV2-V416I-Bid (Figure 4.17). The resulting DNA was used to 
transform super-competent E. coli XL1-Blue cells and incubated overnight on an agar plate 
containing kanamycin. Overnight cultures were inoculated with single colonies from the 
plate, harvested and DNA extracted until a digestion test was performed in order to 
determine whether the insert had been ligated into the vector (Figure 4.18). The pET28a 
vector does not contain a KpnI restriction site whereas the AsLOV2-BID sequence (LDG-TEH) 
does, between the LOV core and the J-helix As a result, samples that cut with KpnI (5.4 
kbp vector plus 474 bp insert) were sequenced to confirm the identity of the desired 
plasmid containing a gene encoding A. sativa Phot1-LOV2-V183I (residue V183 is V416 in full 
length protein containing hisactophilin) with an N-terminal hexa-histidine tag for affinity 
purification (AsLOV2-Bid1, all AsLOV2-Bid proteins described from here onwards 
incorporate the V183I mutation to stabilise their light-state). 
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Figure 4.16: 2 % Agarose gel showing pNCO-Hisact-AsLOV2-Bid (858 bp) and AsLOV2-Bid1 
(474 bp). Lane M: 100 bp DNA marker. Lane 1: uncut (4259 bp). Lane 2-3: cut with NdeI. 
Lane 4: cut with BamHI. Lane 5-7: cut with both NdeI and BamHI. 
 
 
 
Figure 4.17: 1.5 % Agarose gel showing pET28a vector (5.37 kbp). Lane M: 1 kb DNA 
marker.  Lane 1: uncut. Lane 2: cut with BamHI. Lane 3: cut with NdeI. Lane 4: cut with 
both NdeI and BamHI. 
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Figure 4.18: Digestion test: 1 % agarose gel of pET28a-AsLOV2-Bid1 (~5.85 kbp). M: 1 kb 
DNA marker. Lane 1: Uncut. Lane 2: cut with KpnI. 
 
4.3.5 Design of AsLOV2-Bid2-4 
Previous studies by Lungu et al. made conservative changes to the AsLOV2 J-helix, varying 
at a maximum of seven residues151 in order not to disturb photo-switching. In contrast, in 
this investigation the AsLOV2-Bid1 was designed for effective BH3 mimicry where extensive 
changes in the Jα-helix were made by replacement of residues with hydrophobic side-chains 
from the four separate turns of Bid BH3 (Table 4.14). Inspired by the strategy of Lungu et al. 
who tried embedding their peptide sequence at different positions of equivalent helical 
register within the Jα-helix, in order to optimise the dynamic range of their interaction,151 
here a series of AsLOV2-Bid proteins were designed where the Bid BH3 is steadily displaced 
towards the end of the J (Figure 4.19). This was designed to create a series of compromises 
between dark state caging (of the BH3 residues required for protein-protein interaction) and 
light state steric accessibility. 
Residues I532, A536 and I539 of LOV2 are located along the three consecutive turns of the 
Jα-helix that face the hydrophobic LOV2 core (Figure 4.20); these residues have been 
retained in all 4 designs. Residue D540 of LOV2 makes an important electrostatic interaction 
to the hydrophobic core18 and was therefore retained in the AsLOV2-Bid2 and AsLOV2-Bid3 
sequences. In AsLOV2-Bid4 D540 aligns with residue D81 of Bid BH3 helix. Residues A536, 
M               1 2 
kbp 
3 
2 
1.5 
1 
0.5 
6 
 5 
 4 
 
Chapter 4: Genetically Engineered AsLOV2 for Regulating Apoptosis 
 
 
104 
A542 and E545 are highly conserved in LOV domains. Where possible, the fusion designs 
retained these residues but were otherwise constructed so that the key hydrophobic 
interactions of one helix were replaced with those of another to retain the hydrophobic 
stripe that docks the J-helix. Residues I86, L90, V93 and M97 occupy these positions in Bid 
and are vital for interactions with pro-survival proteins.153 Residue I86 is overlapped with Jα-
helix in AsLOV2-Bid1-4, to prevent dark state binding through ‘caging’.51,57 All 25 residues on 
the Jα-helix of LOV2 are identical in AsLOV2-Bid5; the Bid BH3 residues overhang from the 
end of the Jα-helix with only the proximity of the LOV domain to sterically constrain their 
accessibility. 
 
AsLOV2 GTEHVRDAAEREGVMLIKKTAENIDEAAKELPDANLRPEDLWAN 
Bid BH3           DIIRNIARHLAQVGDSMDRSI 
LOV2-Bid1 GTEHVRDAAEDIGVNIARHLAQVGDSIDRSIPDANLRPEDLWAN 
LOV2-Bid2 GTEHVRDAAEREGVMLIKDIARNIDRALAEVGDSIDRSI 
LOV2-Bid3 GTEHVRDAAEREGVMLIKKTADIIDNAARELAQVGDSIDRSI 
LOV2-Bid4 GTEHVRDAAEREGVMLIKKTAENIDIARNIARHLAQVGDSIDRSI 
LOV2-Bid5 GTEHVRDAAEREGVMLIKKTAENIDEAAKELDIIRNIARHLAQVGDSIDRSI 
Figure 4.19: Amino acid sequences of AsLOV2 Jα-helix (blue), Bid BH3-helix (black) and AsLOV2-Bid1-5 hybrid 
Jα-helices. Important residues involved in hydrophobic interactions are shown in bold. 
 
 
 
Figure 4.20: Helical wheel projection of J helix showing the residues associated with 
hydrophobic and polar face. 
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4.3.5.1 Construction of AsLOV2-Bid2-4 
The pET28a plasmid harbouring the gene encoding AsLOV2-Bid1 retains the KpnI and HindIII 
restriction sites used to insert the original Bid sequence and these were used once again to 
excise the AsLOV2-Bid1 Jα-helix (Figure 4.21) in order to insert annealed oligonucleotides 
(Figure 4.22) encoding further the hybrid Jα sequences (AsLOV2-BID2-4, multiple strategies 
aimed at producing an insert to create DNA encoding AsLOV2-Bid5 proved unsuccessful). 
The AsLOV2-Bid1 J-helix is 44 base pairs (bp) and therefore cannot be seen on the agarose 
gel (Figure 4.21: lane 5), however single digests using both enzymes indicate that both 
enzymes cut appropriately (Figure 4.21: lane 2 and 3).  A digestion test was performed using 
KpnI as done with AsLOV2-Bid1, in order to test whether the insert had been ligated into the 
vector (Figure 4.23-4.25), as a result positive clones were also verified by DNA sequencing.  
 
 
 
Figure 4.21: 1 % Agarose gel showing pET28a-AsLOV2-Bid1 (~5.85 kbp). Lane M: 250 bp 
DNA marker. Lane 1: uncut. Lane 2: cut with KpnI. Lane 3: cut with HindIII. Lane 4: uncut. 
Lane 5:  cut with both KpnI and HindIII. 
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Figure 4.22: 2 % Agarose gel showing pET28a-AsLOV2-Bid2-4 annealed oligonucleotides: 
lane M: 100 bp DNA marker, lane 1: AsLOV2-Bid2, lane 2: AsLOV2-Bid3, lane 3: AsLOV2-
Bid4. 
 
 
 
Figure 4.23: Digestion test: 1 % agarose gel of pET28a-AsLOV2-Bid2 (~5.85 kbp). M: 1 kb 
DNA marker. Lane 1: uncut. Lane 2: cut with KpnI. 
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Figure 4.24: Digestion test: 1.5 % agarose gel of pET28a-AsLOV2-Bid3 (~5.85 kbp). M: 1 kb 
DNA marker. Lane 1: uncut. Lane 2: cut with KpnI. 
 
 
 
Figure 4.25: Digestion test: 1.5 % agarose gel of pET28a-AsLOV2-Bid4 (~5.85 kbp). M: 1 kb 
DNA marker. Lane 1: uncut. Lane 2: cut with KpnI. 
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4.3.6 Expression and purification of AsLOV2-Bid1-4 
Expression and purification of all proteins was achieved as previously stated for wild-type 
AsLOV2. AsLOV2-Bid1-4 over-expressed after induction (Figures: 4.26 and 4.28) using IPTG. 
The cells were harvested and lysed using an ultrasonicator (3 seconds on and 5 seconds off 
for 6 minutes), the resulting lysate was centrifuged and the lysate and pellet were analysed 
by SDS-PAGE. All the proteins were present in the supernatant of the cell lysate, additionally 
AsLOV2-Bid1 and AsLOV2-Bid2 contained large amounts of protein in the debris pellet 
(Figures: 4.27 and 4.29). Ni-NTA affinity chromatography was carried out to purify the 
proteins (Figures: 4.27, 4.29 and 4.30). Figures: 4.29 and 4.30 both show that eluted 
fractions for AsLOV2-Bid2-4 are almost pure, however the SDS-PAGE for AsLOV2-Bid1 
showed several other bands in the eluted fraction (Figure 4.27), and therefore required 
further purification. 
 
 
Figure 4.26: SDS-PAGE analysis of crude cells of: AsLOV2-Bid1 before induction (lane 1) and 
after induction (lane 2). 
 
 
 
Figure 4.27: Purification of AsLOV2-Bid1. M: protein marker, lane 1: cell lysate, lane 2: cell 
pellet, lane 3: Ni-NTA column flow-through, lane 4-6: wash and lane 7: eluted fraction.  
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Figure 4.28: SDS-PAGE analysis of crude cells of: AsLOV2-Bid2 before induction (lane 1) and after 
induction (lane 2), AsLOV2-Bid3 before induction (lane 3) and after induction (lane 4), and 
AsLOV2-Bid4 before induction (lane 5) and after induction (lane 6). M: protein marker. 
 
 
Figure 4.29: Purification of AsLOV2-Bid2: M: protein marker, lane 1: cell lysate, lane 2: cell 
pellet, lane 3: Ni-NTA column flow-through, lane 4-5: wash, lane 6-8: eluted fractions. 
 
 
 
 
Figure 4.30: Purification of AsLOV2-Bid3: M: protein marker, Lane 1: cell lysate, lane 2: cell 
pellet, lane 3: Ni-NTA column flow-through, lane 4-5: wash, lane 6-7: eluted fractions. 
Purification of AsLOVBid4: lane 8: cell lysate, lane 9: cell pellet, lane 10: Ni-NTA column 
flow-through, lane 11: wash, and lane 12-13: eluted fractions.  
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AsLOV2-Bid1-4 were further purified to remove impurities by size-exclusion 
chromatography (Figure: 4.31) and the masses were determined by ESI-TOF MS (Figures: 
4.33-4.36). SDS-PAGE analysis of eluted fractions from preparative Superdex-200 column, 
show single bands for AsLOV2-Bid1-4 at the approximately the correct protein mass (Figure: 
4.32). Molecular masses of proteins were calculated from their ESI mass spectra (Tables: 
4.5-4.8), where AsLOV2-Bid2 (including FMN at 456.34) has the lowest calculated mass at 
20438 and AsLOV2-Bid4 (including FMN at 456.34) obtains the highest at 20940. All four 
observed protein masses deviate from the theoretical masses (including FMN at 456.34) by 
less than 0.5 %. 
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Figure 4.31: Size-exclusion chromatograms of AsLOV2-Bid1 (black), AsLOV2-Bid2 (red), 
AsLOV2-Bid3 (blue) and AsLOV2-Bid4 (green) run on an analytical Superdex-200 column. 
Smaller peaks are due to impurities that are referred to in text. 
 
   
Figure 4.32: SDS-PAGE analysis of fractions from size-exclusion chromatography 
purification of AsLOV2-Bid1-4 using preparative Superdex-200 column: Lane 1: AsLOV2-
Bid1, Lane 2: AsLOV2-Bid2, Lane 3: AsLOV2-Bid 3, and Lane 4: AsLOV2-Bid4. 
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Figure 4.33: ESI-TOF Mass spectrum of AsLOV2-Bid1. Illustrating the net charges in bold. 
 
m/z net charge Mass 
 
Mass 
1725.5255 12 20694.306 Calculated 20938.856 
1914.2006 11 21045.2066 Theoretical 20812.569 
2103.3625 10 21023.625 Difference 126.287 
2334.1868 9 20998.6812 %  Difference 0.60 
2617.5576 8 20932.4608 
  
Table 4.5: ESI-TOF MS data for AsLOV2-Bid1. 
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Figure 4.34: ESI-TOF mass spectrum of AsLOV2-Bid2. Illustrating the net charges in bold. 
 
m/z net charge Mass 
 
Mass 
372.27 55 20419.85 Calculated 20438.458 
503.34 41 20595.94 Theoretical 20523.535 
644.51 32 20592.32 Difference 85.077 
680.52 30 20385.6 %  Difference 0.41 
727.48 28 20341.44 
  
781.6 26 20295.6 
  
Table 4.6: ESI-TOF MS data of AsLOV2-Bid2. 
 
+30 
+32 
+41 
+55 
+28 
+26 
Chapter 4: Genetically Engineered AsLOV2 for Regulating Apoptosis 
 
 
113 
 
 
 
Figure 4.35: ESI-TOF mass spectrum of AsLOV2-Bid3. Illustrating the net charges in bold. 
 
m/z net charge Mass 
 
Mass 
347.92 60 20815.2 Calculated 20489.27 
448.84 45 20152.8 Theoretical 20523.55 
506.81 40 20232.4 Difference 34.2825 
590.8 35 20643 %  Difference 0.167 
648.76 32 20728.32 
  
706.72 29 20465.88 
  
790.71 26 20532.46 
  
848.67 24 20344.08 
  
Table 4.7: ESI-TOF MS data of AsLOV2-Bid3. 
+60 
+45 
+40 
+35 
+32 
+29 
+26 
+24 
Chapter 4: Genetically Engineered AsLOV2 for Regulating Apoptosis 
 
 
114 
 
 
 
 
 
Figure 4.36: ESI-TOF mass spectrum of AsLOV2-Bid4. Illustrating the net charges in bold. 
 
m/z net charge Mass 
 
Mass 
1731.94 12 20771.28 Calculated 20940.89 
1887.47 11 20751.17 Theoretical 20928.75 
2108.14 10 21071.4 Difference 12.137 
2353.19 9 21169.71 % Difference 0.058 
Table 4.8: ESI-TOF MS data of AsLOV2-Bid4. 
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4.3.7 Spectroscopic analysis of AsLOV2-V416I-Bid1-4 
AsLOV2-V183I-Bid1-4 (AsLOV2-Bid1-4) produced UV/Vis absorption maxima at 447 nm and 
isosbestic points at 330 nm, 380 nm and 407 nm as observed with the spectra of the parent 
protein. The half-lives (t1/2) of cysteinyl-FMN adducts were determined using the absorption 
at 447 nm (Table 4.9) and the difference in half-life times of Hisact-AsLOV2-V416I-Bid (8.85 
± 0.10 min) and AsLOV2-Bid1 (10.4 ± 0.05 min), indicates that the presence of the N-
terminal hisactophilin has an effect on the FMN-adduct relaxation, a trend also observed for 
Hisact-AsLOV2-V416I and AsLOV2-V416I. However, the light states of AsLOV2-Bid2-4 were 
found to relax at very similar rates (t1/2 = 7-9 min) to the parent proteins (Hisact-AsLOV2-
V416I-Bid) featuring V416I (V183I) mutation. 
 
Protein Half-life (min) 
 
UV/Vis CD 
Hisact-AsLOV2 0.99 ± 0.05 0.66 ± 0.02 
Hisact-AsLOV2-V416I 7.69 ± 0.10 11.1 ± 2.70 
Hisact-AsLOV2-V416I-Bid 8.85 ± 0.10 11.3 ± 3.23 
AsLOV2-V183I 11.4 ± 0.12 13.0 ± 2.80 
AsLOV2-V183I-Bid1 10.4 ± 0.05 12.3 ± 2.40 
AsLOV2-V183I-Bid2 8.60 ± 0.05 10.3 ± 3.05 
AsLOV2-V183I-Bid3 7.50 ± 0.17 7.50 ± 1.00 
AsLOV2-V183I-Bid4 7.80 ± 0.75 7.80 ± 0.80 
Table 4.9: Half-lives of hybrid proteins at 20 °C comparing by UV/Vis observation of adduct 
reversion at 447 nm and mean residue ellipticity at 222 nm. 
 
Complementary measurements using CD spectroscopy at 222 nm were conducted, which 
reports on the photo adduct reversion and protein secondary structural rearrangements 
(Figure 4.37). The CD half-life values were compared to UV/Vis half-life values (Table 4.9) 
revealing that AsLOV-Bid3 and AsLOV-Bid4 relaxed at the same rate for both UV/Vis and CD 
average measurements whereas, both AsLOV-Bid1 and AsLOV-Bid2 cofactor adduct 
reversions (average values) were faster by approximately 2 minutes. However, they all fall 
within error so no overall change between the UV/Vis and CD half-lives can be assumed. 
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Figure 4.37: Mean residue ellipticity at 222 nm for relaxing light state AsLOV2-
V183I (black), Hisact-AsLOV-Bid1 (purple), AsLOV-Bid1 (red) AsLOV-Bid2 (green) 
AsLOV-Bid3 (blue) and AsLOV-Bid4 (yellow). 
 
Circular dichroism spectroscopy was used to analyse the proteins in the far-UV region, 
where negative signals at 208 nm and 222 nm indicated primarily -helical structures, as 
expected (Figure 3.38). However, once irradiated a decrease in the negative signal can be 
seen for all proteins, except AsLOV2-Bid2. The percentage-change in switching between the 
dark and the light state was calculated from the mean residue ellipticity (MRE) at 222 nm. A 
change in MRE at 222 nm was expected, as a result of the undocking and/or unfolding124 of 
the Jα-helix (Section 3.3.4) as seen with the AsLOV2-V416I. As expected, AsLOV2-Bid4 
resulted in the largest change in α-helical content with 28.4 % change (Table 4.10) as its J-
helix has the least number of residue changes, as well as being longer than AsLOV2-Bid1-3 
(Figure 4.19). However, the magnitude of the change is 10 % less than for the wild-type 
LOV2 domain (Table 4.10), indicating that either the hybrid Jα-helices may not completely 
dock or undock from the LOV core, or that they are not fully helical in the docked state. 
AsLOV2-Bid2 shows less than 2 % change in ellipticity at 222 nm, suggesting that the photo-
activation has been disturbed in this design. Once again, interpretation of this data is 
complicated by the uncertainty of the structure in both extended and undocked helices. 
While BH3 peptides are typically unstructured in the absence of constraints,137 the most 
Chapter 4: Genetically Engineered AsLOV2 for Regulating Apoptosis 
 
 
117 
likely interpretation of the data overall is that the presence of residues from the Jα-helix 
have a helix-nucleating effect. 
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Figure 4.38: CD measurements showing proteins in the dark (black) and light (green) 
states: A) AsLOV2-Bid1 B) AsLOV2-Bid2 C) AsLOV2-Bid3 D) AsLOV2-Bid4. 
 
 
Protein % Change in []r at 222 nm 
Hisact-AsLOV2 [a] 39.2 
Hisact-AsLOV2-V416I [a] 38.1 
Hisact-AsLOV2-V416I-Bid1 [a] 7.96 
AsLOV2-V416I [b] 38.5 
AsLOV2- V416I-Bid1 [c] 7.30 
AsLOV2- V416I-Bid2 [d] 1.90 
AsLOV2- V416I-Bid3 [e] 18.9 
AsLOV2- V416I-Bid4 [f] 28.4 
Table 4.10: Length of Jα and Jα hybrid helices according to the number of amino 
acid residues: [a] 288 [b] 160 [c] 178 [d] 173 [e] 176 [f] 179. 
 
Melting curves obtained from CD measurements at increasing temperatures reported 
AsLOV2-Bid1 to be the most stable variant with a melting point at 54 °C and AsLOV2-Bid2-4 
to be the less stable since unfolding starts as low as 40 °C (Figure 4.39). A possible 
explanation for this may be that, as the helix is extended further in length the protein 
becomes structured less like the parent protein, therefore its thermal stability decreases. 
AsLOV2-Bid1 is exactly the same length as AsLOV2-V416I, therefore its melting point is the 
same, (54 °C; Section 3.3.4.2). 
D 
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Figure 4.39: Normalised plots of mean residue ellipticity 222 nm of AsLOV2-Bid1 (red) 
AsLOV2-Bid2 (green) AsLOV2-Bid3 (blue) and AsLOV2-Bid4 (yellow) over a range of 
temperatures (4-96 °C). 
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4.3.8 Fluorescence anisotropy measurements of AsLOV-Bid1-4 
Initial fluorescent anisotropy measurements carried out using Hisact-AsLOV2-Bid-
PD547C(TMR) (Hisact-AsLOV2-Bid) gave KD values of less than 1 M in the light and dark 
state (Section 4.3.3.1) although, it was expected that caging of the helix in the absence of 
light would not allow binding to Bcl-xL in the dark state. CD time-course measurements 
showed a low (7.96 %) change in MRE at 222 nm in comparison to AsLOV2-V183I (Figure: 
4.37, Table: 4.10), indicating that the hybrid-J may not completely dock to the LOV core in 
the dark state, as a result of the steric hindrance caused by the TMR dye at the C-terminal 
end of Jα-hybrid. To avoid any such factors affecting the photo-switching mechanism of the 
AsLOV2-Bid proteins, the Bcl-xL protein was labelled instead. A cysteine residue was 
incorporated at the N-terminus of Bcl-xL by site-directed mutagenesis at the second amino 
acid (S2C) from the methionine start codon, this was confirmed by sequencing (Appendix H). 
Native Bcl-xL contains a cysteine residue whose side chain is buried in the folded protein, 
whereas the mutational cysteine (S2C) is far from the binding site and is located on the 
exterior of the protein (Figure: 4.40) allowing easy access for TMR to react with the cysteine 
thiolate. 
 
 
Figure 4.40: Structure of Bcl-xL (gray) and interacting Bak peptide (green): showing internal 
native cysteine (orange) and solvent exposed cysteine (S2C) inserted via mutation (yellow). 
A) Front view and B) side view. (PDB: 1BXL). 
A B 
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Bcl-xL-S2C was expressed and purified (Figure 4.41) using the same procedure as used for 
wild-type protein. The labelling procedure for Bcl-xL was carried out as previously described 
for Hiscat-AsLOV2-V416I-Bid and an approximate extinction co-efficient of 91,000 M-1cm-1 at 
551 nm (Section 4.3.3) was used to estimate the concentration of labelled protein. Bcl-xL-
TMR conjugation was quantified by comparing the labelled Bcl-xL-S2C(TMR) concentration 
with the total Bcl-xL-S2C concentration before reaction (extinction co-efficient of 41,940 M
-
1cm-1 at 280 nm, Figure 4.42). Protein samples that were 75 % labelled were prepared for 
fluorescent anisotropy measurements. Prior to measuring protein concentrations, excess 
TMR dye was removed by size-exclusion chromatography (Figure 4.43) eluting in 50 mM 
sodium phosphate buffer containing 100 mM sodium chloride and 5 mM β-
mercaptoethanol (SEC buffer B). 
 
 
Figure 4.41: 12 % SDS-PAGE gel of Bcl-xL-S2C purification. M: protein marker, lane 1: cell pellet, 
lane 2: cell lysate, lane 3: Ni-NTA column flow-through, lane 4-7: wash, lane 8-13: eluted 
fractions and lane 14: TMR labelled Bcl-xL-S2C. 
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Figure 4.42: UV/Vis absorption spectra of Bcl-xL-S2C(TMR). 
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Figure 4.43: Size-exclusion chromatogram of Bcl-xL-S2C(TMR) (190 mL) and excess TMR 
(after 290 ml). 
 
Fluorescence anisotropy measurements between the AsLOV2-Bid domains and TMR-
labelled Bcl-xL were carried out at a reduced temperature (15 
oC) to minimise reversion to 
dark state during the recording of individual data points. Titrations were repeated at least in 
triplicate and the data for both dark and light states were normalised and plotted on one 
graph to allow accurate comparison (Figure 4.44).  
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Bcl-xL is specific to BH3 sequences only,
103-107,153 so no binding should be observed with the 
LOV2 wild-type. No change in anisotropy was evident with wild-type AsLOV2 protein in 
either it’s dark or light states (Figure 4.44A). 
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Figure 4.44: Normalised fluorescent anisotropy binding curves of AsLOV-Bid proteins to 
Bcl-xL-S2C(TMR) in the dark (green or no line) and light (red) states. A) AsLOV2 B) AsLOV-
Bid1 C) AsLOV-Bid2 D) AsLOV-Bid3 E) AsLOV-Bid4. 
 
In contrast, light state samples of each of the AsLOV2-Bid hybrids caused significant 
increases in anisotropy suggestive of binding to Bcl-xL with apparent dissociation constants 
between 80 and 300 nM, higher than those observed for the LOV2-Bid peptide. The 
dissociation constants decreased slightly as the length of hybrid Jα-helix increased (Table 
4.11) in agreement with the prediction that these sequences would possess less sterically 
hindered BH3 regions in the photo-activated state and would therefore possess a stronger 
binding affinity for Bcl-xL. AsLOV2-Bid1, AsLOV2-Bid3 and AsLOV2-Bid4 show no binding to 
Bcl-xL in the dark adapted form (Figure 4.44 and Table 4.11). Following the theory adopted 
and proved by Strickland et al.,51,57 sequence overlap with Jα-helix, may have resulted in 
part of the Bid BH3 sequence adopting a sterically blocked or ‘caged’ conformation in the 
D 
E 
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dark state, thereby restricting binding to Bcl-xL. As discussed earlier, residue I86 is vital for 
binding to Bcl-xL,
153 and in AsLOV2-Bid1-4 it is overlapped with Jα-helix to prevent dark state 
binding. 
However, increased light-state affinity correlated with dark-state affinity for AsLOV-Bid2, 
reporting binding in both light (271 nM) and dark (998 nM) states. The CD data for AsLOV2-
Bid2, reporting less than 2 % change in protein secondary structural rearrangement, is in 
agreement with the binding data and implicates that the hybrid J-helix does not properly 
dock to the LOV core, in the dark state. Formation and stability of alpha-helices are 
dependent on intrinsic heIix-forming propensities of adjacent amino acids.6,169,170 Residues 
with charged side chains are known to affect helix formation through helix-propensity and 
coloumbic forces.169,170 It is anticipated that replacement acidic residues, glutamate 537 and 
541 (negatively charged in physiological pH) with positively charged arginine (E537R, 
E541R), and basic lysine 543 with acidic aspartate (K543D), may have an effect on helix 
formation and therefore be partially undocked, allowing the Bid BH3 sequence to interact 
with Bcl-xL in the light and dark state. 
 
Protein KD (Dark state) KD (Light State) 
AsLOV-Bid1 N/A 216 ± 16.3 nM 
AsLOV-Bid2 998 ± 111 nM 271 ± 13.7 nM 
AsLOV-Bid3 N/A 167 ± 2.5 nM 
AsLOV-Bid4 N/A 89 ± 4.9 nM 
Table 4.11: Dissociation constants for binding of hybrid AsLOV-Bid proteins to TMR-Bcl-xL (10 nM). 
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4.4 Conclusion  
Four photo-responsive Avena sativa LOV2 Jα fusions have been designed and synthesised 
based on the pro-apoptotic BH3 domain of Bid. A LOV2-Bid BH3 peptide was tested first in 
order to ensure the modifications made to create the AsLOV2-Bid1 sequence did not abolish 
affinity to Bcl-xL. As expected, the peptide showed strong binding affinity for Bcl-xL with a 
relatively small increase in dissociation constant compared to the wild-type Bid BH3 
sequence. Using the same hybrid design as the LOV2-Bid peptide, Hisact-LOV-V416I-Bid was 
engineered successfully using recombinant DNA technology and the protein expressed and 
purified using the same procedure as wild-type AsLOV2. UV/Vis and CD derived half-life 
values were within the same range calculated for the parent protein (Hisact-AsLOV2-V416I), 
however the changes in the MRE at 222 nm using CD spectroscopy reported that the protein 
showed minimal changes in its secondary structure compared to Hisact-AsLOV2-V416I. This 
tied in with the fluorescence anisotropy data which revealed binding with Bcl-xL in both the 
dark and light adapted states, thus indicating that the hybrid Jα may be partially undocked 
as a result of steric hindrance between modified residues in the Jα, the hisactophilin or the 
TMR dye attached to the Jα C-terminus. Although Hisact-AsLOV2-Bid demonstrated 
significant binding affinity to Bcl-xL, it failed to act as an optogenetics switch.   
To further improve the AsLOV2-Bid hybrid, removal of the hisactophilin domain and varying 
the point of fusion between the LOV J-helix and the Bid BH3 sequence generated 
derivatives with a range of switching properties. UV/Vis and CD characterisation of AsLOV2-
Bid1-4 allowed comparison of their rates of cysteinyl-FMN adduct reversion and protein 
structural rearrangements. AsLOV2-Bid2 showed a diminutive change in α-helical content 
between the dark and light states, with AsLOV2-Bid4 reporting the largest change. These 
data broadly correlated with the fluorescence anisotropy data (in this case Bcl-xL was 
labelled instead of AsLOV2-Bid proteins), where AsLOV-Bid2 showed significant binding to 
Bcl-xL protein in the light and dark states and AsLOV2-Bid4 gave the strongest binding 
affinity to Bcl-xL. No dark state binding was observed with AsLOV2-Bid1, indicating that dark 
state binding of Hisact-AsLOV2-V416I-Bid was as a result to either, the hisactophilin or the 
TMR dye as opposed to modified residues in the Jα.  
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5.1 Introduction 
Following the broadly successful approach for engineering photoreceptors to control 
cellular pathways, as studied so far with the LOV2-Bid hybrid (Chapter 4), we aim to study 
and develop possible fusions using the YtvA photoreceptor (261 amino acids) from Bacillus 
subtilis which has a slow photocycling LOV domain with a half-life of 3600 sec.116 Its longer-
lived light-state is potentially advantageous for creating photo-switchable fusion proteins 
that will allow longer duration for signalling in vivo, in this case to control apoptosis.  
The LOV domain of YtvA is similar to those of plant phototropins (Figure 5.1) and has a high 
sequence homology with LOV2 domains and the Jα linker.45,119 Residue Q123 aligns with 
Q513 of AsLOV2 and has a similar role in forming initial interactions with FMN through 
hydrogen bonding.37,45,115 Residues V29 (A), M111 (H) and Y118 (I) align with AsLOV2 
residues V416, M499 and Y508117,118 (Figure 5.1). 
 
O49003   ---------------- TTLERIEKNFVITDPRLPDNPIIFASDSFLQLTEYSREEILGR  448   O49003_AVESA 
O34627   MASFQSFGIPGQLEVIKKALDHVRVGVVITDPALEDNPIVYVNQGFVQMTGYETEEILGK  60    PHOT_BACSU 
                           
O49003   NCRFLQGPETDRATVRKIRDAIDNQTEVTVQLINYTKSGKKFWNLFHLQPMRDQKGDVQY  508   O49003_AVESA 
O34627   NCRFLQGKHTDPAEVDNIRTALQNKEPVTVQIQNYKKDGTMFWNELNIDPM--EIEDKTY  118   PHOT_BACSU 
          
O49003   FIGVQLDGTEH-----------------------VRD-----------------------  522   O49003_AVESA 
O34627   FVGIQNDITKQKEYEKLLEDSLTEITALSTPIVPIRNGISALPLVGNLTEERFNSIVCTL  178   PHOT_BACSU 
                                 
O49003   ----AAEREGVMLIKKT--AENIDEAAKELP-----------------------------  547   O49003_AVESA 
O34627   TNILSTSKDDYLIIDLSGLAQVNEQTADQIFKLSHLLKLTGTELIITGIKPELAMKMNKL  238   PHOT_BACSU 
              
O49003   DANLRPEDLWA------------  558   O49003_AVESA 
O34627   DANFSSLKTYSNVKDAVKVLPIM  261   PHOT_BACSU 
          
Figure 5.1: ClustalW alignment of AsLOV2 (O49003_AVESA) and YtvA-LOV (PHOT_BACSU), residues that match 
are highlighted in grey. 
 
YtvA-LOV has been reported to be dimeric in solution based on gel filtration experiments.119 
As discussed previously (Section 1.4.5), the crystal structure of the dark-state YtvA-LOV 
domain reveals a head-to-head dimer with the J helix undocked from the core domain 
(Figure 5.2).45 A shorter loop between I and the J in YtvA-LOV may prevent the J from 
folding against the central -sheet, as observed in Avena sativa LOV2 (Figure 5.3).45 The 
exposed hydrophobic face of the -sheet is able to promote dimerisation of the YtvA-LOV. 
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Therefore, it will be ideal to study the hydrophobic surface in greater detail through creating 
point mutations on important hydrophobic amino acids, before any LOV-BH3 fusions are 
designed and implemented. 
 
 
Figure 5.2: Structure of dark state YtvA-LOV showing undocked Jα helices and the key 
residues in the hydrophobic dimer interface (PDB: 2PR5). 
 
 
Figure 5.3 Structure overlay of AsLOV2 (gray) and YtvA-LOV (blue), where the J of AsLOV2 (pink) 
is folded on to the core and the J of YtvA-LOV is open (cyan). (PDB: 2V1B and 2PR5). 
Moglich and Moffat, irradiated YtvA-LOV dark state crystals in order to get a pseudo light-
state structures.45 The results show the Jα-helices do not unfold in the light state, rather a 4-
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5° rotation relative to each dimer was observed. However, to fully acknowledge its 
conformation and that there is no unfolding of the J a light state solution structure is 
indeed required. It is also noted that hydrophobic LOV core ( Sheet) is more extended than 
in AsLOV2,45 thereby possibly promoting dimerisation. However, residue I113 corresponds 
to D501 in AsLOV2, but here forms part of H rather than the loop connecting H to 
Itherefore, limiting the flexibility of the loop and perhaps preventing the J from docking 
to the core and allowing the formation of dimers.  
Residues on the A (V25, V27), B (Y41), H (M111, I113) and I (Y118, V120, I122) strands 
mediate dimer interactions (Figure 5.2). The hydrophobic residue V25 at the start of the A 
strand in YtvA-LOV replaces a polar amino acid denoted as K413 in AsLOV2, and V27 
replaces the less hydrophobic F415 suggesting that these residues may play a role in 
creating the hydrophobic dimer interface (Figure 5.1 and 5.3). These residues were 
therefore selected for mutational studies to provide more information on the driving force 
for dimerisation of YtvA-LOV.  
5.2 Results and Discussion 
5.2.1 YtvA-LOV-STAS and YtvA-LOV modification and characterisation 
The gene encoding YtvA-LOV-STAS (786 bp; Section 1.4.5) was isolated from Bacillus subtilis 
chromosomal DNA using PCR. The YtvA-LOV-STAS gene was cut with NdeI and BamHI 
restriction endonucleases, which were initially incorporated on to the gene by specifically 
designed PCR primers that were used to isolate YtvA-LOV-STAS. A pET19b vector was cut 
also using NdeI and BamHI restriction endonucleases and run on an agarose gel. The 
migration speed of the DNA band corresponded to the calculated size (5717 bp) of the cut 
plasmid (Figure 5.4). The vector sample was purified with the QIAquick PCR purification kit 
using a microcentrifuge, which removed all enzymes and residual buffers. Both the vector 
and insert were ligated using T4 DNA ligase (NEB protocol) and E. coli XL1-blue cells were 
transformed with the ligation mixture. The resulting colonies were picked and the DNA was 
isolated for a digestion test with restriction enzymes NdeI and BamHI, to detect colonies 
whose plasmids contained an insert (Figure 5.5). Ligation of the correct gene was confirmed 
by DNA sequencing. The YtvA-LOV-STAS domain was further modified by insertion of a stop 
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codon after the YtvA-LOV domain via site-directed mutagenesis, removing the STAS domain 
from the translated full length protein (Figure 5.6).  
 
 
Figure 5.4: Agarose gel showing: lane M: DNA marker, lane 1: YtvA-LOV-STAS (~800 bp). pET19b 
vector (5.7 kbp): lane 2: uncut, lane 3: cut with NdeI and lane 4: cut with NdeI and BamHI. 
 
   
Figure 5.5: Agarose gel of digestion tests on ligated pET19b-YtvA-LOV samples using NdeI and 
BamHI:  uncut (lanes 1, 3, 5, 7, 9 11 and 13) and cut (lanes 2, 4, 6, 8, 10, 12 and 14). With visible 
YtvA-LOV-STAS (~800 bp) bands in sample 2 (Lane 4) and sample 5 (Lane 10). 
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Figure 5.6: Diagram representing the cloning steps and modifications on YtvA-LOV-STAS to acquire the single 
YtvA-LOV domain without STAS; NdeI and BamHI sites were incorporated on gene via PCR, which was then 
ligated into the pET19b vector, and stop codons were introduced after the LOV domain by SDM. 
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The proteins were expressed and purified by adapting the procedure of Kay et al.;39 E. coli 
cells harbouring a pET19b plasmid containing the gene encoding YtvA-LOV-STAS (32 kDa) or 
YtvA-LOV (19.6 kDa) over-expressed proteins corresponding to the sizes of the desired 
proteins upon induction at OD600 0.7-0.8, and incubation overnight at 20 °C. The pET19b 
vector includes an N-terminal His-tag which allowed purification by nickel-nitrilotriacetic 
acid (Ni-NTA) affinity chromatography. Fractions were analysed using SDS-PAGE (Figure 5.7 
and 5.8) and followed further purification using size-exclusion chromatography. An m/z ratio 
of 19696 was observed using MALDI-TOF mass spectrometry (Figure 5.9) which 
corresponded reasonably to the theoretical mass of YtvA-LOV at 19623. 
 
 
Figure 5.7: SDS-PAGE analysis of YtvA-LOV-STAS through the stages of purification using affinity 
chromatography. M: protein marker, lane 1: lysate, Lane 2: flow through fraction off the affinity 
column (10 mM imidazole), lane 3 to 5: wash with buffer (40 mM imidazole), lane 6 to 9: elution 
fractions (500 mM imidazole). 
 
 
Figure 5.8: SDS-PAGE analysis of YtvA-LOV through the stages of purification using affinity 
chromatography. M: protein marker, lane 1: lysate, Lane 2: flow through fraction off the affinity 
column (10 mM imidazole), lane 3 to 5: wash with buffer (40 mM imidazole), lane 6 to 9: elution 
fractions (500 mM imidazole). 
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Figure 5.9: MALDI-TOF spectrum of YtvA-LOV. 
 
5.2.2 Spectroscopic characterisation of YtvA-LOV-STAS and YtvA-LOV 
As expected both YtvA proteins showed an absorption maximum at 447 nm with vibronic 
coupling (triplet peak) indicative of association with folded protein and conversion of the 
FMN from light state to dark state45,125 (Figure 5.10). As previously observed for AsLOV2 
(Figure 3.13), the YtvA-LOV domain has 3 isosbestic points at 330 nm, 380 nm and 407 nm 
(Figure 5.10) upon photoswitching.  
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Figure 5.10: UV/ Vis absorption spectra of YtvA-LOV (reading at every 5 min) showing the 
relaxation from light state (red) to dark state (black), the FMN absorption maximum visible 
at 447 nm and three isosbestic points are seen at 330 nm, 380 nm and 407 nm.  
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The half-life of YtvA-LOV-STAS has been determined as 3600 sec by Zoltwoski et al.116 In this 
investigation the half-life of the light state was measured by recovery of absorbance at 447 
nm (20 °C). As expected, YtvA-LOV has a slower recovery rate than the AsLOV2 
domains.118,19,45 It was calculated that YtvA-LOV-STAS has a longer relaxation half-life than 
the smaller YtvA-LOV domain (Figure 5.11, Table 5.1) resulting a difference of 2274 sec (37.9 
min) (Table 5.1).  Moglich and Moffat have determined the half-life of YtvA-STAS at 3880 ± 
20 sec and YtvA-LOV with a faster recovery rate of 2000 ± 400 sec using single crystal 
microspectrophotometry measurements at the FMN absorption maxima.45 A more recent 
study has also revealed that the YtvA-LOV-STAS has a slower photo-recovery than isolated 
YtvA-LOV, 46.1 ± 1.7 min and 42.4 ± 0.3 min.131 This is opposite to the half-life change that 
was observed for phot1 AsLOV2 in the absence Hisact, however structural features for 
autophosphorylation proposed for phot120,62 are different from the direct interaction of the 
STAS domain with the LOV core, thereby perhaps a longer half-life is observed as the STAS is 
likely to compete for the dimerisation surface.119 
 
2D Graph 1
Time (sec)
0 2000 4000 6000 8000 10000
A
b
s
o
rb
a
n
c
e
 a
t 
4
4
7
 n
m
0.0
0.2
0.4
0.6
0.8
1.0
YtvALOV 
YtvA-STAS 
 
Figure 5.11: UV/Vis absorption time-course measurements at 447 nm of YtvA-LOV-STAS 
(black), and YtvA-LOV (red). 
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Protein Half-life (sec) 
YtvA-LOV-STAS 4788 ± 60 
YtvA-LOV 2514 ± 60 
Table 5.1: Half-lives of YtvA-LOV-STAS and YtvA-LOV, listing the average of three 
measurements and their standard deviation. 
 
CD spectroscopy was carried out on purified proteins to assess the change in secondary 
structure upon photo-adduct formation. YtvA-LOV-STAS has a larger -helical content 
(Figure 5.12A) than YtvA-LOV (Figure 5.12B) as the STAS domain contains a helix-turn-helix 
(HTH) motif,44 also observed in previous studies where CD spectroscopy was used for 
secondary structural characterisation.119 Moglich and Moffat observed a 10 % decrease in -
helical content of YtvA-LOV upon switching from dark to light state.131 Although, it is 
complicated to quantitatively evaluate CD spectra, the change in mean residue ellipticity at 
222 nm switching between dark and light states were calculated to be less than 8 % change 
for YtvA-LOV-STAS and 3.8 % change for YtvA-LOV. This is an exceptionally small change in 
comparison to AsLOV2 and implies that the J helix remains relatively ordered in the light 
state, which relates to proceedings in the litrature.45 
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Figure 5.12: Circular dichroism spectra of A) YtvA-LOV-STAS and B) YtvA-LOV in the dark-
state (black) and light state (green). 
 
5.2.3 YtvA-LOV mutants 
Site-directed mutagenesis using Pfu polymerase was performed to generate V27D and 
I113D alterations in YtvA-LOV. Both pET19b-YtvA-LOV-V27D and pET19b-YtvA-LOV-I113D 
were confirmed by sequencing (Appendix E and F). The proteins were expressed in E. coli 
BL21 (DE3) cells (Figure 5.13) using the same conditions as wild-type YtvA-LOV protein. Both 
proteins were purified by affinity chromatography using a Ni-NTA resin and eluted fractions 
were analysed using SDS-PAGE (Figure 5.14).  
 
 
Figure 5.13: SDS-PAGE analysis of the cell lysate of pET19b-YtvA-LOV-V27D (lane 1) pET-19b-
YtvA-LOV-I113D (lane 2).  
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Figure 5.14: SDS-PAGE analysis through the stages of purification using affinity chromatography of YtvA-LOV-
V27D: M: protein marker, lane 1: cell lysate, lane 2: flow through fraction off the affinity column, lane 3: wash 
with buffer, lane 4 and 5: elution fractions. YtvA-LOV-I113D: lane 6: cell lysate, lane 7: flow through fraction off 
the affinity column, lane 8: wash with buffer, lane 9 and 10: elution fractions. 
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5.2.4 Size-exclusion chromatography of YtvA-LOV and mutants 
Size-exclusion chromatography can be used to measure the approximate masses of globular 
proteins under non-denaturing conditions. In this case size-exclusion chromatography was 
used to determine the solution state of YtvA-LOV. A predominantly dimeric form would 
suggest that the adjacent monomer would prevent the Jα from docking on to the β sheet 
and prevent effective use of the domain to mask the Jα.20 To calibrate the elution volume a 
series of standards were injected onto an analytical Superdex-75 size exclusion column 
(Figure 5.15 and Table 5.2). 
 
 
 
Figure 5.15: Protein standards run on a Superdex 75 size-exclusion column and plotted 
using log molecular weight of each protein against the eluted volume. 
 
 
Protein 
Elution 
Volume (mL) 
Log10 
Mass 
Mass (Da) 
BSA 9.2 4.82 66340 
Ovalbumin 11.25 4.64 44000 
Myoglobin 16 4.23 17000 
Vitamin B12 23.75 3.13 1350 
Table 5.2: Proteins standards run on a Superdex-75 size-exclusion column. 
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The molecular masses of each known protein were used to linearly relate the logarithm 
(Log10) of the mass to the elution volume, to derive an equation (y = -0.1229x + 6.0886) to 
estimate molecular masses from elution volumes (Figure 5.16). The elution volume of YtvA-
LOV suggests that the protein exists as a dimer (11.8 mL, calculated mass 44000); this is also 
the case for the YtvA-LOV-V27D mutant which has a calculated mass of exactly two 
monomer units (39200) although the peak is broader and has a pronounced tail. However, a 
small peak (circled in Figure 5.16) was also seen for the YtvA-LOV that suggests some 
monomer may be present in solution. YtvA-LOV-I113D, however gave a calculated mass 
(19800) very close to that expected for a monomer (19600). SDS-PAGE was used confirm 
that the eluted proteins corresponded to YtvA-LOV (Figure 5.17).  
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Figure 5.16: Chromatogram of YtvA-LOV (black) with circle indicating a monomer peak, 
YtvA-LOV-V27D (red) and YtvA-LOV-I113D (blue) run on analytical superdex-75 size-
exclusion column. 
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Protein 
Elution 
Volume (mL) 
 Log10 
 mass 
Calculated 
mass (Da) 
YtvA-LOV[a] 11.77 4.64 43872 
YtvA-LOV[b] 14.15 4.35 22365 
YtvA-LOV-V27D 12.17 4.59 39203 
YtvA-LOV-I113D 14.59 4.30 19746 
Table 5.3: Each maximum peak (protein elution volume) was used to determine the log10 
mass using the equation (y = -0.1229x + 6.0886) from the standard plot (Figure 3.36). YtvA-
LOV has two peaks: [a] peak 1 and [b] peak 2 (blue circle). 
 
 
 
 
Figure 5.17: SDS-PAGE gel of eluted fractions from size-exclusion chromatography to confirm that 
eluted fractions denature to molecules with the same migration speed.  M: protein marker, lane 
1: YtvA-LOV monomer peak, lane 2: YtvA-LOV dimer peak, lane 3: YtvA-LOV-V27D and lane 4: 
YtvA-LOV-I113D. 
 
From this it can be implied that the mutation of uncharged hydrophobic isoleucine 113 to a 
negatively charged aspartate (at physiological pH), may have caused a strong enough 
repulsion (steric clash) with the same residue from the interacting monomer, to prevent the 
formation of dimer (intermolecular contacts) at first instance.  From the dark state crystal 
structure45 (PDB 2PR5, Figure 5.18) it can be seen that I113 is more likely to form initial 
intermolecular contacts as it is located at the outside edge of the -sheet (strand H) as 
opposed to being in the middle (as in the case for V27, Figure 5.18). Whereas, V27 has other 
hydrophobic amino acids (V25, I29, Y41 and M111)45 adjacent (Figure 5.2 and 5.3) and its 
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repulsive force (from the acidic side chain) may not be strong enough to prevent 
dimerisation.  
 
 
 
 
Figure 5.18: Structure of YtvA-LOV showing hydrophobic interface between both monomers: A) V27 (yellow), B) 
V27 and I113 (orange) and C) V27 and I113 (Nitrogen atom in blue and oxygen in red). (PDB 2PR5). 
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5.3 Conclusion 
Producing LOV-Bid hybrids using the slow cycling YtvA-LOV photoreceptor still remains 
unaccomplished, as a result to preliminary investigations on understanding the dimeric 
interface of YtvA-LOV. In agreement with the literature,131 in the absence of the STAS 
domain (YtvA-LOV) the photo-adduct recovery rate was significantly reduced. Circular 
dichroism spectroscopy was used to analyse the proteins in the far-UV region, where 
negative signals at 208 nm and 222 nm indicated primarily -helical structure for YtvA-LOV-
STAS and a mix of both -helical and -sheet was observed for YtvA-LOV, in agreement with 
the literature.119 The lack of change observed in the CD signal at 222 nm between light and 
dark states, implies that the Jα-helices of dimeric YtvA-LOV proteins stays folded (-helical) 
in the light-state. Although, a light state solution structure would achieve a clear insight in to 
the confirmation of J and the changes in the interactions observed within the hydrophobic 
interface, we are limited to light irradiated dark state crystals at present.45 From this data, 
two hydrophobic residues found to be important for dimerisation were chosen for site-
directed mutagenesis (V27D and I113D), to polar amino acids. The YtvA-LOV-V27D mutation 
did not show any change in quaternary structure, whereas the YtvA-LOV-I113D mutation 
caused a disruption to the hydrophobic -sheet that mediates dimerisation, resulting in a 
protein that is monomeric in solution, observed by size-exclusion chromatography. 
However, this investigation remains partial as further repeats are required to justify the 
change observed (dimeric to monomeric) by size-exclusion chromatography. It is also vital 
that the UV/Vis and CD characterisation and half-lives of these mutants are recorded which 
will allow comparison with the wild-type data. 
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 Photo-sensitive protein-switches are used in dynamic researches as optogenetic tools for 
controlling biomolecular interactions in regulatory pathways. The ability to use non-harmful 
blue light to control apoptosis in a reversible manner would results in great scientific and 
therapeutic interest. In this work, the BH3 domain of pro-apoptotic Bid was targeted, to 
create fusions with LOV in order to apply an on/off mechanism of inhibiting anti-apoptotic 
Bcl-xL. 
The work described in this thesis demonstrates the characterisation of two LOV domains, 
Avena sativa LOV2 and Bacillus subtilis YtvA, using UV/Vis and CD spectroscopy to 
determine the photo-recovery time. Hisact-AsLOV2 and the longer half-life Hisact-AsLOV2-
V416I mutant demonstrated temperature dependency with Hisact-AsLOV2 relaxing with a 
half-life of 15.9 ± 1.3 seconds at 37 °C, whilst pH between 6.5 and 8 had minimal effect on 
the photo adduct reversion. Removal of the N-terminal hisactophilin from the AsLOV2-V416I 
mutant resulted in an extended recovery rate, with a half-life of 137.6 ± 2.8 at 37 °C. This 
provides a greater cysteinyl-FMN adduct yield under reduced irradiation intervals, which will 
reduce damage or shock to cells used for in vivo testing. Therefore AsLOV2-V416I was 
selected to produce hybrid proteins engineered with fusions at the J helix to control 
cellular apoptotic signalling, which will benefit from the longer undocked period of J to 
allow interactions to Bcl-xL. 
YtvA-LOV has a 10-fold longer photo-recovery than LOV2, making it advantageous for 
creating photo-switchable fusions, as demonstrated by Moglich et al, with the bacterial 
haem-binding PAS-histidine kinase, FixL/YF1 variants.60 Although YtvA-LOV will allow longer 
signalling duration for protein-protein interactions, fusions with the BH3 domains of pro-
apoptotic proteins would be complicated by the switching limitations of the YtvA J-helix, as 
the protein exists in a homodimeric form in solution.45 Therefore, mutational studies were 
conducted to further understand which amino acid residues were key to the dimeric 
interface of YtvA-LOV. Using size-exclusion chromatography, it was demonstrated that 
mutant YtvA-LOV-I113D exists as a monomer in solution. However, it is yet to be examined 
by UV/Vis and CD spectroscopy to determine the photo-recovery time. To further confirm 
this result, ultracentrifugation (density gradient) studies with purified wild-type and mutant 
protein can be used, as both differ in molecular weight and should appear at different 
sediments after centrifugation. It would be interesting to generate NMR structures of the 
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light state of both wild-type and mutant YtvA-LOV, to understand the switching mechanics 
better. 
The success of an optogenetics tool is highly dependent on the design concept of the photo-
switch, as seen with the success of LOV-Rac76,54-56 and the limitations of LOV-DHFR.53 In this 
case, AsLOV2-Bid hybrid designs were optimised with the BH3 sequence incorporated fully 
and at different positions of the J-helix. Initially the fully incorporated LOV-Bid design was 
tested using the synthesised LOV-Bid-J peptide, which demonstrated that binding was not 
abolished and a strong binding affinity for Bcl-xL (natural binding partner) was determined. 
However, Hisact-AsLOV2-bid displayed binding to Bcl-xL both in the dark and light states, 
thereby failing to act as an optogenetics switch. To further understand the factors that may 
have caused this, it would be helpful to obtain a crystal or NMR structure of the AsLOV2 in 
the light state. This can be conducted through the reconstitution of the FMN in AsLOV2 with 
an 5-deaza-FMN analogue which after blue light irradiation abolishes photo-adduct 
reversion to the dark state until it is irradiated with UV light (313 nm).171 It would also be 
interesting to obtain a dark state structure of Hisact-AsLOV2-Bid protein, to further 
understand what may be causing incomplete docking of the J A 1-deaza-FMN analogue 
may be used in this case (unpublished work by Dr. Andrew Wood, Cardiff University) which 
will diminish the formation of the flavin-cysteinyl covalent adduct. 
Further optimisation of the LOV-Bid design enabled four other fusions (LOV-Bid1-4) to be 
engineered, stably produced, purified and characterised using UV/Vis and CD spectroscopy 
to determine the photo-recovery times of the FMN and the protein. CD spectroscopy 
measurements at MRE 222 also enabled assessment of the change in protein secondary 
structure upon photo-adduct formation, revealing that all fusions did not switch to the same 
magnitude as wild-type LOV2. This correlated with binding affinities determined by 
fluorescence anisotropy measurements, which revealed that all four proteins bound to Bcl-
xL in the light state and all except AsLOV2-Bid2 did not bind in the dark state. We anticipate 
that successful ‘caging’ was observed with AsLOV2-Bid1, AsLOV2-Bid3 and AsLOV2-Bid4, 
rendering these designs competent for optogenetics testing in vivo.  
It will be interesting to record how AsLOV2-Bid5 would bind to Bcl-xL, as it was predicted 
that the proximity of the LOV domain is likely to sterically constrain accessibility to Bcl-xL. 
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However, using the knowledge from the findings in this study and previous studies57 it is 
expected that lack of sequence overlap with the J may prevent ‘caging’ and will become 
more accessible to bind in the dark.  
The light state binding affinities of AsLOV2-Bid3 and AsLOV2-Bid4 for Bcl-xL, are stronger 
than the binding constant reported for wild-type t-Bid in vitro,147 with AsLOV2-Bid4 having 
less than two-fold increase in binding affinity from the LOV-Bid peptide. Therefore these 
two designs are promising photoswitches for controlling apoptosis. Ultimately, in vivo 
studies145 of these AsLOV2-Bid fusions would enable us to investigate how potent these 
proteins are in a live cell environment and potentially pave a way for inducing apoptosis in 
cancer cells using BH3 mimicry. 
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Appendix 
ctcgagaaatcataaaaaatttatttgctttgtgagcggataacaattataatagattca 
 L  E  K  S  -  K  I  Y  L  L  C  E  R  I  T  I  I  I  D  S  
attgtgagcggataacaatttcacacagaattcattaaagaggagaaattaaccatgggt 
 I  V  S  G  -  Q  F  H  T  E  F  I  K  E  E  K  L  T  M  G  
aacagagcattcaaatcacatcacggtcactttttaagcgctgaaggcgaagctgtaaag 
 N  R  A  F  K  S  H  H  G  H  F  L  S  A  E  G  E  A  V  K  
actcaccacggtcatcatgatcatcacacccatttccacgttgaaaaccatggtggtaaa 
 T  H  H  G  H  H  D  H  H  T  H  F  H  V  E  N  H  G  G  K  
gttgcattaaagacccattccggtaaatacctttcaattggtgatcataaacaagtttac 
 V  A  L  K  T  H  S  G  K  Y  L  S  I  G  D  H  K  Q  V  Y  
ctctcacaccacttacacggtgaccactcactcttccacttagaacatcatggcggtaaa 
 L  S  H  H  L  H  G  D  H  S  L  F  H  L  E  H  H  G  G  K  
gtctcaatcaaaggtcatcaccaccactacatttccgctgatcatcatggtcatgtttca 
 V  S  I  K  G  H  H  H  H  Y  I  S  A  D  H  H  G  H  V  S  
accaaagaacaccacgatcacgacaccacctttgaagaaattattattggttccgcggca 
 T  K  E  H  H  D  H  D  T  T  F  E  E  I  I  I  G  S  A  A  
tctggtctggtgccacgcggatccgaatttcttgctactacacttgaacgtattgagaag 
 S  G  L  V  P  R  G  S  E  F  L  A  T  T  L  E  R  I  E  K  
aactttgtcattactgacccacgtttgccagataatcccattatcttcgcgtccgatagt 
 N  F  V  I  T  D  P  R  L  P  D  N  P  I  I  F  A  S  D  S  
ttcttgcagttgacagaatattcgcgagaagaaattctgggtcgtaactgccgttttctt 
 F  L  Q  L  T  E  Y  S  R  E  E  I  L  G  R  N  C  R  F  L  
caaggtcctgaaaccgatcgcgcgacagtgcgcaaaattcgtgatgccatcgataaccaa 
 Q  G  P  E  T  D  R  A  T  V  R  K  I  R  D  A  I  D  N  Q  
acagaggtcactgtacagctgattaattatacaaagagtggtaaaaagttctggaacctc 
 T  E  V  T  V  Q  L  I  N  Y  T  K  S  G  K  K  F  W  N  L  
tttcacttgcagcctatgcgtgatcagaagggtgatgtccagtactttattggtgtccag 
 F  H  L  Q  P  M  R  D  Q  K  G  D  V  Q  Y  F  I  G  V  Q  
ttggatggtaccgaacatgtccgtgatgcggccgagcgtgagggtgtcatgctgattaag 
 L  D  G  T  E  H  V  R  D  A  A  E  R  E  G  V  M  L  I  K  
aaaactgcagaaaatattgatgaggcggcaaaagaacttccagatgctaatctgcgtcca 
 K  T  A  E  N  I  D  E  A  A  K  E  L  P  D  A  N  L  R  P  
gaggatttgtgggctaactaagcttaattagctgag 
 E  D  L  W  A  N  -  A  -  L  A  E   
Appendix A: Nucleotide and amino acid sequence of pNCO-Hisact-AsLOV2. 
 
accaaagaacaccacgatcacgacaccacctttgaagaaattattattggttccgcggca 
 T  K  E  H  H  D  H  D  T  T  F  E  E  I  I  I  G  S  A  A  
tctggtctggtgccacgcggatccgaatttcttgctactacacttgaacgtattgagaag 
 S  G  L  V  P  R  G  S  E  F  L  A  T  T  L  E  R  I  E  K  
aactttattattactgacccacgtttgccagataatcccattatcttcgcgtccgatagt 
 N  F  I  I  T  D  P  R  L  P  D  N  P  I  I  F  A  S  D  S  
ttcttgcagttgacagaatattcgcgagaagaaattctgggtcgtaactgccgttttctt 
 F  L  Q  L  T  E  Y  S  R  E  E  I  L  G  R  N  C  R  F  L  
caaggtcctgaaaccgatcgcgcgacagtgcgcaaaattcgtgatgccatcgataaccaa 
 Q  G  P  E  T  D  R  A  T  V  R  K  I  R  D  A  I  D  N  Q  
acagaggtcactgtacagctgattaattatacaaagagtggtaaaaagttctggaacctc 
 T  E  V  T  V  Q  L  I  N  Y  T  K  S  G  K  K  F  W  N  L  
tttcacttgcagcctatgcgtgatcagaagggtgatgtccagtactttattggtgtccag 
 F  H  L  Q  P  M  R  D  Q  K  G  D  V  Q  Y  F  I  G  V  Q  
ttggatggtaccgaacatgtccgtgatgcggccgagcgtgagggtgtcatgctgattaag 
 L  D  G  T  E  H  V  R  D  A  A  E  R  E  G  V  M  L  I  K  
aaaactgcagaaaatattgatgaggcggcaaaagaacttccagatgctaatctgcgtcca 
 K  T  A  E  N  I  D  E  A  A  K  E  L  P  D  A  N  L  R  P  
gaggatttgtgggctaactaa 
   E  D  L  W  A  N  -   
Appendix B: Nucleotide and amino acid sequence of pNCO-Hisact-AsLOV2-V416I 
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ctcgcgcatatggctagttttcaatcatttgggataccaggacagctggaagtcatcaaa 
 L  A  H  M  A  S  F  Q  S  F  G  I  P  G  Q  L  E  V  I  K  
aaagcacttgatcacgtgcgagtcggtgtggtaattacagatcccgcacttgaagataat 
 K  A  L  D  H  V  R  V  G  V  V  I  T  D  P  A  L  E  D  N  
cctattgtctacgtaaatcaaggctttgttcaaatgaccggctacgagaccgaggaaatt 
 P  I  V  Y  V  N  Q  G  F  V  Q  M  T  G  Y  E  T  E  E  I  
ttaggaaagaactgtcgcttcttacaggggaaacacacagatcctgcagaagtggacaac 
 L  G  K  N  C  R  F  L  Q  G  K  H  T  D  P  A  E  V  D  N  
atcagaaccgctttacaaaataaagaaccggtcaccgttcagatccaaaactacaaaaaa 
 I  R  T  A  L  Q  N  K  E  P  V  T  V  Q  I  Q  N  Y  K  K  
gacggaacgatgttctggaatgaattaaatattgatccaatggaaatagaggataaaacg 
 D  G  T  M  F  W  N  E  L  N  I  D  P  M  E  I  E  D  K  T  
tattttgtcggaattcagaatgatatcaccaagcaaaaagaatatgaaaagcttctcgag 
 Y  F  V  G  I  Q  N  D  I  T  K  Q  K  E  Y  E  K  L  L  E  
gattccctcacggaaattactgcactttcaactcctattgtcccgattcgcaatggcatt 
 D  S  L  T  E  I  T  A  L  S  T  P  I  V  P  I  R  N  G  I  
tcggctcttccgctagtcggaaacctgacagaggagcgatttaattccatcgtttgcaca 
 S  A  L  P  L  V  G  N  L  T  E  E  R  F  N  S  I  V  C  T  
ttgacgaatatcttatcaacatccaaagatgattatttgatcattgatttatccggattg 
 L  T  N  I  L  S  T  S  K  D  D  Y  L  I  I  D  L  S  G  L  
gcccaagtgaacgaacaaacggccgaccaaattttcaagctgagccatttgctgaaattg 
 A  Q  V  N  E  Q  T  A  D  Q  I  F  K  L  S  H  L  L  K  L  
accggaactgagttaatcattactggcattaagcctgaattggctatgaaaatgaataaa 
 T  G  T  E  L  I  I  T  G  I  K  P  E  L  A  M  K  M  N  K  
ctggatgccaatttttcgtcgctgaaaacatattcaaatgtaaaggatgccgttaaagtg 
 L  D  A  N  F  S  S  L  K  T  Y  S  N  V  K  D  A  V  K  V  
cttccgattatgtaa 
 L  P  I  M  -    
Appendix C: Nucleotide and amino acid sequence of YtvA-STAS. 
 
atgggccatcatcatcatcatcatcatcatcatcacagcagcggccatatcgacgacgac   
 M  G  H  H  H  H  H  H  H  H  H  H  S  S  G  H  I  D  D  D  
gacaagcatatggctagttttcaatcatttgggataccaggacagctggaagtcatcaaa   
 D  K  H  M  A  S  F  Q  S  F  G  I  P  G  Q  L  E  V  I  K  
aaagcacttgatcacgtgcgagtcggtgtggtaattacagatcccgcacttgaagataat   
 K  A  L  D  H  V  R  V  G  V  V  I  T  D  P  A  L  E  D  N  
cctattgtctacgtaaatcaaggctttgttcaaatgaccggctacgagaccgaggaaatt   
 P  I  V  Y  V  N  Q  G  F  V  Q  M  T  G  Y  E  T  E  E  I  
ttaggaaagaactgtcgcttcttacaggggaaacacacagatcctgcagaagtggacaac   
 L  G  K  N  C  R  F  L  Q  G  K  H  T  D  P  A  E  V  D  N  
atcagaaccgctttacaaaataaagaaccggtcaccgttcagatccaaaactacaaaaaa   
 I  R  T  A  L  Q  N  K  E  P  V  T  V  Q  I  Q  N  Y  K  K  
gacggaacgatgttctggaatgaattaaatattgatccaatggaaatagaggataaaacg   
 D  G  T  M  F  W  N  E  L  N  I  D  P  M  E  I  E  D  K  T  
tattttgtcggaattcagaatgatatcaccaagcaaaaagaatatgaaaagcttctcgag   
 Y  F  V  G  I  Q  N  D  I  T  K  Q  K  E  Y  E  K  L  L  E  
gattccctcacggaaattactgcactttcaacttaataacctattgtcccgattcgcaat   
 D  S  L  T  E  I  T  A  L  S  T  -  -  P  I  V  P  I  R  N  
ggcatttcggctcttccgctagtcggaaacctgacagaggagcgatttaattccatcgtt   
 G  I  S  A  L  P  L  V  G  N  L  T  E  E  R  F  N  S  I  V  
tgcacattgacgaatatcttatcaacatccaaagatgattatttgatcattgatttatcc   
 C  T  L  T  N  I  L  S  T  S  K  D  D  Y  L  I  I  D  L  S  
ggattggcccaagtgaacgaacaaacggccgaccaaattttcaagctgagccatttgctg   
 G  L  A  Q  V  N  E  Q  T  A  D  Q  I  F  K  L  S  H  L  L  
aaattgaccggaactgagttaatcattactggcattaagcctgaattggctatgaaaatg   
 K  L  T  G  T  E  L  I  I  T  G  I  K  P  E  L  A  M  K  M  
aataaactggatgccaatttttcgtcgctgaaaacatattcaaatgtaaaggatgccgtt   
 N  K  L  D  A  N  F  S  S  L  K  T  Y  S  N  V  K  D  A  V  
aaagtgcttccgattatgtaa  
 K  V  L  P  I  M  -   
Appendix D: Nucleotide and amino acid sequence of pET19b-YtvA-LOV. 
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cctctagaataattttgtttaactttaagaaggagatataccatgggccatcatcatcat 
 P  L  E  -  F  C  L  T  L  R  R  R  Y  T  M  G  H  H  H  H  
catcatcatcatcatcacagcagcggccatatcgacgacgacgacaagcatatggctagt 
 H  H  H  H  H  H  S  S  G  H  I  D  D  D  D  K  H  M  A  S  
tttcaatcatttgggataccaggacagctggaagtcatcaaaaaagcacttgatcacgtg 
 F  Q  S  F  G  I  P  G  Q  L  E  V  I  K  K  A  L  D  H  V  
cgagtcggtgatgtaattacagatcccgcacttgaagataatcctattgtctacgtaaat 
 R  V  G  D  V  I  T  D  P  A  L  E  D  N  P  I  V  Y  V  N  
caaggctttgttcaaatgaccggctacgagaccgaggaaattttaggaaagaactgtcgc 
 Q  G  F  V  Q  M  T  G  Y  E  T  E  E  I  L  G  K  N  C  R  
ttcttacaggggaaacacacagatcctgcagaagtggacaacatcagaaccgctttacaa 
 F  L  Q  G  K  H  T  D  P  A  E  V  D  N  I  R  T  A  L  Q  
aataaagaaccggtcaccgttcagatccaaaactacaaaaaagacggaacgatgttctgg 
 N  K  E  P  V  T  V  Q  I  Q  N  Y  K  K  D  G  T  M  F  W  
aatgaattaaatattgatccaatggaaatagaggataaaacgtattttgtcggaattcag 
 N  E  L  N  I  D  P  M  E  I  E  D  K  T  Y  F  V  G  I  Q  
aatgatatcaccaagcaaaaagaatatgaaaagcttctcgaggattccctcacggaaatt 
 N  D  I  T  K  Q  K  E  Y  E  K  L  L  E  D  S  L  T  E  I  
actgcactttcaacttaataacctattgtcccgattcgcaatggcatttcggctcttccg 
 T  A  L  S  T  -  -  P  I  V  P  I  R  N  G  I  S  A  L  P  
ctagtcggaaacctgacagaggagcgatttaattccatcgtttgcacattgacgaatatc 
 L  V  G  N  L  T  E  E  R  F  N  S  I  V  C  T  L  T  N  I  
ttatcaacatccaaagatgattatttgatcattgatttatccggattggcccaagtgaac 
 L  S  T  S  K  D  D  Y  L  I  I  D  L  S  G  L  A  Q  V  N  
gaacaaacggccgaccaaattttcaagctgagccatttgctgaaattgaccggaactgag 
 E  Q  T  A  D  Q  I  F  K  L  S  H  L  L  K  L  T  G  T  E  
ttaatcattactggcattaagcctgaattggctatgaaaatgaataaactggatgccaat 
 L  I  I  T  G  I  K  P  E  L  A  M  K  M  N  K  L  D  A  N  
ttttcgtcgctgaaaacatattcaaatgtaaaggatgccgttaaagtgcttccgattatg 
 F  S  S  L  K  T  Y  S  N  V  K  D  A  V  K  V  L  P  I  M  
taaaggatccggctgctaacaaagcccgaaaggaagctgagttggct 
 -  R  I  R  L  L  T  K  P  E  R  K  L  S  W   
Appendix E: Nucleotide and amino acid sequence of pET19b-YtvA-LOV-V27D. 
 
cctctagaataattttgtttaactttaagaaggagatataccatgggccatcatcatcat 
 P  L  E  -  F  C  L  T  L  R  R  R  Y  T  M  G  H  H  H  H  
catcatcatcatcatcacagcagcggccatatcgacgacgacgacaagcatatggctagt 
 H  H  H  H  H  H  S  S  G  H  I  D  D  D  D  K  H  M  A  S  
tttcaatcatttgggataccaggacagctggaagtcatcaaaaaagcacttgatcacgtg 
 F  Q  S  F  G  I  P  G  Q  L  E  V  I  K  K  A  L  D  H  V  
cgagtcggtgatgtaattacagatcccgcacttgaagataatcctattgtctacgtaaat 
 R  V  G  D  V  I  T  D  P  A  L  E  D  N  P  I  V  Y  V  N  
caaggctttgttcaaatgaccggctacgagaccgaggaaattttaggaaagaactgtcgc 
 Q  G  F  V  Q  M  T  G  Y  E  T  E  E  I  L  G  K  N  C  R  
ttcttacaggggaaacacacagatcctgcagaagtggacaacatcagaaccgctttacaa 
 F  L  Q  G  K  H  T  D  P  A  E  V  D  N  I  R  T  A  L  Q  
aataaagaaccggtcaccgttcagatccaaaactacaaaaaagacggaacgatgttctgg 
 N  K  E  P  V  T  V  Q  I  Q  N  Y  K  K  D  G  T  M  F  W  
aatgaattaaatattgatccaatggaagatgaggataaaacgtattttgtcggaattcag 
 N  E  L  N  I  D  P  M  E  D  E  D  K  T  Y  F  V  G  I  Q  
aatgatatcaccaagcaaaaagaatatgaaaagcttctcgaggattccctcacggaaatt 
 N  D  I  T  K  Q  K  E  Y  E  K  L  L  E  D  S  L  T  E  I  
actgcactttcaacttaataacctattgtc 
 T  A  L  S  T  -  -  P  I  V  
Appendix F: Nucleotide and amino acid sequence of pET19b-YtvA-LOV-I113D. 
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gaaattttaacgtaattccctctagaatacttttgtttaactttaagaaggagatatacat    
 K  F  -  R  N  S  L  -  N  T  F  V  -  L  -  E  G  D  I  H  
atgagccagtctaaccgtgaactggtcgttgacttcctgtcctacaaactgtcccagaaa 
 M  S  Q  S  N  R  E  L  V  V  D  F  L  S  Y  K  L  S  Q  K  
ggctattcttggtctcagttctctgacgtggaggaaaaccgtacggaagctccagaaggt 
 G  Y  S  W  S  Q  F  S  D  V  E  E  N  R  T  E  A  P  E  G  
accgaaagcgaagccgtcaaacaggctctgcgtgaagctggtgatgaattcgaactgcgt 
 T  E  S  E  A  V  K  Q  A  L  R  E  A  G  D  E  F  E  L  R  
taccgtcgtgcgtttagcgacctgacctctcagctgcacatcactccgggtaccgcatac 
 Y  R  R  A  F  S  D  L  T  S  Q  L  H  I  T  P  G  T  A  Y  
cagtctttcgaacaggttgtgaacgagctgttccgtgatggtgtgaactggggtcgtatc 
 Q  S  F  E  Q  V  V  N  E  L  F  R  D  G  V  N  W  G  R  I  
gttgctttcttctcctttggtggtgcgctgtgcgttgaatctgtggacaaagaaatgcag 
 V  A  F  F  S  F  G  G  A  L  C  V  E  S  V  D  K  E  M  Q  
gttctggtatcccgtatcgcagcctggatggcgacttacctgaacgatcatctggaaccg 
 V  L  V  S  R  I  A  A  W  M  A  T  Y  L  N  D  H  L  E  P  
tggattcaggagaacggtggttgggataccttcgtagagctgtatggcaacaacgcagcg 
 W  I  Q  E  N  G  G  W  D  T  F  V  E  L  Y  G  N  N  A  A  
gcagaaagccgtaaaggtcaggaacgtctggaacaccaccaccatcaccatctcgagcac 
 A  E  S  R  K  G  Q  E  R  L  E  H  H  H  H  H  H  L  E  H  
caccaccaccaccactgagatccggctgctaacaaagcccgaaaggaagctgagttggct 
 H  H  H  H  H  -  D  P  A  A  N  K  A  R  K  E  A  E  L  A  
gctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgagg 
 A  A  T  A  E  Q  -  L  A  -  P  L  G  A  S  K  R  V  L  R   
Appendix G: Nucleotide and amino acid sequence of truncated Bcl-xL. 
 
 
atttgatacgcaaaactttccccctctccaaataattttgtttaactttaagaaggagat 
 I  -  Y  A  K  L  S  P  S  P  N  N  F  V  -  L  -  E  G  D  
atacatatgtgccagtctaaccgtgaactggtcgttgacttcctgtcctacaaactgtcc  
 I  H  M  C  Q  S  N  R  E  L  V  V  D  F  L  S  Y  K  L  S  
cagaaaggctattcttggtctcagttctctgacgtggaggaaaaccgtacggaagctcca  
 Q  K  G  Y  S  W  S  Q  F  S  D  V  E  E  N  R  T  E  A  P  
gaaggtaccgaaagcgaagccgtcaaacaggctctgcgtgaagctggtgatgaattcgaa  
 E  G  T  E  S  E  A  V  K  Q  A  L  R  E  A  G  D  E  F  E  
ctgcgttaccgtcgtgcgtttagcgacctgacctctcagctgcccatcactccgggtacc  
 L  R  Y  R  R  A  F  S  D  L  T  S  Q  L  P  I  T  P  G  T  
gcataccagtctttcgaacaggttgtgaacgagctgttccgtgatggtgtgaactggggt  
 A  Y  Q  S  F  E  Q  V  V  N  E  L  F  R  D  G  V  N  W  G  
cgtatcgttgctttcttctcctttggtggtgcgctgtgcgttgaatctgtggacaaagaa  
 R  I  V  A  F  F  S  F  G  G  A  L  C  V  E  S  V  D  K  E  
atgcaggttctggtatcccgtatcgcatcctgcatggcgacttacctgaacgatcatctg  
 M  Q  V  L  V  S  R  I  A  S  C  M  A  T  Y  L  N  D  H  L  
gaaccgtggattcaggagaacggtggttgggataccttcgtagagctgtatggcaacaac  
 E  P  W  I  Q  E  N  G  G  W  D  T  F  V  E  L  Y  G  N  N  
gcagcggcacaaagtcgtaaaggccaggaacgtctggaacaccacctccatcaccatctc  
 A  A  A  Q  S  R  K  G  Q  E  R  L  E  H  H  L  H  H  H  L  
gagcactaccaccaccaccactgacatccggctgctaacaaagtccgaaaggaagcttga  
 E  H  Y  H  H  H  H  -  H  P  A  A  N  K  V  R  K  E  A  -  
gttggctgctgccaccgctgagcataactagcataatcccttggggcctctaccgggtcc  
 V  G  C  C  H  R  -  A  -  L  A  -  S  L  G  A  S  T  G  S  
tgaggggcttttgctgaaccgaacaactatctcccgattgtcgaatgggacgcaccctgt  
 -  G  A  F  A  E  P  N  N  Y  L  P  I  V  E  W  D  A  P  C  
accagcgcattaaacgccgcgggtgtggtggtacccgcagcgtgaccgctatcttgcccg  
 T  S  A  L  N  A  A  G  V  V  V  P  A  A  -  P  L  S  C  P  
cgccccagcgcccgctcctttccctttctccctttcctttctcgccct  
 R  P  S  A  R  S  F  P  F  L  P  F  L  S  R  P    
Appendix H: Nucleotide and amino acid sequence of truncated Bcl-xL-S2C. 
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ctcgagaaatcataaaaaatttatttgctttgtgagcggataacaattataatagattca 
 L  E  K  S  -  K  I  Y  L  L  C  E  R  I  T  I  I  I  D  S  
attgtgagcggataacaatttcacacagaattcattaaagaggagaaattaaccatgggt 
 I  V  S  G  -  Q  F  H  T  E  F  I  K  E  E  K  L  T  M  G  
aacagagcattcaaatcacatcacggtcactttttaagcgctgaaggcgaagctgtaaag 
 N  R  A  F  K  S  H  H  G  H  F  L  S  A  E  G  E  A  V  K  
actcaccacggtcatcatgatcatcacacccatttccacgttgaaaaccatggtggtaaa 
 T  H  H  G  H  H  D  H  H  T  H  F  H  V  E  N  H  G  G  K  
gttgcattaaagacccattccggtaaatacctttcaattggtgatcataaacaagtttac 
 V  A  L  K  T  H  S  G  K  Y  L  S  I  G  D  H  K  Q  V  Y  
ctctcacaccacttacacggtgaccactcactcttccacttagaacatcatggcggtaaa 
 L  S  H  H  L  H  G  D  H  S  L  F  H  L  E  H  H  G  G  K  
gtctcaatcaaaggtcatcaccaccactacatttccgctgatcatcatggtcatgtttca 
 V  S  I  K  G  H  H  H  H  Y  I  S  A  D  H  H  G  H  V  S  
accaaagaacaccacgatcacgacaccacctttgaagaaattattattggttccgcggca 
 T  K  E  H  H  D  H  D  T  T  F  E  E  I  I  I  G  S  A  A  
tctggtctggtgccacgcggatccgaatttcttgctactacacttgaacgtattgagaag 
 S  G  L  V  P  R  G  S  E  F  L  A  T  T  L  E  R  I  E  K  
aactttattattactgacccacgtttgccagataatcccattatcttcgcgtccgatagt 
 N  F  I  I  T  D  P  R  L  P  D  N  P  I  I  F  A  S  D  S  
ttcttgcagttgacagaatattcgcgagaagaaattctgggtcgtaactgccgttttctt 
 F  L  Q  L  T  E  Y  S  R  E  E  I  L  G  R  N  C  R  F  L  
caaggtcctgaaaccgatcgcgcgacagtgcgcaaaattcgtgatgccatcgataaccaa 
 Q  G  P  E  T  D  R  A  T  V  R  K  I  R  D  A  I  D  N  Q  
acagaggtcactgtacagctgattaattatacaaagagtggtaaaaagttctggaacctc 
 T  E  V  T  V  Q  L  I  N  Y  T  K  S  G  K  K  F  W  N  L  
tttcacttgcagcctatgcgtgatcagaagggtgatgtccagtactttattggtgtccag 
 F  H  L  Q  P  M  R  D  Q  K  G  D  V  Q  Y  F  I  G  V  Q  
ttggatggtaccgaacatgtccgtgattgcgccgaggatattggtgtcaacatcgcgcgt 
 L  D  G  T  E  H  V  R  D  C  A  E  D  I  G  V  N  I  A  R  
catctggcacaggtgggtgatagcattgatcgtagcattccagatgctaatctgcgtcca 
 H  L  A  Q  V  G  D  S  I  D  R  S  I  P  D  A  N  L  R  P  
gaggatttgtgggctaactaagcttaattagctgag 
 E  D  L  W  A  N  -  A  -  L  A  E   
Appendix I: Nucleotide and amino acid sequence of Hisact-AsLOV-Bid1. 
 
 
 
agcggatcgatttcttgctactacacttgaacgtattgagaagaactttattattactgac    
  A  D  R  F  L  A  T  T  L  E  R  I  E  K  N  F  I  I  T  D  
ccacgtttgccagataatcccattatcttcgcgtccgatagtttcttgcagttgacagaa   
  P  R  L  P  D  N  P  I  I  F  A  S  D  S  F  L  Q  L  T  E  
tattcgcgagaagaaattctgggtcgtaactgccgttttcttcaaggtcctgaaaccgat    
  Y  S  R  E  E  I  L  G  R  N  C  R  F  L  Q  G  P  E  T  D  
cgcgcgacagtgcgcaaaattcgtgatgccatcgataaccaaacagaggtcactgtacag   
  R  A  T  V  R  K  I  R  D  A  I  D  N  Q  T  E  V  T  V  Q  
ctgattaattatacaaagagtggtaaaaagttctggaacctctttcacttgcagcctatg   
  L  I  N  Y  T  K  S  G  K  K  F  W  N  L  F  H  L  Q  P  M  
cgtgatcagaagggtgatgtccagtactttattggtgtccagttggatggtaccgaacat   
  R  D  Q  K  G  D  V  Q  Y  F  I  G  V  Q  L  D  G  T  E  H  
gtccgtgattgcgccgaggatattggtgtcaacatcgcgcgtcatctggcacaggtgggt   
  V  R  D  C  A  E  D  I  G  V  N  I  A  R  H  L  A  Q  V  G  
gatagcattgatagccgtatttgctaagctaatctgcgtccagaggatttgtgggctaac   
  D  S  I  D  S  R  I  C  -  A  N  L  R  P  E  D  L  W  A  N   
Appendix J: Nucleotide and amino acid sequence of Hisact-AsLOV-Bid-cys. 
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cctaacttaaccgctcattccctctagaataattttgtttaactttaagaaggagatatacc 
   -  L  N  R  S  F  P  L  E  -  F  C  L  T  L  R  R  R  Y  T  
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat 
 M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
atgtttcttgctactacacttgaacgtattgagaagaactttattattactgacccacgt 
 M  F  L  A  T  T  L  E  R  I  E  K  N  F  I  I  T  D  P  R  
ttgccagataatcccattatcttcgcgtccgatagtttcttgcagttgacagaatattcg 
 L  P  D  N  P  I  I  F  A  S  D  S  F  L  Q  L  T  E  Y  S  
cgagaagaaattctgggtcgtaactgccgttttcttcaaggtcctgaaaccgatcgcgcg 
 R  E  E  I  L  G  R  N  C  R  F  L  Q  G  P  E  T  D  R  A  
acagtgcgcaaaattcgtgatgccatcgataaccaaacagaggtcactgtacagctgatt 
 T  V  R  K  I  R  D  A  I  D  N  Q  T  E  V  T  V  Q  L  I  
aattatacaaagagtggtaaaaagttctggaacctctttcacttgcagcctatgcgtgat 
 N  Y  T  K  S  G  K  K  F  W  N  L  F  H  L  Q  P  M  R  D  
cagaagggtgatgtccagtactttattggtgtccagttggatggtaccgaacatgtccgt 
 Q  K  G  D  V  Q  Y  F  I  G  V  Q  L  D  G  T  E  H  V  R  
gattgcgccgaggatattggtgtcaacatcgcgcgtcatctggcacaggtgggtgatagc 
 D  C  A  E  D  I  G  V  N  I  A  R  H  L  A  Q  V  G  D  S  
attgatcgtagcattccagatgctaatctgcgtccagaggatttgtgggctaactaagct 
 I  D  R  S  I  P  D  A  N  L  R  P  E  D  L  W  A  N  -  A  
taaggatccgaattcgagctccgtcgacaagcttgcggccgcactcgagcaccaccacca 
 -  G  S  E  F  E  L  R  R  Q  A  C  G  R  T  R  A  P  P  P  
ccaccactgagatccggctgctaacaaagcccgaaaggaagctga 
 P  P  L  R  S  G  C  -  Q  S  P  K  G  S  -   
Appendix K: Nucleotide and amino acid sequence of pET-21a- AsLOV-Bid1. 
 
 
tagaaataattttgtttaactttaagaaggagatataccatgggcagcagccatcatcat 
 -  K  -  F  C  L  T  L  R  R  R  Y  T  M  G  S  S  H  H  H  
catcatcacagcagcggcctggtgccgcgcggcagccatatgtttcttgctactacactt 
 H  H  H  S  S  G  L  V  P  R  G  S  H  M  F  L  A  T  T  L  
gaacgtattgagaagaactttattattactgacccacgtttgccagataatcccattatc 
 E  R  I  E  K  N  F  I  I  T  D  P  R  L  P  D  N  P  I  I  
ttcgcgtccgatagtttcttgcagttgacagaatattcgcgagaagaaattctgggtcgt 
 F  A  S  D  S  F  L  Q  L  T  E  Y  S  R  E  E  I  L  G  R  
aactgccgttttcttcaaggtcctgaaaccgatcgcgcgacagtgcgcaaaattcgtgat 
 N  C  R  F  L  Q  G  P  E  T  D  R  A  T  V  R  K  I  R  D  
gccatcgataaccaaacagaggtcactgtacagctgattaattatacaaagagtggtaaa 
 A  I  D  N  Q  T  E  V  T  V  Q  L  I  N  Y  T  K  S  G  K  
aagttctggaacctctttcacttgcagcctatgcgtgatcagaagggtgatgtccagtac 
 K  F  W  N  L  F  H  L  Q  P  M  R  D  Q  K  G  D  V  Q  Y  
tttattggtgtccagttggatggtaccgaacatgtccgtgatgcggccgagcgtgagggt 
 F  I  G  V  Q  L  D  G  T  E  H  V  R  D  A  A  E  R  E  G  
gtcatgctgattaaggatattgcacgtaatattgatcgtgcgctggcggaagtgggtgat 
 V  M  L  I  K  D  I  A  R  N  I  D  R  A  L  A  E  V  G  D  
agcattgatcgtagcatttaagcttgcggccgcactcgagcaccaccaccaccaccactg 
 S  I  D  R  S  I  -  A  C  G  R  T  R  A  P  P  P  P  P  L  
agatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagca 
 R  S  G  C  -  Q  S  P  K  G  S  -  V  G  C  C  H  R  -  A  
Appendix L: Nucleotide and amino acid sequence of pET-21a- AsLOV-Bid2. 
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atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat 
 M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
atgtttcttgctactacacttgaacgtattgagaagaactttattattactgacccacgt 
 M  F  L  A  T  T  L  E  R  I  E  K  N  F  I  I  T  D  P  R  
ttgccagataatcccattatcttcgcgtccgatagtttcttgcagttgacagaatattcg 
 L  P  D  N  P  I  I  F  A  S  D  S  F  L  Q  L  T  E  Y  S  
cgagaagaaattctgggtcgtaactgccgttttcttcaaggtcctgaaaccgatcgcgcg 
 R  E  E  I  L  G  R  N  C  R  F  L  Q  G  P  E  T  D  R  A  
acagtgcgcaaaattcgtgatgccatcgataaccaaacagaggtcactgtacagctgatt 
 T  V  R  K  I  R  D  A  I  D  N  Q  T  E  V  T  V  Q  L  I  
aattatacaaagagtggtaaaaagttctggaacctctttcacttgcagcctatgcgtgat 
 N  Y  T  K  S  G  K  K  F  W  N  L  F  H  L  Q  P  M  R  D  
Cagaagggtgatgtccagtactttattggtgtccagttggatggtaccgaacatgtccgt 
 Q  K  G  D  V  Q  Y  F  I  G  V  Q  L  D  G  T  E  H  V  R 
gatgcggccgagcgtgagggtgtcatgctgattaagaaaactgcagatattattgataac 
 D  A  A  E  R  E  G  V  M  L  I  K  K  T  A  D  I  I  D  N  
gcggcacgtgaacttgcacaggtgggtgatagcattgatcgtagcatttta 
 A  A  R  E  L  A  Q  V  G  D  S  I  D  R  S  I  - 
 Appendix M: Nucleotide and amino acid sequence of pET-21a- AsLOV-Bid3. 
 
 
 
atgggcagcagccatcatcatcatcatcacagcagcggcctggtgccgcgcggcagccat 
 M  G  S  S  H  H  H  H  H  H  S  S  G  L  V  P  R  G  S  H  
atgtttcttgctactacacttgaacgtattgagaagaactttattattactgacccacgt 
 M  F  L  A  T  T  L  E  R  I  E  K  N  F  I  I  T  D  P  R  
ttgccagataatcccattatcttcgcgtccgatagtttcttgcagttgacagaatattcg 
 L  P  D  N  P  I  I  F  A  S  D  S  F  L  Q  L  T  E  Y  S  
cgagaagaaattctgggtcgtaactgccgttttcttcaaggtcctgaaaccgatcgcgcg 
 R  E  E  I  L  G  R  N  C  R  F  L  Q  G  P  E  T  D  R  A  
acagtgcgcaaaattcgtgatgccatcgataaccaaacagaggtcactgtacagctgatt 
 T  V  R  K  I  R  D  A  I  D  N  Q  T  E  V  T  V  Q  L  I  
aattatacaaagagtggtaaaaagttctggaacctctttcacttgcagcctatgcgtgat 
 N  Y  T  K  S  G  K  K  F  W  N  L  F  H  L  Q  P  M  R  D  
Cagaagggtgatgtccagtactttattggtgtccagttggatggtaccgaacatgtccgt 
 Q  K  G  D  V  Q  Y  F  I  G  V  Q  L  D  G  T  E  H  V  R 
gatgcggccgagcgtgagggtgtcatgctgattaagaaaactgcagaaaatgatattgcg 
 D  A  A  E  R  E  G  V  M  L  I  K  K  T  A  E  N  D  I  A  
cgtaatatcgcgcgtcatctggcacaggtgggtgatagcattgatcgtagcatttaa 
 R  N  I  A  R  H  L  A  Q  V  G  D  S  I  D  R  S  I  - 
Appendix N: Nucleotide and amino acid sequence of pET-21a- AsLOV-Bid4. 
 
